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Abstract 
I have explored the infection of human cells by the gammaretroviruses XMLV 
(xenotropic murine leukaemia virus) and FeLV (feline leukaemia virus). For XMLV 
the main aim was to assess the risks and consequences of contamination of 
human-mouse xenografts. For FeLV, the aim was to explore the susceptibility of 
human cells in vitro to assess the risks and identify the barriers to zoonotic 
infection in vivo. 
Xenografting of human cells to mice is used commonly in many disciplines of 
biomedical science. Infection of xenograft-derived cell lines has been reported 
as a common observation but it was unclear how many of these lines were 
infected due to in vitro cross-contamination rather than de novo infection in 
vivo. I conducted a prospective study and demonstrated that more than 40% 
xenografts passaged through BALB/c nude mice acquired XMLV. Xenografts 
passaged through NSG, another commonly used mouse strain for engraftment 
studies, did not yield replication-competent XMLV, although there was some 
evidence of activation of related replication-defective viruses. The source of 
XMLV in BALB/c mice appeared to be Bxv1, a locus encoding a replication 
competent virus which I showed was absent from NSG mice. I also showed that 
de novo isolated XMLV replicates to high copy number in MCF7 breast cancer and 
induces subtle changes in growth properties. Transcriptome analysis suggested 
that up regulation of EGR1 (early growth response gene 1) may be responsible 
for these growth effects. I also analysed susceptibility to XMLV infection in 
human cells and showed that while primary PBMCs are highly resistant, many cell 
lines can be infected. The Raji Burkitt’s lymphoma cell line was found to be 
highly susceptible to XMLV and displayed a much larger transcriptional response 
compared to MCF7, with marked up regulation of a series of markers of innate 
immunity. 
I examined the susceptibility of human cells to infection with FeLV B, the viral 
subtype which appears to be the most likely zoonotic agent. Cell lines of human 
origin were found to vary in susceptibility with no clear relationship to cell 
lineage. While some cell lines were completely susceptible for FeLV B, most 
showed limited virus replication and G to A hypermutation that correlated with 
the expression of APOBEC family members. Primary PBMCs and some leukaemia 
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cell lines showed profound resistance to FeLV B infection at an early stage of 
replication and accumulated proviral DNA with only a few mutations. The 
mediator of this early block has not yet been identified but appears likely to be 
important in preventing cross-species spread of gammaretroviruses to the human 
population. 
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1 Introduction 
1.1 Retroviruses  
Retroviruses are a large group of single stranded enveloped RNA viruses. The size 
of genomic retroviral RNA ranges between 7-12kb. The diameter of a retrovirus 
particle is approximately 80-100nm. All retroviruses replicate via a DNA 
intermediate which is then integrated into the host cell genome1. 
 
1.1.1 Structure and classification of retroviruses 
Retroviruses can be classified into simple and complex retroviruses on the basis 
of the organisation of the viral genome. The genome of both simple and complex 
retroviruses carries basic genetic information comprising group specific antigen 
(gag), polymerase (pol), and envelope (env) regions. In addition to the basic 
genomic structure, the complex retroviruses also encode additional regulatory 
proteins by way of multiple splicing mechanisms2. The structure of a simple 
gammaretrovirus e.g. feline leukaemia virus (FeLV) is shown in the Figure 1.1.  
Figure 1.1 Structure of FeLV 
 
Figure 1.1 Structure of FeLV showing different segments along with the corresponding 
proteins encoded by these segments. See text for details. 
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As shown in Figure 1.1, gammaretroviruses like FeLV (and also murine leukaemia 
virus, MLV) are known to encode an alternate glycosylated form of the Gag 
polyprotein known as glycoGag or glycosylated Gag (gPr80Gag ) in addition to the 
major Gag polyprotein (Pr65Gag ) precursor of viral structural proteins3,4. The MLV 
glycoGag is encoded by a CUG initiation codon4,5 upstream of the AUG initiation 
codon for Pr65Gag whereas the glycoGag initiation codon for FeLV is AUG6. The 
gene product is glycosylated in the rough endoplasmic reticulum and later 
transported to the cell surface where it is cleaved into a 55kDa type II protein 
and a 40kDa protein7.The Gag polyprotein (Pr65Gag) precursor of FeLV is further 
cleaved by protease enzymes in a step wise fashion to produce viral proteins 
that make up the matrix (MA, p15), capsid, (CA, p27) and virus nucleocapsid, 
(NC, p10)8. The Pr180Gag-Pol precursor protein is formed when translation does not 
stop at the end of the gag gene and continues through the pol region. The fusion 
protein is then cleaved into a products of Gag precursor as well as protein 
products encoded by the pol region. The pol region is known to encode the 
enzymes protease (PR), reverse transcriptase (RT) and integrase (IN) enzymes8. 
The genomic RNA is spliced to generate env mRNA which encodes the viral 
proteins that make up the surface (gp70) and transmembrane (p15E) components 
of the viral envelope (Figure 1.1). In murine leukaemia virus (MLV), the capsid 
(CA) has been described as p30 rather than p27 on the basis of its apparent 
molecular size on SDS polyacrylamide gels9. stands for the retroviral packaging 
sequences, which play an important role in packaging the retroviral RNA10. 
Retroviruses (Retroviridae) can be classified into the following seven groups 
(genera) according to the ICTV classification11 given below: 
1. Alpharetroviruses e.g. avian leukosis virus (ALV), Rous sarcoma virus 
(RSV). 
2. Betaretroviruses e.g. mouse mammary tumour virus (MMTV). 
3. Gammaretroviruses e.g. murine leukaemia virus (MLV), feline leukaemia 
virus (FeLV), gibbon ape leukaemia virus (GaLV). 
4. Deltaretroviruses e.g. bovine leukaemia virus (BLV), human T cell 
leukaemia virus (HTLV). 
5. Epsilonretroviruses e.g. walleye dermal sarcoma virus (WDSV). 
6. Lentivirus e.g. human immunodeficiency virus-1 (HIV-1), simian 
immunodeficiency virus (SIV). 
7. Spumaretroviruses e.g. simian foamy virus (SFV). 
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The genus gammaretrovirus includes mammalian, avian and reptilian viruses. 
The gammaretroviruses along with the alpharetroviruses, betaretroviruses and 
epsilonretroviruses are generally classed as simple retroviruses while the 
deltaretroviruses, lentiviruses and spumaretroviruses are complex retroviruses. 
Retroviruses were previously classified on the basis of their morphology under 
the electron microscope12. From these studies the gammaretroviruses were 
previously designated type C retroviruses. Type C particles were observed to 
have a round central electron dense core that is formed during budding at the 
cell membrane. Other classes included intracellular type A particles 
characterised by an electron-lucent core, type B particles with a typically round 
eccentric electron-dense core and the type D particles showing a cylindrical 
electron dense core12. 
 
1.1.2 Replication cycle of retroviruses 
1.1.2.1 Entry into the host cell 
The first important step in the life cycle of retroviruses is entry into the host 
cell. To gain entry into the host cell, an interaction between glycoproteins 
present on the virus envelope and specific host cell receptors present on the 
host cell membrane is required (reviewed by Hunter et al13). This process 
initiates with the binding of a surface (SU) portion of the virus envelope to the 
cell surface receptor. The interaction drives a conformational change in the 
envelope region that leads to membrane fusion and finally entry of the virus into 
the cell2,13.The replication cycle of a simple gammaretrovirus is summarised in 
the Figure 1.2. 
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Figure 1.2 Replication cycle of retroviruses 
 
Figure 1.2 Different stages of a gammaretrovirus life cycle. Adapted from Retroviruses
13
. 
See text for details. 
1.1.2.2 Reverse Transcription 
The retrovirus enters the cell as a viral capsid core containing viral RNA and 
reverse transcriptase enzyme. Reverse transcription takes place while the virus 
particle is in the cytoplasm (Figure 1.2). The reverse transcriptase enzyme 
synthesizes the formation of double stranded DNA from the viral RNA template14. 
During the process of reverse transcription, the reverse transcriptase enzyme 
migrates twice from the 5’ end to the 3’ end of the viral RNA to duplicate the 
sequences present at the two ends, resulting in the formation of long terminal 
repeat sequences (LTR) at both ends of the proviral DNA14. The LTR is known to 
play a very important role in regulating viral gene expression and thus viral 
replication and in the process of insertional mutagenesis15.  
1.1.2.3 Integration 
The viral DNA formed moves from the cytoplasm to the nucleus where it is 
integrated into the host DNA with the help of viral integrase enzyme16. 
Integration is an important step in the life cycle of retroviruses16. It guards the 
virus DNA against degradation in the host cell, provides a stable environment for 
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viral DNA replication (retroviral DNA can’t replicate autonomously) and allows 
transcription of the viral genome using cellular enzymes. 
1.1.2.4 Transcription 
Once integrated, the provirus can be expressed as an infectious virus or can 
remain dormant17. Transcription of the integrated virus takes place as a result of 
interaction between cellular factors and the viral LTR18. 
 
1.1.2.5  Processing, packaging and budding 
As a result of transcription, full length viral RNA transcripts are produced which 
undergo further processing by the cellular RNA processing system. The full 
length viral RNA also undergoes splicing resulting in the generation of smaller 
RNA transcripts (Figure 1.1)19. Both the full length and spliced viral RNA 
transcripts move into the cytoplasm (Figure 1.2). Gag and Pol proteins are 
translated from the full length viral transcripts by cellular ribosomes located in 
the cytoplasm. Env proteins are translated from the spliced virus transcripts 
(Figure 1.1& 1.2). The full length viral RNA also serves as retroviral genomic 
RNA. The full length viral RNA and the viral proteins are assembled at the 
periphery of the cell near the cell membrane where the virus particles finally 
bud off from the cell surface. After budding the virus particles undergo 
maturation by the cleavage action of the viral and cellular proteases on the viral 
proteins19.  
 
1.1.3 Exogenous and endogenous retroviruses 
The exogenous retroviruses described above are responsible for new infection of 
the host cells. However the exogenous retroviruses can become endogenous by 
infecting germ line cells and being vertically transmitted from parents to 
offspring. All vertebrates investigated including humans have been found to have 
endogenous retroviruses in their genome17.  
1.1.3.1 Endogenous mouse retroviruses 
About 37% of the mouse genome consists of retro elements (DNA which has been 
amplified and inserted into the genome via an RNA intermediate). One third of 
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these retro elements comprise endogenous retroviruses20 including MLV21. About 
60 copies of MLV are present in the mouse genome22. Endogenous retroviruses 
(ERV) are either actively expressed or remain silent. Most ERV are non-functional 
due to mutations and deletions 23 but recombination between ERV is very 
common24.  
1.1.3.1.1 Classification of endogenous murine leukaemia viruses 
On the basis of host range of replication-competent representatives, the 
endogenous murine leukaemia viruses can be classified as  
1. Xenotropic murine leukaemia virus (XMLV): Only infects non-mouse cells. 
There are about 1-20 XMLV copies per mouse strain. BALB/c mice have up to 12 
XMLV while C57BL mice have up to 20 XMLV24. 
2. Ecotropic murine leukaemia virus (EMLV): Only infects mouse cells. There 
is a small number (up to six) of ecotropic proviruses in any mouse strain24. 
3. Polytropic murine leukaemia virus (PMLV): Infects both mouse cells and 
non-mouse cells21. There can be up to 40 copies of PMLV in lab mouse strains25. 
PMLV proviruses are replication defective, but can recombine with EMLV to 
produce infectious virus26. 
1.1.3.1.2 Xenotropic murine leukaemia virus (XMLV) 
XMLV is a gammaretrovirus and its genome consists of gag, pol, and env 
regions20. XMLV was isolated for the first time from New Zealand Black (NZB) 
mice27. Mouse strains differ in their capacity to produce infectious XMLV. XMLV is 
highly expressed in NZB and F/ST mice, moderately expressed in C57BL, C57L, 
BALB/c, DBA, AKR, NZW HRS and MA/My mice and rarely expressed in NFS, NIH 
Swiss, A, 129 and SWR mice20. Strains like NZB and F/St spontaneously produce 
XMLV whilst other strains need activation by chemical induction, spleen cell 
stimulation by bacterial lipopolysaccharides (LPS) or by a graft versus host 
reaction28. BALB/c splenocytes can be activated in vitro to express C type 
particles by treatment with bromo deoxyuridine (BrdU) and in vivo by a graft 
versus host reaction29. 
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Four active XMLV proviruses have been mapped20: 
1. Bxv1: Present on chromosome 1 locus30 and can be induced by chemical 
and LPS stimulation30. Bxv1 is present in around 1/3 of inbred mouse strains. 
2. Nzv1 and Nzv2: Present in NZB mice31. 
3. Mxv1: Present in Ma/My mice in addition to Bxv132. 
Bxv1 has been identified in 17 strains. The source of Bxv1 in the laboratory 
mouse has been traced back to the Japanese Mus molossinus house mouse22. 
Nude mice have a low rejection level to xenografting due to thymic aplasia and 
lack of T cell mediated immunity33. T cells may not be completely absent in 
nude mice34, and since Bxv1 is induced by graft versus host reactions, infectious 
XMLV can be found in a tumour xenografted in immune deficient mice positive 
for Bxv120. 
XMLV uses Xenotropic and polytropic retrovirus receptor 1 (XPR1) to enter cells. 
Like other gammaretrovirus receptors, XPR1 has multiple transmembrane 
domains (8 in this case), with four extra cellular loops (ECL)20,35. There are 5 
different forms of XPR1 in mice: XPR1m, XPR1n, XPR1c, XPR1Sxv, XPR1p 20. All of 
these with the exception of XPR1n permit XMLV infection with variable 
efficiency, XPR1Sxv being the most efficient20. Important receptor polymorphisms 
responsible for these differences have been mapped to lysine 500 on ECL3 and 
threonine 582 on ECL4 on the XPR1 receptors36. Human XPR1 is located on 
chromosome 135 and is a homolog of mouse XPR1Sxv. XPR1 is expressed in almost 
all human cell lines except RBCs37 and human cell lines are generally susceptible 
to XMLV infection in vitro in common with many other mammalian species. 
Laboratory mice generally carry the XPR1n receptor and are not susceptible to 
XMLV20, but their progenitor strains Mus domesticus, Mus castaneus, and Mus 
musculus38 have been found to be susceptible to XMLV infection. Recently strains 
of laboratory mice have been found to be susceptible to XMLV infection22 owing 
to expression of XPR1sxv. It appears that ancestral mice were susceptible to XMLV 
infection, but selective pressure has led to loss of receptor entry function in 
most strains39. Chickens, in contrast to other birds, are similarly refractory to 
XMLV. Mutations have been found in the chicken XPR1 receptor that render it 
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resistant to XMLV infection40, leading to the suggestion that chicken may have 
acquired resistant XPR1 receptors due to counter-selection as chickens have 
been shown to catch and eat small rodents40. 
1.2 Host resistance  
1.2.1 The innate and adaptive immune systems 
The innate immune system acts in a less specific manner to combat invading 
viruses and may respond within hours of infection. The innate immune system 
encompasses sentinel cells e.g. macrophages, natural killer cells, dendritic cells 
and soluble factors produced by infected cells such as interferon41. The toll like 
receptors (TLR) play a major role in these processes 42. The TLR known for 
sensing different viruses or their replication intermediates are TLR2, TLR3, 
TLR4, TLR7, TLR8 and TLR942,43. Binding of a ligand to TLR activates an 
intracellular signalling cascade resulting in the production of different cytokines 
including type 1 interferon and also activation of dendritic cells42. Interferon 
signalling stimulates the expression of interferon-responsive genes including 
restriction factors that confer antiviral activity44. Retroviruses have been 
generally been regarded as invisible to the innate immune system, failing to 
induce interferon, but recent studies suggest that retroviruses can induce innate 
immune responses via the cGAS-cGAMP-STING (stimulator of interferon genes ) 
pathway through activation of cyclic GMP-AMP synthase (cGAS) by newly 
synthesized proviral DNA45,46.  
Macrophages and dendritic cells are phagocytes47. After phagocytosis and 
degradation of virus or virus-infected cells, they migrate to the lymph nodes 
where they present the antigen to the helper T cells of the adaptive immune 
system and are therefore known as antigen presenting cells (APC)48. 
The adaptive immune system comprises T cells and the B cells. T cells are 
further subdivided into helper and cytotoxic T cells. Adaptive immunity is highly 
dependent on the information shared by the innate system about the viral 
infection via the APCs. The APCs activate the helper T cells and cause them to 
differentiate into either helper T cell type 1 (Th-1) or helper T cell type 2 (Th-
2). Th-1 cells are formed by the IL12 produced by the activated macrophages 
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and dendritic cells49 while the Th-2 cells are formed by IL4 from the activated T 
cells50. Th-1 cells secrete IL2 and IFN- that favour the activation of cytotoxic T 
cells51. IFN- is also involved in macrophage activation and stimulation of B cells 
to produce complement fixing and opsonising IgG antibodies52. The Th-2 cells on 
the other hand produces IL4 and IL13 that lead to production of IgG neutralising 
antibody and IgE antibody by the B cells52. The adaptive immune system also has 
the ability to develop immune memory as a result of viral infection. Immune 
memory provides more effective protection against repeated infection by the 
same virus53,54. Thus both the innate and adaptive immune systems behave in a 
responsive manner and require time to respond to retroviral infection55. This 
may be advantageous to the invading retrovirus as it can give the retrovirus 
sufficient time to integrate and evade recognition.  
1.2.2 The intrinsic immune system 
Eukaryotes have developed an intrinsic immune system in addition to the innate 
and adaptive immune systems to counteract retroviral infections55. Most of the 
current knowledge about these phenomena stems from studies on HIV and 
primate lentiviruses41. The intrinsic system consists of constitutively expressed 
proteins serving as antiretroviral restriction factors. These proteins are 
expressed at constant level and their antiretroviral activity is independent of 
any retrovirus related signalling. This system exists in a primed state to combat 
invading retroviruses55. However, a retroviral-generated signal can also up-
regulate expression of these restriction factors after activation of the host 
innate system43. Here the demarcation between the intrinsic and innate systems 
breaks down. The intrinsic system restriction factors are constantly expressed in 
cells as components of the intrinsic system primed to restrict retrovirus infection 
as a first line of anti-retroviral defence, but are also stimulated by interferon as 
part of the innate immune response thus reinforcing their antiretroviral 
capabilities56. The most significant intrinsic immune proteins that have been 
described so far include APOBEC3, TRIM5, SAMHD1 and Tetherin. Their 
mechanisms of action are illustrated in Figure 1.3. 
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Figure 1.3 Restriction of retroviruses 
 
Figure 1.3 Different mechanisms used by host cells to restrict retroviruses have been 
shown. See text for details. 
The intrinsic immune system is very efficient due to the fact that it is always 
ready to face the retrovirus infection. It is also extremely specific for 
retroviruses and plays an important role in preventing or weakening a retrovirus 
infection. Due to constant expression levels of restriction factors, the intrinsic 
immune system is able to resist initial retroviral challenge but the system can 
become saturated if very high retroviral titres are present. Thus the intrinsic 
immune system is primarily important as a first line defence to counteract 
retrovirus infection57. The important intrinsic factors (Figure 1.3) are discussed 
below. 
1.2.2.1 APOBEC3 enzymes 
Apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3 or A3) 
comprises a family of cytidine deaminase enzymes. While recognised as 
mediators of intrinsic resistance, the APOBEC3 genes are also interferon 
stimulated genes (ISGs)58,59. They are constitutively expressed in a cell-type 
specific manner60,61. While mice have a single gene, the human genome has 
seven members of the APOBEC3 family viz APOBEC3A, APOBEC3B, APOBEC3C, 
APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H62. 
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1.2.2.1.1  Mechanism of APOBEC3 action 
APOBEC3 can interact with the retroviral RNA and become packaged along with 
the retroviral particles. When these virus particles infect new cells, the 
APOBEC3 enters the cells along with the viral core63. The newly delivered 
APOBEC3 enzyme is capable of deaminating cytidine residues to form uracil in 
the minus DNA strand that is synthesized as a result of reverse transcription. 
This results in G to A hypermutations in the plus DNA strand55,64. APOBEC3 can 
also edit viral RNA thus giving rise C to T mutation in the plus DNA strand65. 
Depending on the number and location of the mutations, APOBEC3 activity can 
prove lethal for the virus. In general the APOBEC3 family results in G to A 
hypermutations in the plus DNA strand, but different members of the family 
have different preferences for dinucleotide/trinucleotides66. The APOBEC3G 
enzyme is unique in preferring GG sites67,68. A mutation occurring at a TGG site 
can result in a stop codon, which will often be fatal for viral replication. 
APOBEC3C can attack both GG and GA sites but it shows preference for the 
latter69. APOBEC3F, APOBEC3B, APOBEC3D, and APOBEC3H enzymes prefer GA 
sites55,68,70,71 which are less likely to induce a non-functional protein but 
hypermutation can still have fatal consequences for the virus. Excessive uracil 
residues in the minus DNA strand can also make the virus susceptible to uracil 
DNA glycosylase (UDG) mediated degradation72. APOBEC3 is also known to 
interfere with the reverse transcription of retroviral RNA73,74 and the integration 
of reverse transcripts75. Thus APOBEC3 is also capable of affecting retroviral 
infectivity by a cytidine-deaminase independent mechanism76–78.  
Gammaretroviruses like XMRV and MLV have been shown to be susceptible to 
human APOBEC3G mediated restriction79. XMRV has been reported to be 
resistant to APOBEC3F, APOBEC3B and APOBEC3C80, however the role of 
APOBEC3F is more controversial as others have claimed XMRV to be susceptible 
to both APOBEC3G and APOBEC3F mediated restriction81. PERV, another 
gammaretrovirus, has also been reported to be significantly restricted by 
APOBEC3G by a cytidine deaminase independent mechanism82. Murine APOBEC3 
(mA3) expressed by mammary epithelial cells is known to play an important role 
in reducing the infectivity of milk borne MMTV transmitted to offspring83. The 
potential use of APOBEC3 over-expression to prevent or treat retroviral infection 
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has been widely discussed82, but may not be completely safe as over expression 
of APOBEC3 has been reported to lead to the development of cancer84,85.  
1.2.2.1.2 Virus infectivity factor (Vif): A retroviral mechanism to counteract 
APOBEC3 
HIV-1 encodes a regulatory protein, Vif protein which antagonises APOBEC3 
activity. Vif protein reduces intracellular APOBEC3 levels by ubiquitin mediated 
degradation86,87. It has been shown that APOBEC3C, APOBEC3D, APOBEC3F, and 
APOBEC3G are all sensitive to Vif mediated degradation71 while APOBEC3A and 
APOBEC3B are resistant, however APOBEC3B has been reported to inhibit both 
Vif negative and Vif positive HIV-188. Others have reported that APOBEC3A, 
APOBEC3B and APOBEC3C are somewhat inefficient at restricting Vif negative 
HIV-1 while APOBEC3G, APOBEC3F, and to some extent APOBEC3D are more 
effective69,71.  
1.2.2.1.3 Glycosylated Gag 
MLV does not express a homologue of HIV-Vif but is nevertheless inefficiently 
restricted by mouse mA389,90. It has been reported that glycoGag plays a role in 
assisting MLV to counteract mouse mA3 mediated resistance both in vivo and in 
vitro 91. XMRV does not encode glycoGag but introduction of MLV glycoGag to 
XMRV increases the infectivity of XMRV independently of human APOBEC3 
expression92. The exact mechanism of glycosylated Gag function is not clear 
though it has been found that glycoGag favours virus budding or release from 
cells93.  
1.2.2.2 TRIM5 
Tripartite motif-containing 5TRIM5is another important antiretroviral 
restriction factor94. TRIM5has 3 protein domains at the N terminal viz RING, B-
BOX and the coiled coil domains95. The C terminal of TRIM5 has a SPRY/B30.2 
domain and is responsible for identifying and binding to the incoming virus 
capsid containing the retroviral RNA and enzymes96. Retroviruses whose capsids 
are not recognised can escape TRIM5mediated inhibition. The RING domain has 
ubiquitin ligase activity and is considered to play a role in TRIM5 mediated 
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restriction97. The coiled coil domain helps TRIM5 to form dimers and the B-Box 
can aid in the formation of multimers. It has been suggested that the formation 
of multimers improves the ability of TRIM5 to recognise incoming viral 
capsid98,99.  
1.2.2.3 Tetherin  
Tetherin is a type II transmembrane protein that plays a role as an antiretroviral 
restriction factor100. It expresses a glycophosphatidyl inositol (GPI) lipid anchor 
at the C terminus and a transmembrane domain at the N-terminus101. Each 
Tetherin monomer has three extracellular cysteines. Disulphide bonds between 
these extracellular cysteines enables Tetherin to exist as a dimer102. One end of 
Tetherin may get embedded in virus particles at the time of budding. The other 
end of the protein, which is still embedded in the cell membrane, prevents the 
newly formed virus particle moving away from the cell surface. Thus Tetherin 
causes virus retention on the cell surface by a tethering mechanism103. HIV-1 
uses its Vpu protein to counteract Tetherin mediated restriction104. Vpu is a type 
I transmembrane protein that can directly bind to Tetherin via interaction 
between their transmembrane domains105,106 and can down regulate Tetherin 
from the cell surface by causing its internalisation and lysosome mediated 
degradation107,108. Vpu can also displace Tetherin from virus assembly sites on 
the cell membrane thus affecting Tetherin’s ability to inhibit virus release 
without changing the total cell surface Tetherin levels105. 
1.2.2.4 SAMHD1 
SAM domain and HD domain-containing protein 1 (SAMHD1) is another ISG and an 
important restriction factor for HIV109. SAMHD1 is known to reduce intracellular 
deoxynucleoside triphosphates (dNTPs), thus interfering with the synthesis of 
viral DNA by reverse transcriptase110. SAMDH1 has been found to restrict HIV-1 
infection in dendritic cells and macrophages111. However SAMDH1 mediated 
restriction was not found to affect HIV-2 infection. This is because HIV-2 
expresses Vpx protein (not encoded by HIV-1) that reduces SAMDH1 activity by 
proteasomal degradation111,112.  
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1.2.2.5 Receptor status and Interference 
Lack of susceptibility to retrovirus infection can be due to the absence of cell 
surface receptors required for infection or a mutation in the receptors 
conferring resistance. Cells can also resist reinfection by the same retrovirus due 
to interference. Following retroviral infection the cell produces envelope 
proteins that bind and block the receptors rendering the cells resistant to re-
infection by the same virus (virus A) but not to viruses that can use alternative 
receptors (virus B). Similarly, cells infected with virus B are resistant to virus B 
but not to virus A. This is known as reciprocal interference. Non reciprocal 
interference can arise when viruses can use more than one receptor113. 
Interference can also take place due to expression of endogenous retroviral 
envelope gene sequences in the host cell genome. The Fv4 gene for example is a 
defective env present endogenously in some mouse strains114, and its expression 
is akin to receptor interference making cells resistant to infection by Friend 
murine leukaemia virus115. Newly acquired proviruses that are restricted by 
interference can recombine with different endogenous envelope sequences to 
form new viruses that enter cells using different envelope glycoproteins thereby 
enabling re-infection. The mink cell focus-forming (MCF) viruses, for example 
arise through recombination of exogenous murine leukaemia viruses with 
endogenous elements and are capable of re-infection using different 
receptors116. Finally a variation or mutation in the retroviral receptors can also 
affect the ability of retrovirus to infect the cell. One example of this is XPR1 
receptor variation and its effect on XMLV infection which has been described 
earlier.  
1.3 Gammaretroviruses as potential zoonotic agents 
1.3.1 Human fossil viruses 
Human endogenous retroviruses (HERV) make up approximately 8% of the human 
genome117. They integrated into human DNA millions of years ago and have been 
transmitted vertically throughout human generations118. The current human race 
is considered to represent the descendants of survivors of pandemics caused by 
exogenous counter-parts of HERV118. HERV have been broadly classified on the 
basis of their sequence resemblance to other retroviruses. Class I HERVs are 
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closely related to gammaretroviruses and are considered to be among the oldest 
HERVs. Examples of class I HERVs include HERV W and HERV H119. The class II 
HERVs are related to beta retroviruses while the class III HERVs are related to 
spumaretroviruses119. HERVs have undergone lethal mutations throughout the 
ages making them incapable of producing infectious virus. Recently the presence 
of HERV sequences has been associated with a number of diseases including 
cancer and autoimmune disease120. 
 
1.3.2 Koala retrovirus: A recent example of trans-species 
infection 
Endogenization of most retroviruses appears to be ancient, dating from millions 
of years ago, but recent information from studies of the koala provides a 
contemporary example. Koala retrovirus (KoRV) is an endogenous 
gammaretrovirus found in koalas121. KoRV uses the PiT1 receptor to enter cells 
and shows up to 78% sequence similarity to gibbon ape leukaemia virus (GaLV), 
an exogenous gammaretovirus of gibbon apes121. Southeast Asian mice are 
considered a likely source of origin for GaLV122. The infection and 
endogenization of koalas with KoRV may have occurred as little as two centuries 
ago123. Current estimates based on 5’ and 3’ LTR divergence are not very 
accurate, however an initial infection could have taken place up to 49,900 years 
ago124. Since gibbon apes and koalas live in different continents, a rodent vector 
has been proposed to be responsible for trans-species transmission from Asia to 
northern Australia125. In support of this hypothesis the prevalence of KoRV is high 
in koalas in northern Australia whereas the prevalence is low in south Australian 
koalas126. KoRV has been related to a high incidence of leukaemia and 
lymphomas in koalas121,125. 
1.3.3 Porcine endogenous retroviruses: A potential zoonotic 
agent 
Porcine endogenous retroviruses (PERV) are endogenous retroviruses present in 
the porcine germ line and are transmitted vertically to offspring. PERV was 
detected in early studies on the basis of type C particles observed in porcine 
cells127,128, and was later on definitively characterised as a gammaretrovirus 
family with three subtypes PERV A, PERV B and PERV C129. 
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In order to cope with the high demand of human organs for transplantation, the 
use of porcine xenografts has been actively considered. The presence of PERV in 
the genome of porcine cells, however poses a potential risk of PERV infection for 
the recipient and also for a new pandemic130,131 and is a real concern132. Work to 
address this hazard has shown that PERV is produced by porcine islet xenografts 
in mice133 and that PERV A and PERV B are capable of infecting human cells in 
vitro131,134. PERV A uses HuPAR-1 and HuPAR-2 receptors135. The receptor(s) for 
PERV B have not been characterised. To date there exists no evidence for human 
infection with PERV in vivo136,137 but the possibility of acquiring PERV by the 
recipient cannot be excluded.  
1.3.4 Potentially widespread human exposure to feline leukaemia 
virus  
Feline leukaemia virus (FeLV) is a naturally occurring retrovirus of household 
cats that can cause a variety of diseases in its host. FeLV is a simple retrovirus 
consisting of LTR, gag, pol and env regions138. Genetic recombination takes place 
when FeLV replicates in vivo and FeLV is a common cause of lymphoma in cats. 
Like MLV, FeLV can cause malignancy by insertional mutagenesis138. 
Members of the FeLV family usually co-exist in the natural host. Three subgroups 
of FeLV i.e. FeLV A, B and C have been widely studied. They use different 
receptors to enter host cells. FeLV A is generally considered to be an ecotropic 
virus. It uses the thiamine transporter THTR1 to enter feline cells but has a very 
low affinity for the human thiamine transporter hTHTR1139. It is virtually always 
present in cats viraemic for FeLV. FeLV A envelope pseudotypes have been 
reported to infect non feline cells thus showing the virus is not ecotropic in the 
true sense140. FeLV B often co-exists with FeLV A in infected cats and arises as a 
result of recombination between FeLV A and endogenous FeLV-related 
sequences141. FeLV B utilizes the phosphate transporters PiT1 or PiT2 to enter 
cells142. FeLV B can infect human cells in vitro and these cells can produce 
infectious virus140. FeLV C arises from FeLV A as a result of mutations in a single 
variable region of the envelope gene143. FeLV C utilizes the heme transporters 
FLVCR1 or FLVCR2144. FeLV C strains cause rapidly fatal aplastic anaemia145. 
Some FeLV strains can utilize both THTR1 receptors as well as FLVCR1/FLVCR2 to 
enter into the host cells146. In this study FeLV B was focussed on as the more 
likely zoonotic agent as it is present in up to 50% FeLV isolates147 and can 
  34 
 
replicate without cytopathic effect in human cells in vitro. In the domestic 
environment, human exposure to FeLV occurs through shedding of virus in the 
saliva of infected cats. While FeLV C strains can also infect non-feline cells, they 
are rare in nature (~1% of isolates) and may induce cytopathic effects due to 
blockade of haem transport140. FeLV is a significant cause of leukaemia and 
lymphomas in its natural host148. There is no evidence of FeLV infection of 
humans in vivo149. With an FeLV infection rate of up to 3% in domestic cats150, 
the mechanism(s) by which humans resist FeLV infection are of obvious interest. 
1.3.5 XMRV controversy and its aftermath: XMLV found in human 
xenografts 
1.3.5.1 XMRV Controversy 
Xenotropic murine leukaemia virus-related virus (XMRV) was initially reported as 
a new cross-species infection of the human population but instead appears to be 
an artefact of xenotransplantation and in vitro reagent contamination. The virus 
appears to have been formed as a result of a recombination event between two 
defective endogenous murine leukaemia viruses, pre XMRV1 and pre XMRV2151. 
XMRV has 93% sequence similarity to XMLV (Bxv1)20. Both XMRV and XMLV use the 
XPR1 receptor to enter cells152. When certain prostate cancer lines were found 
to contain XMRV153,154, there was a concern that there could be a viral aetiology 
to some prostate cancers. An apparent correlation was noted when RNase L 
mutant prostate cancer was described to be associated with XMRV155. XMRV was 
also claimed to be isolated from chronic fatigue syndrome (CFS) patients 
resulting in the experimental use of antiretroviral treatment for CFS156. XMRV 
was also claimed to be related to a number of other diseases157. However these 
results could not be reproduced158. The presence of polytropic murine leukaemia 
virus (PMLV) in CFS patients occurred as a result of contamination of mouse DNA 
in human samples159. PMLV refers to endogenous murine leukaemia virus, which 
can infect both mouse cells and non-mouse cells 21. Using a very sensitive PCR to 
detect mouse mitochondrial cytochrome oxidase and Intracisternal A particles 
(IAP) most samples previously positive for XMRV were also found to be positive 
for mouse DNA160. Moreover many commercial kits used in XMRV related studies 
have subsequently been found to be contaminated with mouse DNA161. Simmons 
et al162 carried out a double blind study and confirmed that most of the previous 
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XMRV related results were due to contamination issues. The human prostate 
cancer cell line 22Rv1 is now considered to be the source of XMRV163. 22Rv1 was 
developed by repeated passaging through nude mice for 7 years. This cell line 
served as prostate cancer model and has been distributed worldwide151.  
1.4 Xenografting and cancer research 
Xenografting of human cancer cells in the laboratory mouse is a well-established 
procedure for the isolation and characterisation of cells that drive tumour 
development33. The leukemic stem cell theory, which led John Dick and co-
workers to establish the cancer stem cell hypothesis mainly depends on the 
mouse as a surrogate host and a detection system for cells capable of 
reconstituting primary tumours164. The development of immune deficient mice 
with reduced ability to reject xenografts165 has further increased the use of mice 
as hosts for cancer cell line development and xenografting. 
 
1.4.1 Infection of xenografts 
1.4.1.1 Historical observations 
Infection of xenografts with retroviruses is not a new observation. For example 
human rhabdomyosarcoma cells passaged through the cat were found to be 
infected with type C virus as early as 1972166. This type C virus known as RD114, 
was characterised as an endogenous feline virus167. Animal vaccines prepared 
using feline cells have recently been found to be contaminated with infectious 
RD114 gammaretrovirus168,169 therefore presenting a potential threat for trans-
species spread of infection.  
Type C particles infecting rhabdomyosarcoma cells passaged through mice were 
also reported in 1973 by Todaro et al170. A study in 1979 observed that a 
substantial number (up to 35%) of human urogenital tumours xenografted into 
nude mice became infected by type C particles expressing MLV antigens171. Type 
C particles were also found in 1 out of 20 human tumours passaged through 
mice. The positive tumour was an oat cell carcinoma and the induction of C type 
particles was attributed by the authors to (unknown) factors produced by these 
carcinoma cells172. 
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1.4.1.2 Horizontal spread of XMLV infection 
XMLV infected cells have the potential to horizontally infect other cell lines used 
in the same tissue culture laboratory173. Spread of XMLV from small cell lung 
carcinoma (SCLC) N417 cells to non-xenografts has been reported174. In a screen 
for XMLV, Hue et al175 reported 9 out of 411 cancer cell lines to be positive for 
the virus. Another study176 identified 3 XMLV positive cell lines out of 58 
commonly used for cancer drug research. Of these the prostate cancer cell lines 
LAPC-4 and VCaP were positive for XMLV (Bxv1) and a non-small cell lung 
carcinoma (NSCLC) cell line, EKVX was infected with DG75 XMLV. Unidentified 
XMLV has also been found in a number of non xenografted melanoma cell lines 
Sk Mel28, Sk Mel25, Mel Juso and MML-1177. Other non xenografted cell lines 
infected with XMLV include A2780 (ovarian cancer cell line), BHY (Squamous cell 
carcinoma), COCM1 (colon cancer), Daudi (Burkitt’s lymphoma cell line), IMR-5 
(Neuroblastoma), MUTZ-1 Myeloid leukaemia175 and Jurkat J6178. In addition 
Zhang et al173 found that XMLV can spread horizontally from xenografted cells to 
other cell lines maintained in the same lab facility. They found that 13 out of 78 
cells lines (17%) treated in the same tissue culture laboratory in which 
xenografts were used were positive for XMLV. In contrast all 50 cultures treated 
in a xenograft free laboratory were free from XMLV contamination. Thus 
contamination of different cell lines with XMLV has been studied retrospectively 
and in vitro spread cannot be excluded. There is no recent prospective study 
however, showing the likelihood of acquiring XMLV in vivo and this may be a 
reason why contamination of xenografts by XMLV has been overlooked as a 
potential confounding factor by most scientists using xenograft models179,180.  
1.4.2 Retroviral insertional mutagenesis 
Retroviral integration is also very important for oncogenesis 181. Retroviruses 
exert their oncogenic action by disrupting host gene expression or coding 
sequences182. Targets for retroviral insertional mutagenesis (RIM) include proto-
oncogenes, tumour suppressor genes and oncogenic miRNAs15. Where and how 
the provirus integrates can determine the mechanism by which it can alter host 
gene function15. Different retroviruses prefer different integration sites. For 
example HIV-1 preferentially inserts within the active genes183 whereas MLV 
integration is biased towards transcriptional start sites. Avian sarcoma leukosis 
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virus, in contrast shows a weak preference for active genes but no preference 
for transcription start sites184. The integration preference of MLV effectively may 
increase the likelihood of effects on adjacent genes. For example X-linked 
severe combined immunodeficiency (X-SCID) is a genetic disorder where lack of 
c gene in children results in immune deficiency185. X-SCID is treated by bone 
marrow transplant186, an attempt to treat X-SCID by MLV vector based gene 
therapy was initially successful but later resulted in the development of 
leukaemia due to insertional mutagenesis187,188. RIM can result in a selective 
advantage to the cells and subsequent clonal outgrowth. Clonal tumours share 
the same viral insertion sites whereas polyclonal tumours have multiple 
insertions at different sites. The insertion sites which are common in polyclonal 
tumours may mediate the initiation and progression of the tumour, while 
subsequent insertions may further aid tumour growth and selection116. For 
efficient oncogenesis, a retrovirus cannot be strongly cytopathic and must be 
capable of overcoming the barriers to super-infection created by the resident 
virus15. 
 
1.4.2.1 Change in cellular behaviour secondary to XMRV infection 
XMRV has been studied to a greater extent as compared to XMLV for its effects 
on cellular behaviour due to its initially reported association with human 
diseases. Since XMRV shares 93% sequence similarity with Bxv1 XMLV (described 
earlier) and both use XPR1 for cell entry, the effects of both viruses on cell 
behaviour will also be discussed here.  
LNCaP, PC3 and 22Rv1 are prostate cancer cell lines used as models for prostate 
cancer research. 22Rv1 is now believed to have acquired XMRV infection as a 
result of repeated passaging in mice and is known to produce high titres of 
infectious XMRV151. 22Rv1 with higher XMRV expression is invasive in vitro. 
Suppression of XMRV expression not only results in reduced invasiveness in vitro 
but also results in reduced angiogenesis and increased necrosis of primary tissue 
xenografts. It appears that the properties of 22Rv1 xenografts with respect to 
migration, invasion and angiogenesis are to some extent dependent on continued 
XMRV expression189.  
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1.4.2.2 Changes in cellular behaviour following XMLV infection 
The XMLV Env protein has been reported to affect tumourigenic properties in 
LNCaP cells. Infection of the LNCaP prostate cancer cell line with XMLV resulted 
in release of a factor that reduces vascular smooth muscle differentiation 
making the tumour more haemorrhagic190. The medium from XMLV infected 
LNCaP cells was also reported to down regulate expression of markers associated 
with the differentiation of vascular smooth muscle cells in vitro, smooth muscle 
cells treated with conditioned medium showed an increase in migration across a 
membrane in vitro190. Conditioned medium from XMLV infected LNCaP cells was 
also reported to induce an increase in tube formation in human umbilical 
endothelial cells in Matrigel in vitro190. 
 
1.4.2.3 Changes in cellular behaviour due to other retroviruses 
Several murine leukaemia viruses have cytopathic or cytotoxic effects on animal 
cells191. Some retroviruses such as avian haemangioma retrovirus, mouse 
mammary tumour virus, spleen focus forming virus and the Jaagsiekte sheep 
retrovirus exert oncogenic transformation via their envelope proteins192–195. The 
MLV envelope protein, in contrast induces spongiform degeneration of nervous 
tissue196 and the glycoprotein precursor, apoptosis in mink cells197.  
 
1.5 Aims of the study 
1.5.1 To conduct a prospective study of the risks of acquiring 
XMLV infection in human cancer xenografts.  
Although human cancer xenografts have been reported to acquire infection 
with murine retroviruses, the extent of this risk to routine experiments was 
unknown and the factors affecting the likelihood of infection (cell lines, 
mouse strain) were poorly understood.  
1.5.2 To investigate the susceptibility of human cells to FeLV and 
XMLV in vitro. 
While human cell express receptors that facilitate entry of murine and feline 
gammaretroviruses, a systematic study of the susceptibility of primary cells 
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and established cell lines of different tissue origin has not previously been 
reported. 
1.5.3 To investigate the mechanisms of resistance of human cells 
to FeLV and XMLV.  
While some of the known retroviral restriction factors have been reported to 
affect murine retroviruses replicating in human cells, no information was 
available for feline leukaemia viruses although human exposure in the 
domestic environment is more likely with these agents. In particular, the 
susceptibility of FeLV to human APOBEC cytidine deaminases was not 
previously explored. These factors are likely to be relevant to the risks of 
cross-species infection with FeLV. 
1.5.4 To examine the significance of XMLV infection for human 
xenograft behaviour.  
If infection of human cancer xenografts with XMLV occurs at any significant 
frequency, the effects of infection on cell behaviour must be considered. 
Apart from the obvious risk of insertional mutagenesis, little was known 
about other chronic infection on human cell behaviour, the effects of XMLV 
infection in two susceptible human cancer cell lines was therefore explored 
at the transcriptome level by gene expression microarray analysis. 
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2 Materials and methods  
2.1 Materials 
2.1.1 Cell culture 
2.1.1.1 Cell lines and media 
2.1.1.1.1  MCF7 cells 
A human mammary adenocarcinoma cell line derived from the pleural effusion of 
a 69 year old Caucasian female who underwent a mastectomy198. MCF7 cells are 
epithelial cells in morphology and express oestrogen receptors199. During 
experiments, two sources of MCF7 cells were used, one was gifted by Karen 
Blyth (Beatson Laboratories, Glasgow) and the other by Anne Terry (Molecular 
Oncology Laboratory, University of Glasgow). Media requirements: MEM 
(10370047 Gibco) containing 10% FCS (HyClone, Perbio), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco), 
0.01mg/ml Insulin (I9278 Sigma, 10mg/ml) and 1mM Sodium pyruvate (11360 
Gibco). 
2.1.1.1.2 DERSE (Detectors of exogenous retroviral sequence elements) cells 
DERSE cells are indicator cells. They were developed at the National Cancer 
Institute by transfection of pBabe.iGFP-puro into LNCaP cells. The pBabe.iGFP-
puro is an MLV vector. It encodes puromycin resistance and a cytomegalovirus 
(CMV) promoter driven Green Fluorescent Protein (GFP) reporter gene which is 
interrupted by an intron. After infection and mobilization by a gammaretrovirus, 
the intron interrupted GFP gene is expressed in the second round of infection. 
The cells were a gift from Dr Kyeong Eun Lee and Vineet Kewal Ramani. Media 
requirements: RPMI 1640 (21875 Gibco) supplemented with 10% FCS (HyClone, 
Perbio), 100ug/ml Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 
Gibco), Puromycin (P9620 Sigma) selection at 1μg/ml medium.  
2.1.1.1.3  CEM cells 
Human T lymphoblastoid cell line derived from the peripheral buffy coat of a 4-
year-old Caucasian female with acute lymphoblastic leukaemia200. CEM cells are 
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T lymphoblasts in morphology. Media requirements: RPMI 1640 (21875 Gibco) 
supplemented with 10% FCS (HyClone, Perbio), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.4  CEMSS cells  
A subline derived from CEM cells201 which does not express APOBEC3G and is 
therefore susceptible to Vif-negative HIV-186. CEMSS cells were a kind gift from 
Michael Malim. Media requirements: RPMI 1640 (21875 Gibco) supplemented with 
10% FCS (HyClone, Perbio), 100μg/ml Penicillin/Streptomycin (15140 Gibco), 
2mM Glutamine (25030 Gibco). 
2.1.1.1.5  Kyo1 cells 
Philadelphia chromosome t(9;22) positive human leukaemia cells established 
from the peripheral blood of a 22-year-old Japanese man with chronic myeloid 
leukaemia (CML) in myeloid blast crisis in 1981202. Kyo1 cells are 
undifferentiated myeloid cells and can differentiate into erythroid and 
monocytic lineages202. Media requirements: RPMI 1640 (21875 Gibco) 
supplemented with 10% FCS (HyClone, Perbio), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.6  K562 cells 
Human leukaemia cell line (Philadelphia chromosome t(9;22) positive) derived 
from pleural effusion of a 53 year-old woman chronic myeloid leukaemia (CML) 
in blast crisis 203. They are multipotent cells and can differentiate into erythroid, 
monocytic and granulocytic lineages203,204. Media requirements: RPMI 1640 
(21875 Gibco) supplemented with 10% FCS (HyClone, Perbio), 100μg/ml Penicillin 
/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.7  U937 cells 
Human histiocytic lymphoblastoid cell line derived from pleural fluid from a 37 
year-old man with generalised diffuse histiocytic lymphoma205. U937 are 
monocytes in morphology. Media requirements: RPMI 1640 (21875 Gibco) 
supplemented with 10% FCS (HyClone, Perbio), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
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2.1.1.1.8  Jurkat cells 
Human acute T cell leukaemia cell line E61 clone206. Jurkat cells are T 
lymphoblasts in morphology. Media requirements: RPMI 1640 (21875 Gibco) 
supplemented with 10% FCS (HyClone, Perbio), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.9  Reh cells 
Reh cell line is derived from acute lymphoblastic leukaemia (non-T; non-B)207. 
Reh cells are lymphoblast cells in morphology, and may represent pre-B 
lymphoblasts208. Media requirements: RPMI 1640 (21875) supplemented with 10% 
FCS (HyClone, Perbio), 0.05mM 2-mercaptoethanol (Sigma M7522), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.10 THP-1 cells 
A human leukemic cell line derived from the blood of a boy with acute 
monocytic leukaemia (AML-5)209. THP-1 cells are monocytes in morphology. THP-
1 can be differentiated into macrophages using Phorbol 12-myristate 13-acetate 
(PMA), Retinoic acid, or 1-25 dihydroxy vitamin D3210–212. THP-1 cells were gifted 
by Anne Terry (Molecular Oncology Laboratory, University of Glasgow). Media 
requirements: RPMI 1640 (21875) supplemented with 10% FCS (HyClone, Perbio), 
0.05mM 2-mercaptoethanol (Sigma M7522), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.11 293 cells 
293 cells are human embryonic kidney cells transformed by Adenovirus213 The 
293 cells are epithelial cells in morphology. 293T cells were derived from 293 
cells and express the simian virus 40 (SV40) large T antigen. They are resistant 
to neomycin. Both 293 and 293T are used interchangeably. Media requirements: 
DMEM (31966 Gibco) supplemented with 10% FCS (HyClone, Perbio), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.12 MDA MB 231 cells 
Human breast adenocarcinoma cell line derived from the pleural effusion of a 51 
year old Caucasian female214. MDA MB 231 cells are epithelial cells in 
morphology. They express epidermal growth factor receptor (EGFR) and 
transforming growth factor receptor alpha (TGF alpha)215. Media requirements: 
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DMEM (31966 Gibco) supplemented with 10% FCS (HyClone, Perbio), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.13 QN10 cells 
S+L- feline embryonic fibroblast cells obtained from Oswald Jarrett, University 
of Glasgow. They are used to titre FeLV. Media requirements: DMEM (42430 
Gibco) supplemented with 10% FCS (HyClone, Perbio), and 1mM Sodium pyruvate 
(11360 Gibco) 100μg/ml Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine 
(25030 Gibco). 
2.1.1.1.14 AH927 cells 
AH927 cells are a feline embryonic fibroblast cell line. Media requirements: 
DMEM (31885 Gibco) supplemented with 10% FCS (HyClone, Perbio), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.1.15 Raji cells 
B lymphocyte cell line derived from Burkitt’s lymphoma. Raji cells were gifted 
by Karen McAulay (LRF virus centre, University of Glasgow). Media requirements: 
RPMI 1640 (21875 Gibco) supplemented with 10% FCS (HyClone, Perbio), 
100μg/ml Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco). 
 
2.1.1.2  Primary cells and media 
2.1.1.2.1 CD34+ human cord stem cells 
Human CD34+ cord blood cells are hematopoietic stem cells. They are primary 
undifferentiated cells having the ability to differentiate into different 
hematopoietic lineages216. Human cord blood CD34+ cells were gifted by Anna 
Kilbey (University of Glasgow). Media requirements: Stem Span medium (Stem 
cell technologies) supplemented with FGF-1 10ng/ml (Miltenyi), SCF 20ng/ml 
(Miltenyi), TPO 10ng/ml (Miltenyi), IGF BP2 100ng/ml (Miltenyi), ANGPTL5 
500ng/ml (Miltenyi), Heparin 10μg/ml (Sigma), 100μg/ml Penicillin/Streptomycin 
(15140 Gibco), 2mM Glutamine (25030 Gibco). 
2.1.1.2.2 Peripheral blood mononuclear cells (PBMCs) 
PBMCs comprise mononucleated cells e.g. lymphocytes (i.e. both T and B 
lymphocytes and Natural killer cells), monocytes and dendritic cells. The PBMCs 
were obtained in two batches; the first from Cambridge Bioscience and the 
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second from the University of Glasgow Transfusion service. The cells were spun 
at 100g for 10 minutes. The cells were then plated at a density of 1x106cells/ml 
in RPMI (21875 Gibco) supplemented with 10% FCS (HyClone, Perbio), 100μg/ml 
Penicillin/Streptomycin (15140 Gibco), 2mM Glutamine (25030 Gibco), 5μg/ml 
PHA (Sigma) and 200units/ml human IL2 (Peprotech) for 3 days at 37oC and 
5%CO2. On Day 3, the cells were washed in RPMI and were further grown in RPMI 
supplemented with 200 units/ml IL2 or were frozen in 10% DMSO with 90% FCS 
(HyClone, Perbio). 
2.1.1.2.3 Primary human childhood leukaemia cancer cells  
Primary human childhood leukaemia cancer cells were donated by Pamela 
Kearns (University of Birmingham). They were grown in RPMI (21875 Gibco) 
supplemented with 10% FCS, IL3 (MACS 130-093-908), 100ng/ml, IL7 (MACS 130-
093-937) 100ng/ml, IL10 (MACS 130-093-947) 100ng/ml and FLT3L 100ng/ml 
(Peprotech). 
 
2.1.1.3 Viruses  
Xenotropic murine leukaemia virus (XMLV) rescued from BALB/c mice. 
FeLV molecular Clone (pFGB). 
FeLV B wild-type (PENHF) and gycoGag mutant (PENHFX). 
 
2.1.2 Chemically competent bacteria 
E. coli One-shot TOP10: (Invitrogen). Genotype: F- mcrA Δ (mrr-hsdRMS-mcrBC) 
Φ80 lacZΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG.  
2.1.3 Commercial kits 
2x Power SYBR green RT PCR kit (4368702, Applied Biosciences) 
2x Reddy mix PCR master mix (AB 0575, Thermo) 
DNeasy blood and tissue kit (69506, Qiagen) 
ECL western blotting detection reagents (Amersham Biosciences) 
EndoFree plasmid maxi kit (12362, Qiagen) 
Lipofectamine transfection kit (Invitrogen) stored at 4oC 
Pfu Ultra II Hotstart PCR master mix (600850, Agilent technologies) 
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QIAprep Spin Miniprep kit (27104, Qiagen) 
QIAquick gel extraction kit (28704, Qiagen) 
QIAquick PCR purification kit (28704, Qiagen) 
QuantiTect reverse transcription kit (205310, Qiagen) 
Quick ligation kit (M2200S, New England Biolabs)  
Reverse transcriptase kit (Qiagen) 
RNeasy mini kit (74104, Qiagen) 
Topo TA cloning kit (K4575-J10, Invitrogen) 
 
2.1.4 Buffers, solutions and reagents  
10x TBST (Tris buffered saline tween) buffer solution: 0.1M Tris base, 1.5M NaCl, 
0.5% Tween-20, pH 8.0. 
1M Tris HCl: 121g Tris base, 800ml dH2O. Adjust pH with concentrated HCl and 
made up to 1L. 
20x NuPAGE MOPS SDS running buffer: Available commercially. Make 1x solution 
for use. 
20x SSC buffer: 3M NaCl in 0.3M sodium citrate (pH 7.0). 
50x TAE (Tris-acetate-EDTA) buffer solution: 2 M Tris base, 50mM Na2EDTA, 1M 
glacial acetic acid. 
Ammonium persulphate: 10% (w/v) stock solution in dH2O, freshly made. 
DNA loading buffer: 30% glycerol, 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol, in dH2O. Stored at room temperature and used at a 1:5 dilution. 
Ethidium bromide: Working solution 3mg/ml. Stored at room temperature in the 
dark. 
NuPAGE blot transfer buffer: For one gel, 20ml of 20x NuPAGE transfer buffer, 
40ml methanol and 0.4ml NuPAGE antioxidant was added to a final volume of 
400ml dH2O. To prepare transfer buffer for two gels transferred simultaneously, 
add 20ml of 20x NuPAGE transfer buffer, 80ml methanol and 0.4ml NuPAGE 
antioxidant in a final volume of 400ml in dH2O. 
NuPAGE top tank buffer: Add 500μl of NuPAGE antioxidant to 200ml of 1x 
NuPAGE MOPS SDS buffer. 
NuPAGE reducing agent (Life Technologies). 
Phosphate buffered saline (PBS): 140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 
1.8mM KH2PO4 (pH 7.3).  
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Protein loading buffer: I added 5μl NuPAGE LDS sample buffer (4x, Life 
Technologies) and 2μl NuPAGE reducing agent (10x) to samples in a 20μl final 
volume. I then heated the samples at 70oC for 10 minutes before loading. 
Stripping solution: 20ml 2M glycine pH 2.5, 20ml 10% SDS to 160ml dH20.  
Taqman lysis buffer (TLB): Tris HCl pH 8 (20mM), IGEPAL (0.9%), Tween 20 
(0.9%), dH2O.  
TE buffer: 10mM Tris-HCl, 1mM Na2EDTA pH 8.0 
Whole cell lysis buffer: Hepes pH7 (20mM), EDTA (5mM), EGTA (10mM), NaF 
(5mM), DTT (1mM), KCL (0.4M), Triton-X-100 (0.4%), Glycerol (10%), dH2O, 
Okadeic acid 0.1μg/ml (Merck), Pepstatin A 5μg/ml (Sigma), Leupeptin 5μg/ml 
(Sigma), PMSF Phenyl methane sulfonyl fluoride 50μg/ml (Sigma), Benzamidine 
1mM (Sigma), Aprotinin 5μg/ml (Sigma).  
Biorad protein dye reagent: for protein estimation (Bio Rad, USA). 
Matrigel: for preparation of cells for xenografting (354230 Becton Dickinson, 
Europe)  
Rapid-hyb buffer: for use with radiolabelled probes (GE Healthcare Amersham) 
RNaseZap: RNase decontamination solution (AM9780, Life technologies).  
Trypsin-EDTA (Invitrogen) 0.5% 1x liquid, stored at –20oC. 
Ultra pure X-Gal (Invitrogen) stored as solid at –20oC.  
LB based agar medium powder (fas-s, InvivoGen). 
LB (Luria Bertani) medium: 20g of LB powder (Sigma) was added and mixed with 
1 litre of water until a uniform solution was formed. 200ml was aliquoted into 
glass bottles and autoclaved at 121oC for 15 minutes and stored at 4oC. 200μl 
(100mg/ml) ampicillin was added to 200ml before use. 
SOC media: 2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4, and 20mM glucose (Invitrogen, UK).  
Water soluble oestrogen: (E4389-100MG Sigma). 
 
2.1.5 Enzymes 
Antarctic phosphatase enzyme (M0289S, NEB) 
BamHI restriction enzyme (R3136S, NEB) 
EcoRI restriction enzyme (Invitrogen) 
EcoRV restriction enzyme (Promega) 
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2.1.6 Antibiotics 
Puromycin (Sigma), stored as 5mg/ml solution at –20oC.  
Ampicillin (Sigma) 100mg/ml stored at –20oC. 
 
2.1.7 Antibodies 
Mouse anti-human HLA-ABC antibody (BD 560965/FITC). 
APC mouse anti-human CD54 antibody (559771, BD Biosciences).  
Mouse monoclonal antibody VPG19.1 against FeLV p27Gag and also Pr65Gag 
precursor protein. VPG19.1 was gifted by Brian Willett, University of Glasgow.  
Goat anti-mouse IgG antibody with HRP conjugated to it (P0260, DAKO UK Ltd).  
Rat IgG monoclonal antibody R187 against p30Gag capsid (CA) polypeptide of MLV 
and also Pr65Gag precursor protein217. R187 was gifted by Sam Wilson, University 
of Glasgow.  
Anti-rat IgG antibody with HRP conjugated to it (A9037-1ML, Sigma). 
APC mouse IgG1 antibody (555751, BD Biosciences) used as an isotype control. 
 
2.2 Methods 
2.2.1  Infecting cells with virus 
2.2.1.1 Infecting cancer cell lines with virus 
The source of FeLV B for infection was supernatant from FeLV B infected AH927 
cells (unless specified). The source of XMLV (Bxv1/BALB/c origin) was 
supernatant from MCF7 cells infected with XMLV (unless specified). Wild-type 
and glycoGag mutant FeLV B Plasmids (PENHF and PENHFX) were used to 
transfect 293T cells (described later). These 293T cells transfected with PENHF 
and PENHFX FeLV B were the source of normal and glycoGag mutant FeLV B for 
glycoGag experiments. Viral infections were carried out by growing the virus 
producing cells (MCF7 or 293T or AH927 cells) at 2x105/ml medium in a T25 flask 
and taking off the supernatant after 48 hours of culture and using filtered 
(0.45m) supernatant to infect fresh cells. Fresh medium was added after 2 
hours of infection and cells were grown for at least 14 days (unless specified) 
before extracting DNA. Pellets were made and stored in -80oC freezer. 
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2.2.1.2 Infecting human CD 34+ cells 
To infect human CD34+ cord blood stem cells, 4 wells in a 24 well plate were 
coated with retronectin and left at 4oC overnight. On the next day the 
retronectin was completely drained off using a pipette tip. Then 0.9ml of fresh 
filtered (0.45μm filter) virus containing supernatant was added to each well. The 
plate was then spun for 60 minutes at 4oC at speed of 2000g in an Eppendorf 
centrifuge. The viral supernatant was removed and 0.5ml of fresh viral 
supernatant was added to each well and spun again at 2000g for 60 minutes at 
4oC. CD34+ cells suspended in 0.5ml cell span medium with 2x cytokines were 
added to each well supplemented with 8μg/ml polybrene and incubated at 37oC 
for 7 hours. After 7 hours, the medium was removed (cells adherent to 
retronectin) and replenished with 0.5ml fresh cell span medium with 1x 
cytokines (as described earlier) and incubated overnight at 37oC with 5% CO2. On 
the next day, 0.5ml fresh filtered (0.45μm) viral supernatant with 1x cytokines 
was added and left for 6 hours at 37oC. Medium was transferred into a 15ml 
Falcon tube. The wells were rinsed with PBS and added to Falcon tubes. 0.5ml of 
dissociation buffer was added to each well and left for 2-3 minutes, then added 
to Falcon tubes. The wells were then rinsed twice with 1ml fresh cell span 
medium and transferred to Falcon tubes. The volume in each Falcon tube was 
then made up to 9ml and spun at 1000 rpm with no brakes for 5 minutes. The 
cells were resuspended in 0.5ml cell span with cytokines. The cells were 
incubated for 40 hours, then harvested and pellets made for DNA extraction with 
a DNeasy blood and tissue kit (Qiagen) according to the manufacturer’s 
instructions. Standard PCR was carried out using appropriate primers and 
thermal cycling conditions given in the Appendix 1.  
 
2.2.1.3 Infecting PBMCs 
To infect PHA treated PBMCs, 1x106 cells were suspended in filtered (0.45μm) 
virus supernatant (FeLV B molecular clone, XMLV, PENHF and PENHFX FeLV B) 
and incubated for 6 hours at 37oC and 5% CO2. The PBMCs were then washed in 
RPMI and grown in RPMI with 200 units/ml human IL2 for 2 weeks at 37oC and 5% 
CO2. 2ml cell supernatant was harvested at Days 3, 7, 10 and 14 and 
immediately frozen in dry ice and stored at -80oC. Cell supernatant at Day 14 
was titrated on QN10 cells as described later. Cell supernatant was also used to 
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infect MCF7 cells. XMLV supernatant was titrated on MCF7 cells as described 
later. The PBMCs were harvested at Day 14 and cells pellets made for DNA and 
RNA extraction using appropriate kits as described later. Standard PCR was 
carried out using appropriate primers and thermal cycling conditions given in 
Appendix 1. 
 
2.2.2 Confirmation of virus infection 
2.2.2.1 DERSE assay 
3x104 cells/ml were seeded in 6 well plates (2ml per well). After 72 hours, 
supernatant was removed from the DERSE cells and replaced with 100μl virus 
supernatant (virus dilutions for FeLV B and XMLV) and 300μl fresh medium. 0.5ml 
of medium was added after one hour. The whole medium was replaced the 
following day with fresh medium (2ml). GFP expression was monitored every 3-4 
days for a total period of 3 weeks using fluorescence microscope. 
 
2.2.2.2 Standard PCR 
Standard PCR was carried out using Reddy mix (AB 0575 Thermo) according to 
manufacturer’s instructions. A G-Storm Thermal Cycler was used for cycling. 
Agarose gel (16500-500 Invitrogen) electrophoresis carried out with ethidium 
bromide used to stain the gel. Different sets of primers used to detect and 
confirm viral infection along with the thermal cycling conditions are given in 
Appendix 1. 
 
2.2.3 Virus titration 
2.2.3.1 QN10 assay 
QN10 cells S+L- feline embryonic fibroblast cells were used as an assay to titrate 
FeLV. FeLV-producing cells were plated at a density of 2x105/ml in a T25 flask 
(Corning). QN10 cells were counted and plated at 2x105/plate in 4ml medium in 
gridded plates. These were incubated at 37oC overnight. The next day serial 
dilutions of cell free viral supernatant were prepared in medium supplemented 
with 4μg/ml polybrene. Medium was removed from the plates and replaced with 
1ml of virus dilutions. Plates were returned to the incubator and shaken every 15 
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minutes for 2 hours. After 2 hours virus supernatant was removed and cells were 
fed with 4ml fresh medium. Foci were counted on Day 7-10 to calculate the virus 
titre. 
 
2.2.3.2 Serial dilutions/infection of susceptible cells and PCR 
For viruses which could not titrated on QN10 cells, serial dilution and infection 
of susceptible cells was used as an alternative option. The viral supernatant was 
filtered using a 0.45μm filter and then serially diluted in suitable medium. The 
dilutions were then used to infect a susceptible cell line (MCF7 or 293T). DNA 
extraction was carried out using a Qiagen DNeasy blood and tissue kit as 
described earlier. Standard PCR using the primers for virus detection were used 
(given in Appendix 1). 
 
2.2.4 Xenografting human cells into mice 
Female BALB/c mice nude mice were obtained from Charles River. In one 
experiment they were fed on oral oestrogen (E4389-100MG Sigma, 1μg/ml) 
treated drinking water for at least a week before inoculations were performed. 
MCF7 cells (5x106 cells) suspended in 50μl Matrigel (354230/BD) were inoculated 
into the BALB/c nude mice. Both subcutaneous and intramammary xenograting 
was carried out. In another experiment, slow release oestrogen pellet (SE-121 
Innovative research of America) was implanted subcutaneously into BALB/c and 
NSG mice one day prior to MCF7 intramammary xenografting. The NSG mice 
were also obtained from Charles River UK Ltd (Margate), and bred locally in the 
Veterinary Research Facility, University of Glasgow. 
THP-1 cells (106 cells) suspended in 100μl PBS were inoculated IV via the tail vein 
into NSG mice (24 hour after 1Gy radiation) and into BALB/c nude mice. 
Raji cells (106 cells) suspended in 100μl PBS were xenografted subcutaneously 
into BALB/c mice. All animal experimentation was carried out with appropriate 
ethical approval and a Home Office licence. 
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2.2.4.1 Processing post-xenografted cells 
Cells derived from tumour masses in the liver and mouse blood cells following 
xenotransplantation were harvested. These cells, which contained a mixture of 
human (THP-1) cells and contaminating mouse cells, were grown in in RPMI 1640 
supplemented with 0.05mM 2-mercaptoethanol (Sigma M7522). Once they 
started growing, cell pellets were made for DNA and checked by PCR (G-Storm). 
Meanwhile, filtered supernatant from THP-1 primary tumour cells was used to 
infect 293T cells. These cells were checked for the presence of XMLV using 
primers for env173.  
MCF7 primary tumour cells were grown in MEM medium for 4 weeks. Once they 
started growing, flow cytometry (BD Accuri C6) and FACS (BD FACSAria) were 
carried out using mouse anti-human HLA-ABC antibodies (560965/FITC ) to 
detect the percentage of human cells in the explant cells and to sort the human 
MCF7 cells from the mouse cells. Filtered supernatant from the post xenografted 
MCF7 cells was used to infect fresh MCF7 cells. These cells were checked for the 
presence of XMLV using primers for XMRV gag and XMLV env173. Spleen DNA from 
BALB/c nude mice was used as a positive control. Filtered blood plasma was 
used to infect MCF7 cells which were later checked for XMLV infection by PCR. 
Blood was also grown in MEM medium to let any MCF7 cells grow out in culture.  
Post xenografted primary human childhood leukaemia cancer cells were donated 
by Pamela Kearns (University of Birmingham). These were grown in tissue 
culture (as described above) and supernatant was used to infect 293T cells. DNA 
was made from the infected 293T cells and checked for XMLV.  
 
2.2.5 Molecular biology 
2.2.5.1  DNA and RNA extraction from cells 
DNA extraction was carried out using a DNeasy kit (69506 Qiagen). All DNA 
extraction work was carried out at the bench in the Molecular Oncology main 
laboratory. The surfaces were cleaned before and after DNA extraction and 
special care (e.g. changing gloves and using filtered pipette tips) were taken to 
avoid cross contamination between samples.  
DNA extraction was carried out according to manufacturer’s instructions. Cells 
(up to 106) were suspended in 200μl PBS. 20μl proteinase K (0.15mg/ml) was 
then added, followed by the addition of 4μl RNase. The cell suspension was 
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vortexed and left for 2 minutes at room temperature. 200μl of lysis buffer (AL) 
supplied in the kit was then added and the cell lysate vortexed and incubated at 
56oC for 10 minutes. Then 200μl of 100% ethanol was added and the whole 
mixture vortexed. The mixture was then pipetted into a DNeasy mini spin 
column (supplied with the kit) and centrifuged for 1 minute at 8000 rpm. The 
flow through was discarded. The column was then washed using buffer AW1 and 
then buffer AW2. Finally DNA was eluted using buffer AE into a clean Eppendorf 
tube. Quantification was carried out using a Nanodrop spectrophotometer 
(Thermo Scientific). The DNA was used for PCR and stored at 4oC. 
To carry out PCR directly from cells, Taqman Lysis buffer (TLB) was used. Cells 
were pelleted by spinning at 6000 rpm for 2 minutes. The supernatant was 
removed and the cell pellet stored at -20oC or lysis carried out immediately in 
TLB buffer. For lysis, the cell pellet was suspended in 10μl TLB with proteinase K 
(10mg/ml). The suspension was incubated for 1 hour at 55oC and heated at 95oC 
for 10 minutes to inactivate proteinase K. The cell lysate was used directly as a 
template for standard PCR reaction at 2μl/reaction.  
RNA extraction was carried out using an RNeasy mini kit (74104 Qiagen). All the 
surfaces and pipettes were wiped with RNaseZap, an RNase decontamination 
solution (Life Technologies, AM9780). RNase free pipette tips and Eppendorfs 
were used throughout.  
RNA was extracted according to the manufacturer’s instructions. A cell pellet 
(maximum of 107 cells) was lysed using 350-600μl of lysis buffer (RLT) supplied 
with the kit. One volume of 70% ethanol was added to the lysate and vortexed. 
The lysate was then transferred into RNeasy mini spin column and spun at 8000 
rpm for 15 seconds. This was followed by serial washes with buffer RW1 and 
buffer RPE, provided with the kit. Finally the RNA was eluted in RNase free 
water. Quantification was carried out using a Nanodrop spectrophotometer 
(Thermo Scientific) and Agilent 2100 Bioanalyzer. The RNA was stored at -20oC. 
 cDNA was made from 1g RNA using a Quantitect RT kit (205311, Qiagen).  
 
2.2.5.2 DNA extraction from animal tissue (spin column protocol) 
A DNeasy kit (69506 Qiagen) was used to extract DNA from animal tissues, 
including mouse tail tissue according to manufacturer’s instructions as follows: 
25mg tissue (10mg spleen) was cut into small pieces, ground down in liquid 
nitrogen and placed in a 1.5ml micro centrifuge tube. 180µl buffer ATL and 20µl 
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proteinase K were added and mixed thoroughly by vortexing, then incubated at 
56oC until the tissue was completely lysed, vortexing occasionally during the 
incubation period to disperse the sample. Lysis usually took place within 1-3 
hours. If the lysate appeared gelatinous then either the incubation period was 
extended or the amount of proteinase K was increased to 40µl, ensuring the 
sample was completely submerged in buffer containing proteinase K. RNase A 
(100mg/ml) was added, vortexed and incubated at room temperature for 2 
minutes (liver and kidney have high levels of RNA while rodent tails have low 
levels). 200μl buffer AL was added to the sample and mixed thoroughly by 
vortexing, then 200μl ethanol (100%) was added and mixed again to produce a 
white precipitate. Extracted DNA was pipetted into a DNeasy mini spin column, 
placed in a 2ml collection tube and centrifuged at 8000 rpm for 1 minute. The 
mini spin column was placed in a new 2ml collection tube and 500µl buffer AW1 
was added (provided in the kit) and spun for 1 minute at 8000 rpm. The mini 
spin column was placed in a new 2ml collection tube, 500µl buffer AW2 added 
and centrifuged at 14000 rpm to dry the DNeasy membrane. The mini spin 
column was placed in clean 1.5ml microcentrifuge tube and 200μl buffer AE 
pipetted directly onto the DNeasy membrane. The sample was incubated at 
room temperature for 1 minute and then spun for 1 minute at 8000 rpm. This 
procedure was repeated to increase yield. The DNA was quantified using a 
Nanodrop spectrophotometer (Thermo Scientific) and stored at 4oC.  
2.2.5.3 cDNA synthesis  
cDNA synthesis was carried out using a Qiagen reverse transcriptase kit (205311, 
Qiagen) according to manufacturer’s instructions. The template RNA was thawed 
on ice. gDNA wipe-out buffer, Quantiscript reverse transcriptase enzyme and 
Quantiscript RT buffer (provided with the kit), RT primer mix and RNase free 
water were thawed at room temperature, centrifuged and stored on ice. Each 
DNA elimination reaction was prepared by adding 7 x gDNA wipe-out buffer, 1µg 
RNA, and water to make a total volume of 14µl and incubated for 2 minutes at 
42oC. To prepare the reverse transcription mix, 1µl Quantiscript reverse 
transcriptase enzyme was added to 4µl Quantiscript RT buffer, 1µl RT primer, 
and all of the DNA elimination reaction (14µl) and incubated at 42oC for 15 
minutes. The Quantiscript reverse transcriptase enzyme was inactivated by 
incubating at 95oC. The cDNA was stored at -20oC after adding the 20µl reaction 
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to 380µl PCR grade water (DEPC) and aliquoted 100µl into 0.5ml tubes at a 
concentration of 2.5ng/µl cDNA. 
2.2.5.4 Southern blotting 
Day 1  
20µg of DNA was digested with 100 units of appropriate restriction enzyme in 
suitable buffer. The final volume was always less than 300µl. The samples were 
mixed gently so as not to damage the DNA and were incubated at 37oC 
overnight. 
Day 2 
The digests were vortexed and incubated again for 2 hours at 37oC. DNA was 
then precipitated by adding a half volume of 7.5M NH4OAC and two volumes of 
ethanol e.g. to a 300µl digest, 150µl NH4OAC and 900µl ethanol were added. The 
precipitate next was vortexed to mix. The digests were left for 20 minutes to 
precipitate and then the tubes were spun for 10 minutes at 13000 rpm in a 
microcentrifuge. The supernatant was then removed and the DNA pellet was air 
dried. The pellet was then resuspended overnight in 35µl TE buffer at 37oC.  
Day 3 
Resuspended digests were mixed and kept at 37oC. A 200ml 0.8% agarose TAE gel 
was then prepared and the gel was then poured into a cast with an appropriate 
comb. After the gel set, it was placed in the buffer tank in 1x TAE buffer. 
Loading dye was added to the samples to a final 1x concentration and a short 
vortexing followed by spinning was carried out. One or two lanes of markers (2µg 
λ HindIII and 500cpm/minute labelled λ HindIII markers, water and loading dye) 
were prepared. The samples were then loaded on the gel with markers in the 
outer lanes. An overnight electrophoresis was carried out at 22V. 
Day 4 
The gel was allowed to run until the bromophenol dye reached 2/3rd of the gel’s 
length. The gel was then stained with ethidium bromide and visualised under a 
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UV transilluminator. DNA appeared as a continuous smear with no defined bands. 
The gel area above the wells, outside the markers and the bottom of the gel was 
cut and discarded. One of the corners of the gel was marked for orientation 
purposes. The gel dimensions were also measured. The gel was then placed in 
denaturation buffer for 30 minutes. The gel was next transferred into 
neutralisation buffer for 30 minutes. Meanwhile, two pieces of Whatman blotting 
paper were cut according to the gel size. One piece of Hybond N hybridisation 
membrane was also cut of the same size. One corner of the membrane was 
labelled with a pen for orientation purposes. A platform was prepared in a Pyrex 
dish containing 20x SSC buffer. The gel was placed facing down on 3 sheets of 
Whatman blotting paper wet with 20x SSC. Then Hybond N membrane was 
placed on top of the gel and all air bubbles were removed. Two pieces of 
Whatman blotting paper wet with 20x SSC buffer were placed on top of the gel 
and all air bubbles were removed. The area around the gel was covered and 
paper towels were placed at the top to draw 20x SSC via the gel and the 
membrane. A paperweight was placed on the top and the blot was left 
overnight. 
Day 5 
The capillary suction setup for the blot was dismantled the next day. The 
Hybond N membrane was then placed facing up on a dry piece of Whatman 
blotting paper. The DNA on the membrane was bonded by putting the membrane 
in Stratalinker set to work at optimal crosslink. The membrane was then stored 
in a dry place or was used for hybridisation using a suitable probe. 
Probing the blot 
The hybridisation oven was pre-warmed to 65oC and 10-15ml aliquot of Rapid-
hyb buffer was heated. The Hybond N membrane was then made wet with 2x SSC 
buffer and placed in a hybridisation bottle. The excessive 2x SSC was poured 
away and replaced with warm Rapid-hyb buffer. It was then allowed to rotate 
slowly in the hybridisation oven at a rotation speed of 5-6 for 20 minutes. The 
probes were labelled in a supervised radiation room. DNA probe was labelled 
with 32P-dCTP according to the manufacturer’s protocol. The labelled probe 
fragment was purified by passing it through a NICK Column as described in the 
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protocol. The labelled probes were heated at 95-100oC for 5 minutes and then 
chilled rapidly on ice. 2x105-1x106 cpm/ml of probe was added to filter in the 
bottle avoiding direct contact with the filter. These were then mixed in the oven 
at a speed of 5-6 for 1-2 hours at 65oC. The probe was poured off down a 
suitable radiation sink. The membrane was then rinsed with 2x SSC and poured 
off without letting the membrane dry at any point. The pre-warmed wash buffer 
0.1x SSC & 0.5% SDS was filled to 1/3rd the length of bottle. The bottle was then 
allowed to rotate in the oven at full speed for 20 minutes. The membrane was 
removed using 2x SSC and rinsed in 2x SSC. Keeping the membrane damp, it was 
transferred to a fold of transparent plastic. The plastic was sealed with heat 
after removing any liquid. The membrane was applied to a film and placed it in 
a cassette overnight. The corner of the film was cut to match that of the blot to 
allow orientation.  
2.2.5.5 Western blotting 
Lysate preparation 
The cell pellet was first thawed on ice and then resuspended in 100μl lysis buffer 
per 106 cells. The lysates were then rotated for 10 minutes at 4oC. After this, the 
lysates were spun for 30 minutes at a speed of 13000 rpm at 4oC in a centrifuge. 
The supernatant was then removed into precooled 1.5μl tubes and the protein 
concentration was then determined. The lysates were stored at -80oC.  
Protein estimation 
To prepare a standard protein curve, a range of increasing BSA protein 
concentrations was prepared in water. Biorad protein dye reagent was diluted 
1:5 in dH2O and filtered through 1mm Whatman paper. Standard BSA protein 
solution (20μl) was then mixed with 1000μl of dye reagent in a plastic cuvette 
and read at OD 595nm against a water-blank in a plastic cuvette. The graph was 
plotted with OD 595nm on the Y-axis and protein concentration on the X-axis. To 
estimate the protein concentration of the lysates, 2μl of lysate and 18μl of dH2O 
were added to a plastic cuvette along with 1000μl of protein dye reagent and 
was read as above. The protein concentration of samples were read directly 
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from the graph and multiplied by 10 (dilution factor) to get the actual protein 
concentration.  
Preparing and running protein gels 
800ml of 1x NuPAGE MOPS SDS running buffer was made from 20x stock. To make 
top tank buffer, 500μl of NuPAGE antioxidant was added to 200ml of 1x NuPAGE 
MOPS SDS buffer. 5μl NuPAGE LDS sample buffer (4x) and 2μl NuPAGE reducing 
agent (10x) were added to samples in a 20μl final volume. The samples were 
then heated at 70oC for 10 minutes.  
At the same time, the gel pouch was cut open and packaging buffer was poured 
away. The gel was rinsed with ionised water. The tape at the bottom of gel 
cassette was peeled off. The comb from the gel was then gently removed in a 
single movement. The wells were then rinsed with 1x running buffer and then I 
filled with top tank buffer removing any bubbles present. The buffer core was 
placed in the tank with electrodes on opposite sides. The unlocked tension 
wedge in the tanks was put behind the buffer core. The gel cassettes were then 
put in the tank on either sides of the buffer core with wells facing each other. In 
case of running one gel, buffer dam was used and was placed opposite to the 
gel. The gel was locked by pulling the lever on tension wedge. The top tank 
buffer was then poured in between the two gels and was checked for any 
leakage. Next the samples were loaded into the wells. Then 600ml 1x running 
buffer was poured into lower tank through the gap in the tension wedge. The lid 
on the tank then placed in its position. The gel was run at 200V for 50 minutes or 
until the dye front reached the bottom of the gel.  
Protein transfer 
400ml of 1x NuPAGE transfer buffer was prepared according to manufacturer’s 
instructions. The Hybond ECL and 2 pieces of Whatman blotting paper were cut 
into 8.7cm x 7.7cm size for each gel. Blotting pads and Hybond ECL were soaked 
in 1x transfer buffer. The gel cassettes were removed from the buffer tank. The 
plates were split apart using a gel knife. The wells were then removed from the 
gel. A soaked Whatman blotting paper was placed on the gel and any bubbles 
removed. The gel was removed from the cassette and a soaked Hybond ECL was 
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placed on gel and the soaked Whatman blotting paper on top of it. All bubbles 
were removed. The gel sandwich was then put in a Blot Module in between pre-
soaked blotting pads. The blotting module was then placed in a buffer tank and 
the tension wedge was locked. The transfer buffer was then poured into Blot 
Module to cover the gel-membrane sandwich. The outer chamber was filled with 
650ml deionised water. The process of transfer was carried out at 30V for one 
hour.  
Protein detection 
The blot was blocked overnight in 5% milk in TBST buffer at 4oC and then washed 
for 10 minutes thrice with 1x TBST. After washing, the blot was incubated with 
primary antibody diluted in 5% milk in TBST. The blot was then washed for 10 
minutes thrice with 1x TBST. The blot was then incubated with secondary 
antibody diluted in 5% milk in TBST. The blot was then washed again for 10 
minutes thrice with 1x TBST. ECL detection solution (Thermo Scientific) was 
used according to manufacturer’s instructions to detect proteins on the blot. 
The blots were evenly coated with the ECL solution and incubated for 4 minutes. 
The blot was then wrapped in Saran wrap and exposed to 18 × 24 cm Hyperfilm 
ECL (28-9068-36, Amersham) for 2 minutes. The film was then developed and 
assessed for intensity of the band. Longer exposures were carried out if needed.  
2.2.5.6 XMLV and FeLV B proof reading PCR for sequencing  
DNA made from MCF7 cells infected with XMLV was used as template for 
sequencing XMLV. Forward and reverse primers were designed based on N417 
XMLV accession number HQ246218 and are given in Appendix 1. DNA made from 
cell lines and primary cells infected with FeLV B was used as template for 
sequencing FeLV B pol region. The primers used to amplify FELV B pol region are 
given in Appendix 1.  
Pfu Ultra II Hotstart PCR master mix (600850, Agilent technologies) was used 
according to manufacturer’s instructions to amplify the DNA. The thermal 
cycling conditions are given in the Appendix 1. A Reddy mix PCR step to add A-
overhangs to the amplified PCR product followed this. To add A-overhangs, 5μl 
of Pfu PCR reaction, 7.5μl of distilled water, and 12.5μl Reddy Mix were added 
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together and this was heated for 10 minutes at 72oC. After this, the product was 
purified using QIAquick PCR purification kit (Qiagen, 28704). 
2.2.5.7 PCR product purification 
PCR product purification was carried out using a QIAquick PCR purification kit 
(Qiagen, 28704). PCR product purification was carried out according to the 
manufacturer’s instructions. 5 volumes of buffer PB were added to 1 volume of 
PCR reaction mix. The mixture was then transferred to a QIAquick column and 
washed with buffer PE. Finally the DNA was eluted in buffer EB (10mM Tris.Cl, 
pH 8.5) or water. It could then be used for cloning purposes. 
2.2.5.8 Preparation of agar plates 
One sachet of LB based agar medium powder (fas-s, InvivoGen) was put into a 
conical flask and 200ml of water was added to it. It was then heated in 
microwave for 3 minutes. After cooling to room temperature, 200l (100mg/ml) 
ampicillin was added and left for a few minutes to get rid of bubbles. It was 
then poured gently into 10cm2 petri dishes. The petri dishes were kept slightly 
open for some time to let the agar set. Dishes were stored for up to two weeks 
at 4oC before use. Before use 40l of 40mg/ml X-Gal in DMF 
(dimethylformamide) was added and spread with a spreader. 
2.2.5.9 Transformation and cloning 
Transformation was carried out using One Shot Top-10 chemically competent E. 
coli (C4040-10, Invitrogen). The PCR product to be cloned was ligated using a TA 
Topo cloning kit (k4575-j10, Invitrogen). 1μl of salt solution was added to 4μl of 
purified PCR product with A-overhangs (A-overhangs were added to PCR product 
by carrying out an extra Reddy Mix PCR step at 72oC for 12 minutes) and 
incubating it at room temperature for 5 minutes. 2μl of this was added to 
chemically competent E. coli without pipetting and then it was incubated for 10 
minutes on ice. The E. coli cells were heat shocked at 42oC for 30 seconds 
without shaking and then immediately transferred to ice. 250μl of SOC solution 
was then added to the tube containing E. coli and the tube was shaken 
horizontally at 200 rpm at 37oC for 1 hour. 10 and 50μl of the transformation mix 
was then transferred onto pre-warmed X-Gal coated agar plates (20μl of SOC was 
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used to spread the 10μl transformation mix) and incubated at 37oC overnight. 
The next day, the plates were examined for any white colonies (blue colonies 
were discarded). 
All the white colonies in the petri dish were marked and a number was assigned 
to each of them. A master plate was made from a fresh X-Gal coated agar plate. 
Slots for the number of white colonies that were going to be selected were made 
on the master plate. Each white colony was touched with a plastic loop and 
transferred to a slot on the master plate. Then the loop was dipped into LB 
medium in a bijou (2ml LB medium per Bijou). The same process was repeated 
with all white colonies. The master plate was kept inverted in an incubator at 
37oC overnight. The Bijou was kept in a shaker at 37oC 200 rpm overnight. On 
the next day plasmid extraction was carried out. 
2.2.5.10  Plasmid extraction (Miniprep) 
For small scale plasmid extraction, a QIAprep Spin Miniprep kit (Qiagen, 27104) 
was used. Plasmid extraction was carried out according to manufacturer’s 
instructions. The bacteria grown overnight were pelleted by centrifugation at 
8000 rpm for 3 minutes at room temperature. The bacterial pellet was then 
resuspended in buffer P1 and transferred to a microcentrifuge tube. Buffer P2 
was then added and mixed by inverting 4-6 times. Buffer N3 was then added and 
mixed thoroughly by inverting 4-6 times. Buffer P1, P2 and N3 were provided 
with the kit. The lysate was centrifuged for 10 minutes and the supernatant 
carefully removed. The supernatant was then applied to a QIAprep spin column 
and washed with buffer PB and buffer PE. The plasmid DNA was then eluted in 
buffer EB or water. Quantification was carried out using Nanodrop. The plasmids 
were then digested with EcoRI enzyme (15202013, Invitrogen) and run on an 
agarose gel. The gel was then imaged using a UV transilluminator. The 
appropriate plasmids were then sent to Source Bioscience for sequencing. 
Sequence data was analysed using CLC Genomics 5 software. 
 
2.2.5.11 Plasmid extraction (Maxiprep) 
For endotoxin-free large-scale plasmid extraction, an EndoFree plasmid Maxi kit 
(Qiagen, 12362) was used. Plasmid extraction was carried out according to 
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manufacturer’s instructions. The overnight LB culture was centrifuged at 6000g 
for 15 minutes at 4oC. The pellet was then resuspended in 10ml buffer P1. 10ml 
buffer P2 was then added and the mixture incubated at room temperature for 5 
minutes. 10ml of chilled buffer P3 was then added and the whole lysate was 
transferred into the barrel of a QIAfilter Cartridge and incubated for 10 minutes. 
The lysate was then filtered through the QIAfilter Cartridge using a plunger. 
2.5ml of buffer ER was then added to the filtrate and incubated on ice for 30 
minutes. The filtered lysate was then applied on a Qiagen-tip 500 and allowed to 
empty by gravity flow. The Qiagen-tip 500 was equilibrated with 10ml buffer 
QBT prior to adding the lysate. Qiagen-tip 500 was then washed twice with 
buffer QC. The DNA was then eluted with buffer QN in an endotoxin free tube. 
The DNA was then precipitated by adding 10.5ml isopropanol and centrifuged at 
15000g for 30 minutes at 4oC. The supernatant was then decanted carefully. The 
DNA pellet was then washed with 5ml of endotoxin free 70% ethanol and 
centrifuged at 15000g for 10 minutes. The supernatant was then decanted and 
the pellet air dried for 5-10 minutes. The DNA was then dissolved in 200μl of 
buffer TE. The quantification was carried out using a Nanodrop. The plasmid 
could then be used for transfection. 
2.2.5.12 Restriction factor expression analysis 
Expression analysis of different restriction factors was carried out by qRT-PCR 
(described ahead). Expression of the following restriction factors was carried 
out: APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, 
Tetherin, TRIM5, and SAMHD1. Restriction factor expression analysis was 
carried out for the following cell lines and primary cells: 293, CEM, CEMSS, THP-
1, PBMC, Reh, Raji and Kyo1 cells. The primers assays used for qRT-PCR were 
ordered from Qiagen and are shown in Table 2.1. 
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Table 2.1 qRT-PCR assays for expression of restriction factors 
Primer assay Catalogue no. 
 APOBEC3A QT00042763 
 APOBEC3B QT00040733 
 APOBEC3C QT00058198 
 APOBEC3D QT00044639 
 APOBEC3F QT00045262 
 APOBEC 3G QT00070770 
 SAMHD1 QT00084322 
 BST2 
(TETHERIN) QT00019663 
 TRIM5 QT01028125 
 
Table 2.1 showing the qRT-PCR assays used to determine the expression of different 
restriction factors. 
2.2.5.13 Validation of microarray data 
The validation was carried out by qRT-PCR as described ahead. The primers 
assays used for qRT-PCR validation were ordered from Qiagen and are shown in 
Table 2.2.  
Table 2.2 qRT-PCR assays for microarray validation 
Primer assay Catalogue no. 
 CCL4 QT01008070  
 EGR1  QT00218505 
 TSPAN2 QT00046480 
 PCOLCE2 QT00003479  
 IL7R QT00053634 
 SLC30A4 QT00031255 
 IFI44 QT00014399   
 CCNB1 QT00006615 
 
Table 2.2 showing the qRT-PCR assays used to validate the microarray data. 
2.2.5.14 XPR1 expression analysis 
XPR1 expression analysis was carried out for the following cell lines and primary 
cells: CEM, CEMSS, Kyo1, Jurkat, Reh, K562, 293, PBMC, MCF7, THP-1, and 
mouse cells (negative control). Human XPR1 QuantiTect primer assay 
(QT01882741, Qiagen) was used for this analysis was carried out by qRT-PCR as 
described below. 
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2.2.5.15 Real Time PCR 
Real time PCR was carried out using SYBR Green (1112324, Applied Biosciences) 
on a 7500 ABI RT PCR system. Anne Terry assisted in some Real Time PCR 
experiments. All primers were ordered from the Qiagen. Each primer was diluted 
in DEPC water to make a 6μM 10x master stock. The forward and the reverse 
primers were then mixed in 1:1 to make a 5x primer mix. To get a final 0.6μM 
(1x) concentration, 5μl of this primer mix was used per 25μl of reaction. 100ng 
cDNA was used for each reaction. Human genomic DNA (4ng/μl) was used as a 
“no amplification control”. Water was used as a “no template control”. Human 
HPRT primers were used as endogenous control primers. A plate map was used 
to plan sample position on the plate. Each sample was plated in triplicate. 
Standard cycling conditions were used with an additional dissociation stage. 
Results were analysed on 7500 system software.  
2.2.5.16  Gel electrophoresis and UV imaging 
PCR products and digested DNA were analysed by running on agarose gel by 
electrophoresis. A 1% agarose gel was made by adding ultrapure agarose powder 
(16500-500, Invitrogen) in 1x TAE buffer. This was then heated until the agarose 
melted completely. Then 10μl ethidium bromide (10mg/ml) was added. It was 
then poured into appropriate sized casts with comb. Once the gel was set, it was 
then placed in tanks containing 1x TAE buffer. Samples were mixed with 10x 
loading dye. An appropriate size ladder (100bp or 1kb) was also loaded beside 
the samples on the gel. Gel electrophoresis was carried out for an hour at 
110V/75mA. The gel was then visualised using a UV transilluminator (Syngene Bio 
imaging, Cambridge) and a digital image was recorded. If needed, the DNA bands 
were excised and extracted. 
2.2.5.17 Gel extraction 
Gel extraction was carried out using a QIAquick gel extraction kit (Qiagen, 
28704). Gel extraction was carried out according to manufacturer’s instructions. 
After cutting the selected bands on an agarose gel with a clean sharp scalpel 
under UV light, the slice was weighed and then 3 volumes of buffer QG was 
added. It was then incubated at 50oC for 10 minutes or until the gel became 
completely dissolved with constant vortexing after 2-3 minutes. Then 1 volume 
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isopropanol was added and mixed. The whole mixture was then transferred to a 
QIAquick column and washed with buffer QG and buffer PE according to 
manufacturer’s instructions. Finally the DNA was eluted in water or buffer EB 
(provided with the kit). 
 
2.2.5.18 Designing the XMLV probe for southern blotting 
A probe was designed to carry out southern blot of XMLV infected cells. The 
primers used for the probe along with the thermal cycling conditions are given in 
the Appendix 1. The PCR product was purified using PCR purification kit 
according to manufacturer’s instructions as described earlier. The cleaned PCR 
product was run on a 1% agarose gel and visualised under a UV transilluminator 
to confirm the appropriate size of the probe. The probe was stored at -20oC. 
 
2.2.5.19 GlycoGag sequencing  
Primers were designed on the basis of the FeLV B gag sequence and are given in 
Appendix 1. Plasmids for wild-type (PENHF) and glycoGag mutant FeLV B 
(PENHFX) were sent to Source BioScience for sequencing. 
 
2.2.5.20 Mycoplasma detection 
Primers used to detect Mycoplasma by PCR are given in Appendix 1. The 
Mycoplasma status was also confirmed by a commercial kit, Venor-Gen (Minerva 
Biolabs). 
 
2.2.5.21 XMLV env cloning  
2.2.5.21.1 Designing primers  
Primers were designed with and without restriction sites to amplify XMLV env. 
The primers are given in the Appendix 1. 
2.2.5.21.2 XMLV env amplification by nested PCR  
Pfu Ultra II Hotstart PCR master mix (Agilent technologies, 600850) was used 
according to manufacturer’s instructions to amplify XMLV env from XMLV 
infected MCF7 cell DNA. In the first round of nested PCR, the primers without 
restriction enzyme site (F4 and R1) were used. The thermal cycling conditions 
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are given in the Appendix 1. 1μl PCR product from the first round was used in 
the 2nd round of nested PCR. The primers used in the 2nd round were F4-BamHI 
and R1-SalI. The same cycling conditions were used for the 2nd round as well.  
After adding A-overhangs to the PCR product from the 2nd round, PCR 
purification using a QIAquick PCR purification kit, ligation using a TA Topo 
cloning kit and transformation of One Shot E. coli was carried out as described 
earlier. Plasmid extraction was also carried out using a QIAprep Spin Miniprep kit 
(Qiagen, 27104) as described earlier.  
2.2.5.21.3 Digestion of plasmids 
The plasmid DNA was digested using BamHI restriction enzyme (NEB, R3136S). 
5μg of plasmid DNA was incubated with 1μl of BamHI enzyme and 2μl of 10x 
Cutsmart buffer for 1 hour at 37oC. In a similar fashion, 5μg pBabe vector was 
also digested with 1μl of BamHI enzyme.  
2.2.5.21.4 Phosphatase treatment  
The digested pBabe vector (5g) was treated with 1μl of Antarctic phosphatase 
enzyme (M0289S, NEB) to prevent spontaneous re-ligation of cut ends. 
Incubation was carried out at 37oC for 15 minutes. To inactivate the enzyme, it 
was then heated for 5 minutes at 65oC. 
2.2.5.21.5 Ligation of XMLV env and pBabe vector 
PCR purified and BamHI digested XMLV env (50ng) insert was ligated with 
phosphatase treated pBabe vector (64ng) using a T4 DNA ligase enzyme (NEB, 
M2200S) kit according to manufacturer’s instructions. The incubation was carried 
out for 5 minutes at room temperature. The ligation mix was then used directly 
for transforming One Shot chemically competent E. coli as described earlier. The 
plasmid extraction was carried out using a QIAprep Spin Miniprep kit (Qiagen, 
27104) as described earlier. The plasmid was digested with EcoRI and run on 
agarose gel to check the size of insert. To determine the orientation of the 
insert, plasmid was sent to Source BioScience for sequencing.  
2.2.5.21.6 Transfection of 293T cells 
293T cells were transfected using a Lipofectamine Transfection Reagent kit 
(Invitrogen, 18324-012). First of all, 6g DNA plasmid (to be transfected) was 
diluted in 300l serum free medium. Then the PLUS reagent (provided in the kit) 
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was vortexed and 48l of it was added to the diluted DNA. This DNA mixture was 
vortexed and then incubated at room temperature for 15 minutes. 12l 
Lipofectamine reagent (provided in kit) was diluted in 300l serum free medium 
and then vortexed. The pre-complexed DNA mixture and the diluted 
lipofectamine were combined and vortexed and then incubated at room 
temperature for 15 minutes. Then 2.4ml serum free medium was added per 
transfection mix and the entire contents transferred to a 60mm dish of cells 
(media removed). The cells were incubated for 3 hours after which 3ml fresh 
media containing 2x FCS was added to it. On the Day 3 (72 hours later) the cells 
were split in 1:10. The cells were kept growing for at least 14 days. DNA was 
then extracted to be checked by PCR for successful transfection. 
 
2.2.5.22 Specific infectivity XMLV and FeLV B 
CEM, CEMSS, Kyo1, THP-1, Reh and 293T cells were infected with XMLV multiple 
times to saturate the cells. The supernatant was used to prepare the virus pellet 
and also to titrate onto 293T cells. Cell pellets were prepared for protein, DNA 
and RNA analysis. 
CEM, CEMSS, Kyo1, THP-1, Reh, AH927 cells were infected with FeLV B multiple 
times to saturate the cells. The supernatant was used to prepare the virus pellet 
and also to titrate on QN10 cells. Cell pellets for protein, DNA and RNA analysis 
were prepared. 
Kyo1 cells were infected with PENHF and PENHFX (wild-type and glycoGag 
mutant FeLV B respectively) multiple times to saturate the cells. The 
supernatant was used to obtain the virus pellet and also to titrate on QN10 cells. 
Cell pellets were prepared for protein, DNA and RNA analysis.  
 
2.2.5.23 Wound assay  
MCF7 cells (both infected and non-infected) were seeded (at 1x106 cells/well) in 
a 6 well plate and were grown to confluence. A wound was made with a pipette 
tip, washed with PBS and fresh medium added. The cells were grown for another 
three days and serial images were taken at regular intervals using Leica camera 
and software. The wound size was measured using Image J and a graph was 
plotted using Microsoft Excel. 
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2.2.5.24 Ficoll separation of viable cells 
The cells were spun and resuspended in 5ml of medium. The cells were layered 
very slowly and gently, on to 5ml Ficoll (Sigma) so that the two layers were 
separated with an interface. The mixture was then spun for 10 minutes at 
3000rpm (brakes at 5). The viable cells formed a white granular layer at the 
interface of the medium and Ficoll layers. The viable cells were carefully 
removed with a pipette while holding the tube with the interface at eye level. 
The viable cells were washed twice with 10ml of medium by spinning at 1000 
rpm for 5 minute to remove Ficoll. The cell pellet consisting of viable cells was 
obtained. The cells were resuspended in fresh medium, were counted and then 
plated. 
 
2.2.5.25 Flow cytometry and fluorescence activated cell sorting (FACS) 
Flow cytometry and FACS were carried out using BD Accuri C6 flow cytometer 
and BD FACSAria cell sorter respectively. Adherent cells were harvested using 
trypsin and it was ensured that cells were separated from each other by 
pipetting them up and down several times. This was followed by three washes 
(three cycles of spinning and re-suspension in 0.1% BSA +PBS). BSA was prepared 
on the same day and was chilled by keeping in the fridge for at least an hour 
before use. 1x107cells/ml were suspended using PBS+0.1% BSA and 50μl 
(5x105cells) and was put into flow cytometry/ FACS tubes (Falcon 12mm x 75mm 
tubes). 1μl Fc block antibody was added per tube in order to prevent non-
specific binding. Cells were incubated with this antibody for 10-15 minutes in 
the fridge in the dark. The specific antibody (e.g. anti HLA-antibody) was then 
added to the samples without any washes and incubated in the dark in the fridge 
for 30 minutes. The cells were washed twice using 0.1% BSA +PBS. Finally they 
were resuspended in 0.5ml 0.1%BSA+PBS and strained using a 70m strainer (BD 
70m Strain) into a fresh tube on ice. The rack was then wrapped in foil and 
placed in the fridge to do flow cytometry in 3 hours. Non-antibody control 
sample and an isotype antibody control samples were also prepared. In case of 
FACS, collection tubes (15ml Falcon with 5ml medium) were prepared and kept 
on ice. Approx. 2.5 x 105 cells were collected (takes 15min) into the collection 
tube. Sorted cells were grown in T25 flask in 5ml warm medium and kept at 37oC 
and 5%CO2 in a tissue culture incubator.  
  68 
 
 
2.2.5.26 Single cell cloning of MCF7 XMLV cells 
MCF7 single cell cloning was carried out by serial dilutions (Corning). MCF7 XMLV 
single cell suspension (1x105 cells/ml) was prepared. First the dispensing tray 
was filled with 12ml of conditioned medium (50% fresh medium and 50% 
conditioned medium from uninfected MCF7 cells) and then using an 8-channel 
pipette, 100l of medium was added to all the wells in 96 well plate except A1 
which is left empty. 200l of cell suspension was added to well A1. Using a single 
channel pipette, 100l was transferred from the first well to the second well 
(B1) and 1:2 dilutions were repeated down the entire column discarding 100l 
from the last well (H1). Using an 8–channel pipette 100l of fresh medium was 
transferred to each well in column 1. Then 100l from wells in the first column 
was transferred to the second and this was repeated for each column, discarding 
100l from each well in the last column (A12-H12). The final volume of each 
well was made up to 200l by adding fresh medium. The cells were incubated at 
37oC in 5% CO2. Wells with single cells were marked the next day and grown for 
10 days. Medium was replaced with conditioned medium after every 3-4 days. 
Cells were transferred to a 24 well plate after 10 days then subsequently to a 12 
well plate and were further expanded as required. DNA was extracted and 
southern blotting carried out. The pattern of XMLV insertion was observed and 
compared with the MCF7 XMLV from BALB/c mice.  
 
2.2.5.27 Affymetrix RNA expression Array  
MCF7 cells and Raji cells were grown in two sets of three T25 flasks at 2x105 
cells/ml. One set was infected with XMLV supernatant filtered with a 0.45m 
filter. Both sets were kept under the same conditions for 15 days after infection. 
DNA was made using a Qiagen DNeasy kit and the XMLV infection was confirmed 
by PCR. RNA was prepared using a Qiagen RNeasy kit according to 
manufacturer’s protocol. The concentration was measured by Nanodrop and 
Bioanalyzer. The RNA samples were analysed by Atlas Biolabs (Germany). 
Affymetrix Expression Profiling was carried out using GeneChip Human Gene 2.0 
ST Array. 
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2.2.5.28 Analysis of data 
Primer designing and alignment & analysis of sequence data was carried out 
using CLC Genomics Workbench 5 software. The National Centre for 
Biotechnology Information (NCBI) online Basic Local Alignment Search Tool 
(http://blast.ncbi.nlm.nih.gov/) was used to search the de novo rescued viral 
sequences for similarity. Phylogenetic trees were generated by the neighbour-
joining method with bootstrap analysis at 100 replicates using CLC Genomics 
Workbench 5 software. The Los Alamos National Laboratory online tool for 
hypermutation analysis218 was used to analyse hypermutations. The data for flow 
cytometry and FACS were analysed using CFlow Plus and FlowJo software 
respectively. Microsoft Excel was used to perform basic statistical data analysis. 
Image J was used to analyse wound size in wound assay and for western blot 
densitometry. Ingenuity Pathway Analysis online (IPA) was used to analyse gene 
expression data. 7500 ABI software was used to analyse RT PCR data. 
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3  Infection of human xenografts with XMLV 
 
3.1  Introduction 
The use of human-mouse xenografts is an important research tool in many fields 
of biological research219–221. While infection of human xenografts with murine 
retroviruses is a long-standing observation170,171, earlier experiments did not 
clearly demonstrate the risk of acquiring infection or the potential impact of 
these viruses as confounding factors. The recent emergence of XMRV as an 
apparent aetiological agent of several human diseases153,154,156,222–224 followed by 
discrediting of these claims with evidence that XMRV was a laboratory 
contaminant158, led to a renewed interest in the role of murine retroviruses as 
xenograft contaminants. A recent study reported that up to 23% of human cancer 
cell lines that have undergone xenografting in mice were found to be infected 
with XMLV but at the same time 17% of non-xenograft derived cell lines in the 
same laboratory facility were also infected. As cells maintained in a xenograft-
free laboratory facility were found to be uniformly free of XMLV, in vitro cross-
contamination appeared to be the major source203. I therefore decided to carry 
out a prospective study of XMLV generation using two different mouse strains 
commonly used for xenograft study models.  
The aim of the studies described in this chapter was to prospectively test 
whether xenografting human cancer cells into mice can lead to the infection of 
cancer cells by endogenous murine leukaemia viruses. A secondary aim was to 
test whether infection of xenografted cells is dependent on the type of cancer 
cells or the strain of mice used for xenografting. A further aim was to rescue and 
characterise any endogenous retrovirus that has infected cancer cell xenografts. 
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3.2 Materials and methods 
Materials and methods have been discussed in detail in Chapter 2. 
3.3 Results 
3.3.1 MCF7 cells xenografted into BALB/c mice become infected 
with XMLV 
To initiate my study on the risks of xenograft infection with endogenous murine 
retroviruses, I chose the MCF7 human breast cancer cell line which the host 
laboratory had previously shown was highly susceptible to infection with another 
gammaretrovirus, feline leukaemia virus (FeLV B). The chosen recipient strain 
was BALB/c as cells from this strain were shown in early studies to activate 
viruses with high efficiency in response to mitogen stimulation225 . Eight BALB/c 
nude mice were used for xenografting. The inoculations were carried out on my 
behalf and in my presence by Susan Mason (Beatson Laboratories). In the 
literature both intramammary and subcutaneous sites have been used for MCF7 
xenografting180,226. In my experiment MCF7 cells (5x106) were inoculated into the 
intramammary region in six out of the eight BALB/c mice, while the remaining 
two BALB/c mice received subcutaneous inoculations. In order to test whether 
oestrogen had any impact on xenografting, mice receiving subcutaneous 
inoculations were kept on oral oestrogen dissolved in drinking water, while the 
mice receiving intramammary inoculations did not receive oestrogen. Only one 
mouse (out of 8) developed a tumour. The tumour developed in one of the two 
mice that received inoculation in the subcutaneous region (kept on oral 
oestrogen). None of the mice that received the intramammary inoculations (kept 
on non-oestrogen diet) developed any tumour. The mouse with the tumour was 
culled on the 74th day. The size of tumour was 0.6cm at that time as shown in 
Figure 3.1. 
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Figure 3.1 MCF7 BALB/c tumour explant 
 
Figure 3.1 MCF7 tumour explant from a BALB/c mouse showing its size. 
The tumour explant cells were dissociated by finely dissecting with a scalpel 
blade. The cell suspension was washed with fresh MEM medium and grown in 
vitro in tissue culture incubator at 37oC. Cells were passaged every 5 days. Flow 
cytometry with mouse anti-human HLA-ABC antibodies (BD 560965/FITC) was 
carried out (as described in Chapter 2) after the 5th passage. The results are 
shown in the Figure 3.2. 
Figure 3.2 Flow cytometry of MCF7 explant cells 
 
Figure 3.2 Flow cytometry of MCF7 explant cells using mouse anti-human HLA-ABC 
antibodies to determine the percentage of cells of human origin. (a) MCF7 cells with no 
antibody. (b) MCF7 cells with HLA-ABC anti-human antibody. (c) MCF7 explant cells with no 
antibody. (d) MCF7 explant cells with HLA-ABC anti-human antibody. Flow cytometry 
analysis was carried out using CFlow Plus software. 
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Figure 3.2 shows that the flow cytometry results confirmed that more than 50% 
of the explanted cells were of human origin. The next step was to see whether 
or not the explant cultures produced replication competent viruses. The DERSE 
assay was used for this purpose. The DERSE assay is of general use for the 
detection of replication competent gammaretroviruses. DERSE cells contain a 
vector in which GFP expression is interrupted by an intron. If the vector is 
spliced and packaged by an incoming retrovirus it may be transferred to a 
bystander cell where it will express intact GFP. If DERSE cells are exposed to 
replication competent gammaretrovirus, the cells would produce foci of green 
fluorescence under the fluorescence microscope. In this experiment DERSE assay 
was performed using filtered (0.45μm) supernatant taken from the explant cells. 
On the 5th day, GFP-positive green cells were seen under the fluorescence 
microscope as shown in Figure 3.3b indicating that the explant cells were 
releasing a replication competent gammaretrovirus. 
Figure 3.3 DERSE assay for gammaretrovirus detection 
 
Figure 3.3 (a) DERSE cells exposed to filtered supernatant from uninfected MCF7 cells were 
used as a negative control. (b) DERSE cells infected with MCF7 explant supernatant. (c) 
DERSE cells infected with MCF7 FeLV B supernatant used as positive control.  
The DERSE assay was carried out in triplicate and repeated on three separate 
occasions. The DERSE assay revealed that MCF7 primary tumour explant cells 
were releasing a replication competent gammaretrovirus. As the MCF7 primary 
tumour cells were contaminated with mouse cells, and there are many 
endogenous mouse retrovirus sequences in the mouse genome, the virus could 
not be directly identified from the explant cells by PCR. The virus released from 
the explant cells needed to be isolated first by passage to uninfected human 
cells before further characterisation. Fresh MCF7 cells (1 x 106 cells) were 
infected with filtered MCF7 primary tumour explant supernatant (10th passage). 
The infected MCF7 cells were grown for 14 days and DNA was extracted. The 
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likely identity of this virus as XMLV was demonstrated by PCR with specific 
primers as shown in the Figure 3.4. 
Figure 3.4 PCR for detecting XMLV in BALB/c explants 
 
 
Figure 3.4 PCR using envelope primers specific for XMLV and gag primers specific for 
XMRV. Human GAPDH primers and mouse GAPDH primers were used as internal control for 
human and mouse DNA respectively. Non-infected MCF7 cells were used as a negative 
control. 
In Figure 3.4, MCF7 explanted cells were positive when tested with XMLV 
primers. The MCF7 cells exposed to explant supernatant were also positive for 
XMLV env primers showing that explanted tumour cells were producing an 
infectious XMLV-like virus. Mouse tissues were also positive for both XMRV and 
XMLV-related sequences as demonstrated by a positive signal in BALB/c spleen 
mouse DNA because these viral sequences are present in the mouse germline. 
The MCF7 explant contained mouse tissue, which explains the positive signal 
with XMRV gag and mouse GAPDH primers, but infectious XMRV was not present 
in the explanted cells.  
This experiment showed that naive MCF7 cells have been infected with an 
infectious virus related to XMLV that is released from MCF7 explant cells. 
The Figure 3.2 showed that the MCF7 explant cells contained a good proportion 
of mouse cells in addition to the human MCF7 cells. In order to see if the MCF7 
cells in the explant cells were infected with XMLV, fluorescence activated cell 
sorting (FACS) was carried out as described in Chapter 2 using anti-human HLA-
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ABC antibody (BD 560965/FITC) as shown in Figure 3.5(a-c) and cells were grown 
for two weeks after FACS. DNA from the post FACS MCF7 cells was analysed by 
PCR for the presence of XMLV infection and the presence of mouse cells (Figure 
3.5d). 
Figure 3.5 FACS sorting of MCF7 explant cells and PCR after FACS 
 
Figure 3.5 FACS carried out on MCF7 explant cells using mouse anti-human HLA-ABC 
antibodies to sort human cells. (a) MCF7 explant cells without antibody (b) MCF7 explant 
cells with HLA-ABC antibody (c) FACS redone on the sample collected in Figure 3.5b using 
HLA-ABC anti-human antibody to make sure the collected cells were of human origin. (d) 
PCR carried out on MCF7 explant cells after FACS using env primers specific for XMLV. 
Human GAPDH primers and mouse GAPDH primers were used as internal control for human 
and mouse DNA respectively. FACS analysis was carried out using FlowJo software. 
Figure 3.5 shows that MCF7 explant cells lost the mouse cells after FACS, but 
still retained the XMLV signal, showing that they were infected with XMLV. 
My host laboratory had not previously grown or worked with endogenous murine 
retroviruses and the next step was to identify and characterise the XMLV-like 
virus rescued from the MCF7 explant cells. For this purpose primers were 
designed on the basis of N417 (accession number HQ246218) viral genome 
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sequence information. Using these primers, segments of the virus were 
amplified, cloned and fully sequenced. The newly recovered virus was found to 
be 99.96% identical to the Bxv1 proviral locus, confirming its identity as XMLV. 
There were 3 base differences in the MCF7 explant compared to Bxv1. Two were 
G to A mutations and one was an A to G mutation. The first G to A mutation was 
at position 1781 (gag), the second was at 5731 in the pol region. The third 
mutation which was an A to G mutation was at position 5825 in the env region. 
The alignment of Bxv1 (accession no.AC115959.17) and BALB/c XMLV rescued 
from MCF7 explants is given in Appendix 2. 
BALB/c mice are known to carry locus for an inducible endogenous ecotropic 
murine leukaemia virus Emv1 on chromosome 5227. To rule out the possibility of 
Bxv1Emv1-pseudotype MLV virus228, MCF7 cells exposed to supernatant from the 
MCF7-BALB/c explants were also checked by PCR for the presence of Emv1 as 
shown in the Figure 3.6. 
Figure 3.6 PCR for Emv1 in cells exposed to MCF7-BALB/c explant supernatant 
 
Figure 3.6 PCR using two sets of primers specific for Emv1 env. Human and mouse GAPDH 
primers were used an internal control to detect human and mouse DNA. XMLV env primers 
were used to detect XMLV infection. MCF7 XMLV represents MCF7 cells exposed to MCF7-
BALB/c explant supernatant. 
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The MCF7 cells exposed to MCF7 BALB/c explant supernatant were free of Emv1 
virus, thus showing that the MCF7 explants were releasing only XMLV and not any 
Bxv1Emv1 pseudotype MLV virus. 
3.3.2 Primary childhood leukaemia cells passaged in NSG mice 
show no evidence of XMLV infection. 
The results above demonstrated that xenotransplanted cells can be infected 
with XMLV when passaged in BALB/c nude mice. NSG mice are now widely 
regarded as the strain of choice for the xenotransplantation and passage of 
leukemic cells due to their strong immune deficit and lack of rejection 165,229,230. 
To investigate whether human cells passaged through NSG mice become infected 
with XMLV, I examined primary childhood B cell acute lymphoblastic leukaemia 
(B-ALL) cells that were previously passaged extensively in NSG mice. The 
primary cell explants named B-ALL HB spleen and B-ALL CL spleens were grown 
in vitro for 10 days. Filtered (0.45μm) supernatant from the primary B-ALL was 
used to perform DERSE assay and also to infect 293Tcells (Both MCF7 and 293T 
cells are susceptible to XMLV as shown in Chapter 4). No evidence of infection 
was detected by DERSE assay. The DERSE assay was carried out in triplicate. PCR 
of 293T cells exposed to primary cells supernatant using primers specific for 
XMLV is shown in Figure 3.7. 
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Figure 3.7 PCR to detect XMLV in primary childhood leukaemia cells 
 
 
Figure 3.7 PCR using envelope primers specific for XMLV. Human GAPDH primers and 
mouse GAPDH primers were used as internal control for human and mouse DNA 
respectively. Uninfected 293T cells were used as a negative control for XMLV and mouse 
DNA. MCF7 XMLV was used as a positive control for XMLV.  
Figure 3.7 shows that both (HB spleen and CL spleen) explanted samples of 
primary B-ALL cells were positive for XMLV sequences. However, 293T cells 
exposed to the supernatant of these primary explants were negative for XMLV 
suggesting that the primary B-ALL explants were not producing infectious XMLV. 
As the primary explants were also positive for mouse GAPDH (indicating mouse 
tissue contamination) it was considered most likely that the positive XMLV signal 
was due to the presence of XMLV sequences in the mouse germline.  
3.3.3 THP-1 cells xenografted into NSG mice do not become 
infected with XMLV 
While I was unable to detect infectious XMLV in primary B-ALL xenograft 
samples, I had the opportunity to test whether THP-1 cells, an acute monocytic 
leukaemia cell line, would acquire XMLV infection when xenografted into NSG 
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mice. This experiment represented the control arm of another study in which 
the effect of FeLV infection on xenograft behaviour was being tested. THP-1 
cells were inoculated into NSG mice. Four mice were used for this experiment. 
All of the mice i.e. NSG6, NSG8, NSG9, NSG10 developed lumps in the liver 
region and were culled humanely at 71, 44, 47 and 50 days respectively. Tumour 
tissue was identified post mortem and liver nodules removed. One liver nodule 
from each mouse was finely chopped and plated in vitro in RPMI in tissue culture 
incubator. THP-1 explant cells began to grow out within 2-3 days in tissue 
culture. Filtered (0.45μm) supernatant of THP-1 explants (at passage 5 and 10) 
was used to perform the DERSE assay and passage 10 supernatant was used to 
infect 293T cells. No evidence of infection was detected by DERSE assay. PCR of 
293T cells exposed to THP-1 explants supernatant using primers specific for 
XMLV is shown in Figure 3.8. 
Figure 3.8 PCR to detect XMLV in NSG explants 
 
 
Figure 3.8 PCR using envelope primers specific for XMLV. Human GAPDH primers and 
mouse GAPDH primers were used as internal control for human and mouse DNA 
respectively. The uninfected 293T cells were used as negative control for XMLV and mouse 
DNA. MCF7 XMLV was used as positive control for XMLV. 
Figure 3.8 shows that all explanted samples of THP-1 cells (NSG6, 8, 9 & 10) are 
positive for XMLV sequences. But the 293T cells exposed to the supernatant of 
these THP-1 explants (293T NSG6, 8, 9 & 10) were negative for XMLV thus the 
THP-1 explants were not producing any infectious XMLV. All the THP-1 explants 
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were also positive for mouse GAPDH (indicating mouse tissue contamination), 
thus the positive XMLV signal appears to be due to the presence of murine DNA.  
THP-1 explant cells were also established from NSG6 and NSG10 mice blood. NSG 
mouse blood was washed in RMPI medium twice to remove any plasma and the 
blood cells were cultured in RPMI and incubated in a tissue culture incubator. 
THP-1 explant cells took 4 passages (20 days) to start appearing among the blood 
cells. These THP-1 blood explants were grown in tissue culture until the 10th 
passage. At the 10th passage, filtered (0.45μm) supernatant from THP-1 NSG6 
and NSG10 blood explants was used to perform the DERSE assay and also used to 
infect 293T cells. No evidence of infection was detected by the DERSE assay. 
Standard PCR of 293T cells exposed to THP-1 blood explant supernatant using 
primers specific for XMLV is shown in Figure 3.9. 
Figure 3.9 PCR for XMLV in NSG mouse blood 
 
 
Figure 3.9 PCR using envelope primers specific for XMLV. Human GAPDH primers and 
mouse GAPDH primers were used as internal control for human and mouse DNA 
respectively. Uninfected 293T cells were used as negative control for XMLV and mouse 
DNA. MCF7 XMLV was used as positive control for XMLV. 
Figure 3.9 shows that both blood explant samples of THP-1 cells (NSG6, 10) were 
positive for XMLV sequences. But the 293T cells exposed to the supernatant of 
these THP-1 explants (293T NSG6, 10) were negative for XMLV thus the THP-1 
blood explants did not produce any infectious XMLV. All the THP-1 explants were 
also positive for mouse GAPDH (indicating mouse tissue contamination), thus the 
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positive XMLV signal was likely due to the presence of XMLV sequences in the 
mouse germline.  
The next step was to test whether THP-1 cells xenografted into BALB/c nude 
mice would acquire any XMLV. For this purpose, THP-1 cells were inoculated via 
tail vein into BALB/c mice. Four mice were used for this experiment. The mice 
were observed for 16 weeks post-inoculation. None of the mice developed 
detectable tumours. So this experiment was inconclusive.  
3.3.4 The Bxv1 provirus is present in BALB/c and C57BL mice but 
not in NSG mice 
The results discussed above demonstrate that neither primary B-ALL nor THP-1 
cells acquired infectious XMLV following passage in NSG mice. It was conceivable 
that these cells are not susceptible to XMLV infection or that the NSG mice do 
not release any infectious virus when used for xenografting. An obvious question 
was whether Bxv1 locus, the probable major source of XMLV in BALB/c mice30,172, 
is present in NSG mice or not. This question could not be answered without 
experimental test because NSG mice have a breeding history that includes the 
Bxv1 positive C57BL strain231. To answer this question I generated primers which 
could specifically detect the Bxv1 locus but not other XMLV sequences present in 
the mouse genome. Primers based on the Mus musculus chromosome 1 
(accession no. AC115959) were used to amplify the junction between Bxv1 
provirus and the adjacent mouse genome (Figure 3.10b). The use of junctional 
primers to specifically identify Bxv1 has been previously validated by others22. 
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Figure 3.10 Analysis of Bxv1 provirus 
 
Figure 3.10 (a) PCR using Bxv1 primers specific for the Bxv1 locus in the mouse genome. 
Mouse GAPDH primers were used as internal control for mouse DNA. *Pamela Kearns B-
ALL HB spleen primary xenograft sample, ** Pamela Kearns B-ALL CL spleen primary 
xenograft sample. Naseer stands for NSG samples that I obtained from NSG mice (b) Bxv1 
provirus in Mus musculus chromosome1 showing the location of the junctional Bxv1 primer 
binding. 
Figure 3.10a shows that the C57BL and BALB/c mouse DNA samples were both 
positive for Bxv1 junctional primers demonstrating that the Bxv1 locus is present 
in both of these strains. The NSG samples I obtained and those received from 
Pamela Kearns were negative for Bxv1 junctional primers thus showing that the 
Bxv1 locus was not present in NSG mice. NSG mice presumably lost the Bxv1 
locus during repeated inbreeding with NOD/Shi-scid mice. These results show 
that the Bxv1 locus is present in BALB/c and C57BL mice and may be responsible 
for the acquisition of XMLV by xenografted cells. The absence of the Bxv1 locus 
in NSG mice may explain why XMLV was not detected in leukemic cells passaged 
through these mice. It is theoretically possible that other loci could produce 
infectious MLV but no replicating virus was detected in these experiments.  
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3.3.5 MCF7 cells do not get infected with XMLV when passaged in 
NSG mice but may acquire a non-replication competent 
defective virus 
In order to confirm my previous result and to explore the importance of the 
mouse strain in acquisition of XMLV infection, MCF7 cells were xenografted into 
four BALB/c and four NSG mice at intramammary sites. Though both the 
subcutaneous and intramammary site were used for xenografting in the earlier 
experiment involving BALB/c mice, tumour development was only seen in the 
mouse receiving a subcutaneous xenograft that also received oral oestrogen. In 
light of the importance of oestrogen for MCF7 xenograft development 232, I 
elected to use subcutaneous oestrogen pellets for all mice receiving xenografts. 
The intramammary site was used for MCF7 cell-xenografting as this site has been 
used successfully in many studies in combination with the use of oestrogen 
pellets180,233. Oestrogen pellets were inserted subcutaneously 1 day before 
xenografting.  
In this round of experiments all mice developed tumours in a very short time. All 
tumours were observed as isolated masses in the mammary region and were 
monitored for size. Mice were culled when the tumour mass reached 0.8-1 cm in 
size, which occurred from 10 to 25 days after xenografting. Each tumour tissue 
was separately extracted, finely diced to produce a single cell suspension and 
grown in MEM medium in vitro at 37oC and 5% CO2 in a tissue culture incubator. 
These MCF7 explants were established and grown in tissue culture until the 10th 
passage. At the 10th passage filtered (0.45μm) supernatant from MCF7 explants 
was used to infect fresh MCF7 cells.  
While XMLV env primers can detect XMLV by PCR with reasonable efficiency, the 
PCR product obtained using XMLV env was very small (70bp) and migrated on 
gels close to primer dimers. I therefore tested further primers to ensure 
sensitive and specific detection of MLV-related sequences in MCF7 cells exposed 
to the NSG explants. I was able to detect BALB/c XMLV (and also a defective 
virus from the NSG explants, described below) using both the XMLV env primers 
and XMLV-LTR primers and also with another set of primers (Fn3, Rn3) given in 
Appendix 1. As compared with XMLV env, the band was very clear with XMLV-LTR 
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primers (due to larger PCR product size) and easily distinguishable from primer 
dimers; for this reason I used LTR primers in this and subsequent experiments for 
detecting XMLV (Bxv1). PCR of MCF7 cells exposed to MCF7 explant (BALB/c and 
NSG) supernatant using XMLV-LTR primers is shown in Figure 3.11. 
 Figure 3.11a shows that MCF7 cells infected with BALB/c-4 supernatant were 
positive with the XMLV LTR primers, while the MCF7 cells exposed to 
supernatants from the BALB/c-1, 2 and 3 were negative for XMLV. All the MCF7 
cells exposed to BALB/c supernatants were negative for mouse DNA showing that 
positive XMLV signal for MCF7 cells exposed to BALB/c-4 supernatant was likely 
due to being infected with XMLV and not mouse DNA contamination. The Figure 
3.11b shows that when the supernatant from MCF7 cells previously exposed to 
BALB/c-4 explant supernatant were used to infect fresh MCF7 cells, the cells 
became infected with XMLV. This showed that the virus from the BALB/c-4 mice 
was replication competent. The virus from the BALB/c mice was sequenced and 
it was found to be virtually identical to the XMLV proviral locus Bxv1. 
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Figure 3.11 PCR for XMLV in NSG and BALB/c explants 
 
 Figure 3.11 PCR using LTR primers specific for XMLV. Human GAPDH primers and mouse GAPDH primers were used as internal control for human and 
mouse DNA respectively. (a) PCR of MCF7 cells exposed to MCF7 BALB/c explant (1-4) supernatant. (b) Secondary infection of MCF7 cells with supernatant 
from MCF7 cells previously exposed to BALB/c-4 explant supernatant, indicating that the virus was replication competent. (c) PCR of MCF7 cells exposed 
to MCF7 NSG explant (1-4) supernatant (passage 10). (d) PCR of MCF7 cells exposed to MCF7 NSG explant (1-4) supernatant (passage 12). (e) Secondary 
infection of MCF7 cells with supernatant from MCF7 previously exposed to passage 10 NSG explant supernatant indicating the virus was not capable of a 
further round of spread and did not appear to be replication competent. In all the experiments involving MCF7 cells exposed to supernatant from explants 
(both NSG and BALB/c), uninfected MCF7 cells were used as a negative control, MCF7 XMLV was used as positive control for XMLV. 
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I also cultured blood cells in vitro from the BALB/c mice in this experiment 
(Figure 3.11a & b). The blood cells were washed in MEM medium and then grown 
in MEM in a tissue culture incubator. Fresh uninfected MCF7 cells were also 
exposed to plasma from these mice and the cells were grown for two weeks in a 
tissue culture incubator. No human cells were found in blood cells cultured from 
the BALB/c mice showing that MCF7 were not metastasised in the blood. PCR to 
detect XMLV in MCF7 cells exposed to BALB/c plasma is shown in the Figure 3.12. 
Figure 3.12 PCR for exposure of MCF7 cells to BALB/c plasma 
 
Figure 3.12 PCR using LTR primers specific for XMLV. Human GAPDH primers were used as 
an internal control. Uninfected MCF7 cells were used as a negative control. MCF7 cells 
infected with XMLV were used as a positive control. 
Figure 3.12 shows that no infection was seen by PCR in MCF7 cells exposed to 
mouse plasma suggest that free XMLV was not present in these mice.  
In Figure 3.11c a positive signal was seen with XMLV-LTR primers when 
supernatant from each of the four NSG mice explants was used to infect fresh 
MCF7 cells. The experiment was repeated by infecting fresh MCF7 cells with 
supernatant from NSG explants (12th passage) and this time only two explants 
had a positive signal (Figure 3.11d) showing that the capacity for infection was 
lost in 2 NSG explants. On later passage the infectivity was completely lost in all 
the four NSG explants (15th passage -not shown). Supernatants from MCF7 cells 
previously exposed to passage 10 NSG explants (Figure 3.11c) were also used to 
infect fresh MCF7 cells but the viral sequences could not be transmitted to the 
fresh MCF7 cells as shown in the Figure 3.11e. This suggests that the virus that 
initially came from the NSG explants may have been a non-replicating defective 
virus that was transiently induced. It is possible that the defective virus may 
have been released from the mouse cells present among the NSG explant cells 
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and that as the non-established mouse cells died off in culture, virus release was 
lost. The MCF7 cells, which were positive with the defective virus, were free of 
mouse cells confirming that they became infected with the defective virus but 
were unable to produce infectious particles.  
The defective virus was sequenced, revealing homology to murine endogenous 
PMLV like MLV sequences on mouse chromosome 13, but it was clearly distinct 
from Bxv1 XMLV as shown in the Figure 3.13.  
Figure 3.13 Phylogenetic trees for NSG defective virus  
 
Figure 3.13 Phylogenetic trees for (a) LTR and (b) gag-pol sequences from the defective 
virus in the MCF7 tumour explants derived from NSG mice. The accession numbers are 
shown in brackets for Mo MLV, endogenous PMLV like MLV (chromosome 13) and Bxv1 
(chromosome 1). Trees were generated by the neighbour-joining method with bootstrapping 
at 100 replicates using CLC Genomics Workbench 5 software. 
The NSG-derived defective virus sequences showed close resemblance to 
endogenous PMLV like MLV, (derived from chromosome 13, C57BL/6J BAC 
library) from which it differed only by a few G to A transitions. This suggested 
cytidine deamination during replication as a possible cause of this divergence234. 
The alignment of NSG-derived defective virus sequences, endogenous PMLV like 
MLV, Bxv1 and Mo MLV sequences is shown in the Appendix 3 and 4. 
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3.3.6 Raji cells xenografted into BALB/c mice formed regressing 
tumour nodules  
As described above, I was able to induce and rescue XMLV by xenografting MCF7 
cells into BALB/c mice. When THP-1 cells were used for xenografting in BALB/c 
mice, no tumour tissue developed. Next I wanted to see if it was possible to 
induce and rescue XMLV using another susceptible cell line. For this purpose I 
used the Raji cell line, a Burkitt’s lymphoma cell line, as in vitro experiments 
had confirmed that these cells were highly susceptible to XMLV infection 
(described in Chapter 4). Raji cells were inoculated subcutaneously into eight 
BALB/c nude mice. The Raji cells formed tumour nodules initially in all the 
mice. However, these nodules rapidly regressed and no viable explants could be 
recovered from this experiment. 
3.4  Discussion 
In this chapter I have demonstrated that MCF7 explant cells obtained from 
BALB/c mice acquired XMLV, although whether infection of human cells was 
initiated in vivo or after explant was not addressed directly. I have also 
confirmed that both BALB/c and the C57BL mice have a provirus at the Bxv1 
locus on chromosome 1. This endogenous proviral locus has been identified in 17 
strains of mice22, representing a third of all inbred strains and can be induced by 
graft versus host reaction172. The results presented here suggest that the use of 
mice carrying a provirus at the Bxv1 locus is likely to present a significant risk 
for acquisition of XMLV infection of cancer cell grafts. In these experiments, two 
MCF7 BALB/c xenografts infected with XMLV out of a total of 5 samples (one in 
each experiment, i.e. 40% overall) became infected. The same experiment was 
later repeated by Anne Terry in our group with my assistance. Using 12 BALB/c 
mice, our results confirmed that >40% of MCF7 explants from the BALB/c mice 
acquired XMLV. Various factors are likely to affect the risk of XMLV infection of 
xenografts, including the duration of in vivo passage. Strain-specific differences 
in immune function may also influence the likelihood of XMLV induction. It is 
even possible that mouse cells may be induced to produce XMLV when co-
cultured in vitro with human cells. However, XMLV would not be expected to 
reinfect and replicate in the mouse cells due to the polymorphic XPR1 receptor 
which does not support viral entry in this strain36. The extent to which XMLV 
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infection was present in the xenograft cells in vivo is unknown but could be 
analysed in future by analysis of explants cells e.g. by immunofluorescence for 
viral gene products.  
XMLV infection of xenografts is likely to pass unnoticed unless samples are 
specifically screened for XMLV, and at present many researchers using xenograft 
approaches appear to be unaware of the potential for contamination. For 
example Warrington et al180 recently used an MCF7-BALB/c xenograft model to 
demonstrate the effects of dietary selenium on the growth of MCF7 
intramammary tumours. They made no reference to the XMLV status of their 
MCF7 xenografts and were presumably unaware of confounding effects that 
XMLV might have had on their results. Similarly Huuse et al179 used the MCF7-
BALB/c xenograft model to explore the effects of docetaxel, an anti-cancer 
drug, on MCF7 xenografts, once again ignoring XMLV as a possible confounding 
factor. Thus the use of xenografting for reconstituting primary tumours and cell 
line development164 or for other experimental purposes demands that XMLV 
status should be established especially when Bxv1 positive mice have been used. 
XMLV infection could potentially alter the characteristics of the cell line under 
investigation e.g. by insertional mutagenesis or could also act as a source of 
contamination for other cell lines or samples used in the laboratory173. The 
example of XMRV also highlights the danger of false associations of retroviral 
infection with human diseases158. Despite the demise of XMRV as a human 
pathogen, XMLV is formally classed as a potential biohazard for workers in tissue 
culture or those handling these xenografts in the animal house.  
While my studies indicate that NSG mice lack a provirus at the Bxv1 locus on 
chromosome 1, there are about 1-20 XMLV copies per mouse strain20 suggesting 
that other loci might contribute to the generation of viruses capable of infecting 
xenografts. Moreover, loci known to generate fully replicative XMLV are present 
in other strains of mice. For example the Nzv1 and Nzv2 variants of XMLV are 
present in NZB mice. The Ma/My strain of mice has Mxv1 XMLV in addition to 
Bxv1. The NSG mouse strain does not have a locus known to release a fully 
replicative XMLV, but it does have many defective XMLVs. An apparently 
defective replication-incompetent virus was observed to be released from the 
NSG cancer cell explants when screened at the 10th passage. This defective virus 
signal was sequentially lost on subsequent passages. Only 2 out of 4 NSG explants 
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displayed detectable viral sequence at the 12th passage while at passage 15, no 
sequence was detected in the explant cultures. It is possible that the defective 
virus was being released by mouse cells present along with the explant cells and 
that the gradual loss of these non-immortalised cells with passage explains the 
disappearance of infectivity. The sequence alignment of the defective virus 
showed that it was not Bxv1 rather it showed sequence similarity to an 
endogenous polytropic like MLV (PMLV). Recently it has been shown that 
endogenous ecotropic murine leukaemia virus (EMLV) can become activated and 
replicate in NSG mice235. The source of this EMLV has been described as the 
endogenous proviral locus Emv30. Replicating EMLV has been shown to be 
capable of generating murine myeloid leukaemia by insertional mutagenesis in 
NSG xenograft recipients. Since EMLV can recombine with other endogenous 
retroviral sequences and result in the generation of PMLV, the possibility of 
direct infection of human xenografts with a recombinant variant from NSG mice 
cannot be excluded. Since the defective virus sequences resembled an 
endogenous PMLV- like MLV, the possibility of pseudotype formation must be 
considered. The potential for generation of human-tropic viruses from NSG mice 
may therefore compromise additional published results.  
Raji cells xenografted into BALB/c mice initially formed nodules but these 
regressed rapidly before explant samples could be obtained. The basis for this 
regression is not known. Raji cells have been previously shown by others to form 
subcutaneous tumours in other mouse strains236,237. As the Raji cells I used in this 
study are highly susceptible to XMLV infection, it is conceivable that the cells 
became infected with XMLV during the process of xenografting, and that this 
might have an influence on xenograft behaviour in the BALB/c nude mice which 
are athymic but retain some aspects of immune function including natural killer 
cell activity34. The effects of XMLV infection on the Raji cell transcriptome 
would be potentially interesting in this respect and are considered later in this 
thesis (Chapter 8).  
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4  Susceptibility of human cells to XMLV infection 
4.1 Introduction 
While MCF7 cells are readily infected with XMLV, the extent of sensitivity of 
other human cancer cell lines was not clear, although some studies of host range 
had been conducted for XMRV238.  
The main aim of the experiments described in this chapter was to investigate 
which human cell lines are susceptible to XMLV. To assess whether cells might be 
resistant at the level of entry receptor expression, I also decided to determine 
the expression of XPR1 receptor in different cells. 
4.2 Materials and methods 
Materials and methods have been discussed in detail in Chapter 2. 
4.3 Results 
4.3.1 XPR1 receptor expression 
The expression of XPR1 in different cell lines and primary cells was checked by 
qRT-PCR as described in Chapter 2 and is shown in Table 4.1.  
Table 4.1 XPR1 expression in cells 
Cells Human XPR1 expression 
CEM 1.7 
CEMSS 1.3 
Kyo1 2 
Jurkat 1.7 
Reh 1.6 
K562 4.1 
293 1 
PBMC 1.6 
MCF7 1.4 
THP-1 1.6 
Mouse 0 
 
Table 4.1 Expression of XPR1 in different cells relative to 293 cells. Mouse cells were used 
as a negative control.  
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Table 4.1 shows that XPR1 mRNA was found to be expressed in all human cells 
tested, this suggested that difference in the receptor expression was not a major 
determinant of their differential susceptibility to XMLV infection. 
 
4.3.2 Single cell cloning of MCF7 XMLV cells indicates multiple 
XMLV insertions/integrations at different sites in different 
clones of MCF7 cells 
As discussed in Chapter 3 MCF7 cells can grow as xenografts in mice and 
explanted tissue can be used as a source of infectious virus for subsequent 
infection of fresh MCF7 cells in vitro. To investigate the susceptibility of MCF7 
cells to XMLV further and potential implications for insertional mutagenesis of 
xenografts I examined the number of proviral copies that had integrated in 
individual infected cells. For this purpose, MCF7 cells were infected with XMLV 
and grown as single cell clones as described in Chapter 2 so that viral copy 
number per cell could be estimated. Twelve sublines, derived from single cell 
clones, were developed and southern blotting was carried out on these lines to 
look at the number and pattern of proviral insertions.  
To explore the integration pattern of XMLV in the MCF7 genome, a probe was 
designed as shown in Figure 4.1. The probe was designed so that I could detect a 
constant internal fragment and variable flanking fragments when used with a 
single restriction enzyme, in this case EcoRV. 
Figure 4.1 Probing XMLV insertions in XMLV infected MCF7 clones 
 
Figure 4.1 The XMLV probe (380 bp) can bind to both LTR regions of the inserted XMLV 
provirus. After EcoRV restriction-enzyme digestion of XMLV infected MCF7 DNA, constant-
sized internal (3.3kb) and variable-sized junction fragments were generated. The size of 
junction fragment was dependent on the gap between the EcoRV restriction enzyme site in 
the LTR of inserted XMLV provirus and the nearest EcoRV restriction enzyme site located in 
the adjacent MCF7 genome.  
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The blot was probed using the probe described above. The southern blot is 
shown in the Figure 4.2. 
Figure 4.2 Southern blot for XMLV-infected MCF7 single cell clones 
  
Figure 4.2 (a) Southern blot MCF7 XMLV clones 1-12. MCF7 XMLV cells from which the 
clones were derived were used as positive control (+). Non-infected MCF7 cells were used 
as negative (-) control. (b) XMLV DNA estimated copy number in MCF7 XMLV clones.  
 As shown in Figure 4.2a all twelve MCF7 sublines showed the presence of the 
XMLV internal fragment band of 3.3kb demonstrating that all clones were 
successfully infected. This band was absent from uninfected MCF7 cells 
indicating that it was specific to the recently acquired XMLV proviral DNA. The 
positive control showed the internal band and a smear rather than the presence 
of identifiable individual flanking bands. The different cell lines showed some 
variation with regard to both the intensity of the internal fragment and the 
number of obvious flanking bands suggesting that viral copy number varied 
between the different clones (Figure 4.2b), with an estimated 3-13 copy per cell 
(an average of 6 copy per cell). In principle, viral receptor interference should 
prevent reinfection of already infected cells but the copy number variation 
observed here would suggest that this blockade was not complete. In addition, 
the observation that even within a clone the flanking bands showed different 
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intensities indicates a degree of oligoclonality with regard to insertion sites and 
the likelihood that some integrations are present only in a subset of cells. The 
possibility that continued reintegration of XMLV could be occurring in these 
clonal sublines is supported by previous observations by Laurent et al239 who 
showed that XMRV proviral copy number per cell could accumulate over time in 
LNCaP prostate cancer cells. These authors demonstrated that low viral gene 
expression could result in inefficient interference thus permitting ongoing 
infection. The likelihood of retroviral DNA inserting adjacent to a cellular proto-
oncogene or within a tumour suppressor gene in a single cell is extremely low 
but in a natural infection the frequency of such events increases as the virus 
spreads through a large and susceptible population240. The low level continued 
infection observed in the MCF7 cells could increase the risk of altered cell 
properties due to insertional mutagenesis, especially if each newly infected cell 
can be re-infected after an initial hit of integration. MLVs operate as insertional 
mutagens in their natural host and induce leukaemias and lymphomas in which 
multiple integration events and activation of cooperating oncogenes has been 
widely documented241,242. Thus the possibility that XMLV infection of xenografts 
and xenograft derived cell lines could result in dysregulation of genes involved in 
controlling cell behaviour with resultant clonal outgrowth should be considered. 
 
4.3.3 Titration of XMLV  
The next step was to determine the titre of XMLV produced from XMLV infected 
MCF7 cells. For this purpose serial 1/10 dilutions of filtered XMLV supernatant 
were prepared and were used to infect 1x106 fresh MCF7 cells. The supernatant 
from these MCF7 cells on Day 14 were used to perform DERSE assay as shown in 
the Figure 4.3. 
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Figure 4.3 DERSE assay for XMLV titration 
 
Figure 4.3 DERSE assay for XMLV titration. The GFP positive green cells indicate a positive 
DERSE test. 
Figure 4.3 shows that the GFP activity could be seen in neat and 1/10 dilutions 
but was only weakly detected in the DERSE cells exposed to supernatant from 
1/100 XMLV dilution. PCR was also performed using the DNA extracted from the 
day 14 samples using primers specific for XMLV as shown in Figure 4.4.  
Figure 4.4 PCR for XMLV titration 
 
Figure 4.4 PCR for XMLV titration using env primers specific for XMLV and human GAPDH 
primers as an internal control. MCF7 cells infected with XMLV were used as positive control. 
Figure 4.4 shows that on the Day 14, XMLV infection was detected in MCF7 cells 
infected with 10-4 diluted XMLV. Thus PCR was the more sensitive method to 
analyse XMLV titre. The titration of XMLV by PCR method was repeated three 
times and each time the results were found to be the same. The supernatant 
from the MCF7 cells infected with XMLV (titre=104 virus particles/ml) was used 
as a stock solution for subsequent infections unless stated otherwise. 
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4.3.4 Infection of a panel of cell lines with XMLV 
A panel of cell lines including Kyo1, K562, U937, Reh, Jurkat, MCF7 and CEM 
were infected with XMLV at a multiplicity of infection (MOI) of 0.02 (5x105 
suspension cells infected with 1 ml of XMLV supernatant and 1x106 adherent 
MCF7 cells infected with 2 ml of supernatant). The cells were grown for 2 weeks 
before DNA extraction. XMLV infection was confirmed by PCR using primers 
specific for XMLV as shown in Figure 4.5. 
Figure 4.5 PCR for XMLV infection of panel of cell lines 
 
Figure 4.5 PCR using env primers specific for XMLV and human GAPDH as an internal 
control. MCF7 cells infected with XMLV were used as a positive control. 
Figure 4.5 shows that by PCR the order of susceptibility of the cell lines was 
MCF7>CEM>K562>Jurkat>Kyo1>U937>Reh. The uninfected cells were negative for 
XMLV confirming that the cells were not previously contaminated. The 
supernatants from these infected cells were used to perform the DERSE assay. 
The result is shown in Figure 4.6. 
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Figure 4.6 DERSE assay for XMLV infected cells 
 
Figure 4.6 DERSE assay for different cell lines infected with XMLV for 14 days. The GFP 
positive green cells indicate a positive DERSE test. 
Figure 4.6 shows that GFP positive green cells were seen only in MCF7 cells. No 
GFP activity was observed in the assays performed for other cell lines, showing 
that either the titre of infectious virus released by other cell lines is low or that 
any virus released from these cells is defective and not capable of producing a 
positive result using the DERSE assay. It may also mean that the DERSE assay is 
relatively insensitive to low titre virus and unsuitable for end-point titration. 
The principles of the DERSE assay system are shown in Figure 4.7 and a rationale 
for its failure to detect low titre virus is considered below. The DERSE assay was 
carried out in triplicate for each cell line. 
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Figure 4.7 Principles of the DERSE assay 
 
Figure 4.7 Shows the principles of the DERSE assay system. The figure is partially adapted 
from Aloia et al
243
.The DERSE cells are LNCaP cells transfected with a pBabe MLV vector 
carrying an intron interrupted GFP sequence. The orientation of GFP sequence is reverse as 
compared to the vector with the intron oriented in the forward direction. The CMV promoter 
drives transcription of the minus strand GFP sequence which can be spliced to remove the 
intron but retain the viral RNA packaging signal. When a replication competent 
gammaretrovirus infects DERSE cells, the minus-strand GFP sequence can be packaged 
and delivered to a neighbouring DERSE cell. When this spliced vector infects a new cell, the 
integrated vector can express the intact GFP sequence from the CMV promoter. 
 High titre incoming virus will infect the DERSE cells at high multiplicity, 
increasing the chance of generating particles carrying the spliced GFP vector and 
carrying it to a neighbouring cell. Low multiplicity infection may generate a sub-
threshold level of infectious particles with a low probability of vector-containing 
particles (Figure 4.7). This effect may be magnified if the vector is packaged less 
efficiently than the RNA of the incoming virus. If my hypothesis is correct, it may 
be possible to activate the system with a high titre of a second gammaretrovirus 
that uses a different receptor even after saturation of the DERSE cells following 
low titre spread of XMLV. It would have been interesting to explore this question 
further if time has permitted.   
 
A further experiment was carried out with a panel of cells including 293T, CEM, 
CEMSS, Kyo1 and Reh exposed to XMLV at MOI=0.2 (5x105 suspension cells 
infected with 1 ml of XMLV supernatant and 1x106 adherent MCF7 cells infected 
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with 2 ml of supernatant) using supernatant from the MCF7 cells infected with 
XMLV. CEMSS is a subline of CEM that differs in its very low expression of 
APOBEC3G, a restriction factor known to play an important role in restricting HIV 
and MLV244. The cells were re-infected with filtered XMLV supernatant from the 
MCF7 cells on Day 3 and Day 7 to ensure saturation of XMLV infection. In the 
experiment I tested the effects of saturating infection with three separate 
exposures to XMLV. The cells were grown for 2 weeks and DNA was extracted 
from the 14 day samples. XMLV infection was confirmed by PCR using primers 
specific for XMLV as shown in Figure 4.8. 
Figure 4.8 PCR for XMLV infected panel of cells 
 
Figure 4.8 PCR using LTR-gag primers specific for XMLV and human GAPDH primers as 
control. Uninfected 293T cells were used as negative control. MCF7 cells infected with 
XMLV were used as a positive control for XMLV.  
Figure 4.8 shows that 293T cells, CEM cells and CEMSS cells are susceptible to 
XMLV. The Kyo1 cells again appeared to be only partially susceptible to XMLV 
even after multiple rounds of infection though the infection was much increased 
when compared to single round of infection. The Reh cells appear to be highly 
resistant to XMLV infection even after multiple rounds of infection. This 
experiment was carried out once with the cells infected in a panel, however 
they were individually infected with XMLV in multiple other experiments. To 
compare the specific infectivity of XMLV in these different cell lines, this 
experiment was further analysed as described later in this chapter. 
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4.3.5 Infection of THP-1 cells with XMLV 
As THP-1 cells were being used by my colleagues in xenograft-experiments in 
NSG mice (Chapter 3) this provided an opportunity to test whether THP-1 cells 
become infected with XMLV in vivo. To test in vitro susceptibility I infected THP-
1 and MCF7 cells at MOI=0.2 (5x105 THP-1 cells infected with 1 ml of XMLV 
supernatant and 1x106 adherent MCF7 cells infected with 2 ml of supernatant). 
Cells were grown for 2 weeks before DNA extraction. XMLV infection was tested 
by PCR using primers specific for XMLV as shown in Figure 4.9. 
Figure 4.9 PCR for XMLV infection of THP-1 cells 
 
Figure 4.9 PCR using LTR-gag primers specific for XMLV and human GAPDH primers as 
control. Uninfected THP-1 cells were used as negative control. MCF7 cells infected with 
XMLV used as positive control for XMLV. 
Figure 4.9 shows THP-1 cells infected with XMLV in triplicate. We can see that 
the LTR-gag band for the MCF7 cells, (positive control for XMLV) was very strong 
compared with the THP-1 cells. Thus THP-1 cells were considered to be only 
weakly susceptible to XMLV infection. A southern blot analysis of these THP-1 
cells infected with XMLV was carried out with Nancy Mackay’s help as shown in 
Figure 4.10. 
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Figure 4.10 Southern blot for XMLV infection of THP-1 cells 
 
Figure 4.10 Southern blot using probe specific to detect XMLV LTR region. The probe was 
described in detail in earlier in this chapter. EcoRV enzyme was used to digest DNA for 
southern blotting. The probe can detect internal fragment of 3.3kb and external fragments of 
variable size depending on the location of XMLV insertion in the host genome and the 
nearby EcoRV restriction site.  
Figure 4.10 shows that THP-1 cells infected with XMLV showed no detectable 
internal fragment on southern blotting. The relevant band can be seen clearly in 
MCF7 cells infected with XMLV (positive control). Note that this analysis would 
be expected to detect the internal fragment from unintegrated as well as 
integrated XMLV. Together with the weak PCR detection of XMLV in infected 
THP-1 cells in Figure 4.9, these results indicate that very few of the THP-1 cells 
are infected with XMLV. Furthermore, PCR is more sensitive than southern blot 
for the detection of low levels of proviral DNA.  
4.3.6 Infection of Raji cells with XMLV 
I also infected Raji cells with XMLV at MOI=0.2 (5x105 cells infected with 1 ml of 
XMLV supernatant). The XMLV infection was confirmed by PCR using primers 
specific for XMLV as shown in Figure 4.11. 
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Figure 4.11 PCR for XMLV infection of Raji cells 
 
Figure 4.11 PCR carried out using LTR-gag primers specific for XMLV and human GAPDH 
primers as an internal control. Uninfected MCF7 cells were used as a negative control. 
MCF7 cells infected with XMLV were used as a positive control. 
Figure 4.11 shows that Raji cells are susceptible to infection with XMLV. The PCR 
band intensities for Raji cells infected with XMLV and the MCF7 cells infected 
with XMLV were comparable. This experiment was further analysed and is 
discussed in Chapter 7. 
4.3.7 Infection of human breast cancer cells with XMLV 
I also attempted to infect human breast cancer cell lines MDA MB 231 cells, and 
MCF7 cells (control) with XMLV at MOI=0.2 (1x106 cells infected with 2 ml of 
supernatant). XMLV infection was confirmed by PCR using primers specific for 
XMLV as shown in Figure 4.12. 
Figure 4.12 PCR for XMLV infection of MDA MB 231 cells 
 
Figure 4.12 PCR analysis with env primers specific for XMLV and human GAPDH primers as 
an internal control. MCF7 cells infected with XMLV were used as a positive control. 
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Figure 4.12 shows that MDA MB 231 cells are susceptible to XMLV infection. 
Susceptibility to XMLV infection appeared to be lower for MDA MB 231 than for 
the highly susceptible MCF7 cells. This experiment was carried out twice.  
4.3.8 Infection of CD34+ human cord cells with XMLV 
In order to test the susceptibility of primary human cells to XMLV infection, 
CD34+ cord blood cells were also exposed to XMLV at MOI= 0.1 (1.6x105 cells 
infected with 2ml supernatant) as described in Chapter 2. CEMSS were used as 
control cells. PCR was carried out using appropriate primers for XMLV as shown 
in Figure 4.13.  
Figure 4.13 PCR for XMLV infection of CD34+ cells 
 
Figure 4.13 PCR carried out using env primers specific for XMLV and human GAPDH 
primers as an internal control. MCF7 cells infected with XMLV were used as positive control. 
The Figure 4.13 shows that human cord blood CD34+ cells can be infected with 
XMLV. CEMSS cells used as a control were also infected with XMLV (Figure 4.13).  
4.3.9 Infection of human peripheral blood monocytic cells with 
XMLV 
PHA treated PBMCs were infected with XMLV at MOI=0.01 (106 cells exposed to 1 
ml of supernatant). PCR was carried out using appropriate primers for XMLV as 
show in Figure 4.14. 
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Figure 4.14 PCR for XMLV infection of PBMCs 
 
Figure 4.14 PCR carried out using env primers specific for XMLV and human MYC primers 
as an internal control. MCF7 cells infected with XMLV were used as positive control. 
Figure 4.14 shows that PBMCs can get infected with XMLV. However the 
susceptibility of PBMCs to XMLV appears to be low. This is indicated by the weak 
band from PBMCs infected with XMLV as compared to the MCF7 cells infected 
with XMLV (positive control). 
4.3.10 Specific infectivity of XMLV in human cells 
The panel of cell lines 293T, CEM, CEMSS, Kyo1 and Reh infected with XMLV 
(Figure 4.8) were also assessed for the specific infectivity of XMLV released by 
these cells. These experiments paralleled ongoing experiments with FeLV which 
were pursued in greater depth and are described in Chapter 5. It was noted that 
some human leukaemia cell lines released abundant FeLV particles with reduced 
infectivity, indicating a late restriction to replication to FeLV and possibly also 
XMLV infection.  
Serial 1/10 dilutions of filtered supernatant from these infected cells were used 
to infect 293T cells as described in Chapter 2. The XMLV titre was determined by 
PCR using primers specific for XMLV as shown in Figure 4.15. 
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Figure 4.15 Titration of XMLV from different cell lines 
 
Figure 4.15 Titration of XMLV from different cell lines by PCR using XMLV LTR-gag primers 
specific for XMLV and human GAPDH primers as an internal control. MCF7 cells infected 
with XMLV were used as positive control. 
No XMLV infection was observed in 293T cells infected with neat supernatant 
from the Reh and Kyo1 cells (Figure 4.15). XMLV infection can be detected in 
293T cells infected with neat supernatant from CEM cells as well as CEMSS cells. 
Bands can be seen in the 293T cells infected with neat and 1/10 dilution of XMLV 
supernatant from the saturated 293T cells. This analysis indicates that the titre 
of XMLV released by 293T cells is ~10 infectious units per ml, while the titre of 
virus released from CEM and CEMSS is ~1U/ml. No infectious virus was detected 
in supernatant from the Kyo1 or Reh cells.  
Next I compared the total level of virus released by different cell lines infected 
with XMLV with the infectivity of the released XMLV. I also analysed the virus 
protein content within the infected cells. For this purpose, the supernatants 
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from day 14 XMLV infected cells were used to prepare clarified lysates after viral 
pelleting by ultracentrifugation (at 25000 rpm). Cell protein lysates were also 
prepared from cells harvested on Day 14 and western blots were performed as 
shown in Figure 4.16. 
Figure 4.16 Western blot of viral and cell protein lysates from XMLV infected cells 
 
Figure 4.16 (a) Western blot of cellular and viral proteins from the XMLV infected cell lines 
using anti p30
Gag 
antibody. (b) Densitometry of XMLV intracellular Pr65
Gag
 western blot. (c) 
Densitometry of XMLV intracellular p30
Gag
 western blot. (d) Densitometry of XMLV virion CA 
p30
Gag
 western blot. Densitometry of cellular proteins was determined after normalising for 
the actin loading control. Background has been subtracted from all the densitometry values. 
The level of XMLV precursor Pr65Gag intracellular protein was greatest in the 
293T cells, followed by CEM cells, Reh cells, CEMSS cells and Kyo1 cells 
respectively. The levels of cell-associated processed p30Gag were highest for 
CEM, followed by 293T cells, CEMSS cells while it was undetectably low in Reh 
cells and Kyo1 cells. In the western blot analysis of viral particle-related protein, 
the highest p30Gag XMLV capsid (CA) protein level was found in 293T cells 
followed by CEM cells, and CEMSS cells while it was detectably low in Reh cells 
and Kyo1 cells. A comparison of the western blot data with titration data showed 
a reasonable correlation for all the cell lines.  
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Human PBMCs were also exposed to XMLV. The presence of XMLV DNA in exposed 
PBMCs was confirmed by PCR as shown in Figure 4.14. The supernatant on Day 14 
was used to infect 293T cells. No infectious XMLV was detected. 
4.4  Discussion  
In this chapter, I have demonstrated that XMLV can infect MCF7 cells and 
accumulate high copy numbers of integrated proviruses per cell. The ability of 
XMLV to insert at multiple sites in individual cell clones means that there is an 
increased chance of inserting adjacent to important oncogenes or within tumour 
suppressor genes and therefore a risk of affecting cell behaviour by insertional 
mutagenesis181. The pool of MCF7 XMLV cells from which the clones were derived 
was presumed to be polyclonal with respect to XMLV insertions. The clones were 
selected randomly from the pool without intentionally applying any selective 
pressure. However, the low density culture environment may have increased 
selection pressures, possibly enhancing the likelihood of a competitive 
advantage in cells sustaining insertions at specific loci. Such pressures could also 
arise when culturing the cells in the presence of cytotoxic drugs or repeat 
xenografting.  
Different retroviral subfamilies and genera display different integration 
preferences and this has implications both for the lifecycle of virus and the host. 
For example, HIV-1 displays a preference for integration within active 
genes/transcription units183, whilst MLV tends to insert near transcription start 
sites245. XMRV, which shares 93% sequence similarity with XMLV20, and uses the 
same receptor i.e. XPR1152, also shows a strong preference for transcription start 
sites182. By analogy with other MLVs it is therefore possible that XMLV can play a 
role in gene activation resulting in a potential selective advantage to infected 
cells. In my experiments, the position of insertions or their proximity to 
important cellular genes was not investigated. Similarly, differences in the 
growth characteristics of the different clones were not explored. Future studies 
could include monitoring the clonal expansion and investigating the insertion 
sites conferring defined advantages in adverse or challenging conditions. Such 
experiments might formally demonstrate that XMLV can act as an efficient 
mutagen in human cells. 
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I have demonstrated that XPR1 mRNA was expressed in all the human cells 
investigated, and the difference in receptor expression was unlikely to be a 
major determinant of their differential susceptibility. This could be confirmed in 
future experiments by the use of pseudotype vectors expressing the XMLV 
envelope protein.  
Different cell lines did not appear to be equally susceptible to XMLV infection. 
MCF7 cells, 293T cells, Raji cells K562 cells, CEM cells and CEMSS cells were 
found to be significantly susceptible. I demonstrated that MCF7 was the most 
susceptible cell line, releasing the highest titre of XMLV. 293T cell line was 
found to be the next in terms of susceptibility to XMLV infection and infectious 
XMLV titre released. CEM and CEMSS produced a similar virus titre. THP-1 cells, 
Kyo1 cells, U937 cells, Jurkat cells and MDA MB 231 cells were found to be 
partially susceptible. The infection was clearly detectable in Kyo1 cells by PCR 
but they did not release any infectious XMLV. Reh and PBMCs were found to be 
the least susceptible. The infection could easily be detected by PCR in PBMCs 
but not in Reh cells. Neither of these cell lines released detectable infectious 
XMLV. This shows that there is some restriction to replication in the Kyo1 cells, 
PBMCs and Reh affecting susceptibility to XMLV infection in case of Reh and 
PBMCs, and the infectiousness of the released virus (if any) in all three cell lines. 
I was also able to infect CD34+ primary human cord cells. Cancer cells undergo 
various genetic abnormalities during the process of cancer development. This 
could result in the differential behaviour of the cell lines. For example both 
MCF7 and MDA MB 231 cells are epithelial cell and are derived from breast 
adenocarcinoma pleural effusions198,214. MCF7 was highly susceptible to XMLV 
infection while the MDA MB 231 was relatively less susceptible. K562 appeared to 
be more susceptible as compared to Kyo1 cells though both of them are 
undifferentiated myeloid cells derived from CML patients202,203. THP-1 and U937 
both are undifferentiated monocytes205,209 and both appeared to show low 
susceptibility to XMLV infection. Jurkat cells are T lymphoblast206 while Reh are 
pre-B lymphoblast207,208, Jurkat cells seem to be better susceptible to XMLV as 
compared to the Reh. Possible reasons for the differences in susceptibility are 
explored further in subsequent chapters. The susceptibility of these cell lines for 
another simple gammaretrovirus e.g. FeLV would be worth studying as this will 
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provide us with useful information on general features affecting gammaretroviral 
susceptibility of human cells.   
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5 Susceptibility of human cells to FeLV  
5.1 Introduction 
In the previous chapter, different cell lines and primary cells were investigated 
for susceptibility to XMLV infection. This was carried out to discover which cell 
lines and primary cells are at risk of acquiring XMLV during the process of 
xenografting or by horizontal transfer in laboratory facilities where xenografts 
are used. An important question arising from these experiments is whether the 
susceptibility of different cell lines to XMLV represents a general resistance to 
gammaretroviral infection. As my colleagues in the host laboratory were 
studying feline leukaemia viruses with the aim of using these agents as cancer 
gene discovery tools in human cells, I was able to make use of the groundwork 
and the viruses that they had selected for study. The possibility that FeLV may 
cause zoonotic infection and the factors affecting resistance of human cells to 
these gammaretroviruses becomes the second major theme for my thesis 
studies. In earlier studies my colleagues identified FeLV B strains as the most 
likely zoonotic agents on the basis of their presence in many field isolates and 
their ability to infect human cells without obvious cytopathic effect.  
The main aim of the studies described in this chapter was to test which human 
cell lines are susceptible to FeLV B. As cells displayed differential susceptibility I 
also decided to examine the level at which resistance was operating by testing 
the ability of cell lines to support early entry and reverse transcription and to 
compare the specific infectivity of virions released after saturating infection of 
several human cell lines.  
5.2 Materials and methods 
Materials and methods have been discussed in Chapter 2. 
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5.3 Results 
5.3.1 PiT1 receptor expression 
The expression of PiT1 receptor mRNA (Anne Terry’s unpublished results) is 
shown in the Table 5.1. PiT1 is expressed in all cells and shows no correlation 
with the susceptibility of various cell-types to FeLV B infection.  
Table 5.1 PiT1 expression in different cells 
 Cells  PiT1 expression  
293 1 
Kyo1 1.8 
THP-1 1.4 
CEM 1.6 
CEMSS 1.5 
Reh 3.5 
PBMC 1 
MCF7 1.1 
 
Table 5.1 The expression of PiT1 in different cell lines and PBMCs relative to 293 cells (Anne 
Terry’s unpublished results). 
5.3.2 Infection of cell lines with FeLV B 
Supernatant from the AH927 cells infected with FeLV B (titre=5x105 
particles/ml) was used to infect all cells with FeLV B unless otherwise stated. A 
panel of cell lines including CEM, CEMSS, Reh, MCF7 and Kyo1 were infected with 
FeLV B at MOI=1 (5x105 suspension cells infected with 1 ml of FeLV B supernatant 
and 1x106 adherent MCF7 cells infected with 2 ml of supernatant). The cells 
were grown for 2 weeks and DNA was extracted from the Day 14 samples. FeLV B 
infection was confirmed by PCR using primers specific for FeLV B as shown in 
Figure 5.1. 
  112 
 
Figure 5.1 PCR for FeLV B infection of cell line panel 
 
Figure 5.1 PCR using env primers specific for FeLV B. Human GAPDH primers were used as 
an internal control.  
Figure 5.1 shows that CEM, CEMSS, MCF7 and Kyo1 cells are susceptible and get 
infected with FeLV B. The Reh cells were also detectably infected although the 
level of proviral DNA was low as compared to other cell lines. This experiment 
was carried out twice. 
293T cells were also infected with FeLV B at MOI=1. The FeLV B infection was 
confirmed by PCR using primers specific for FeLV B as shown in Figure 5.2.  
Figure 5.2 PCR for FeLV B infection of 293T cells 
 
Figure 5.2 PCR using env primers specific for FeLV B and human GAPDH primers as an 
internal control. As the previous experiment demonstrated that MCF7 cells were capable of 
being infected, DNA from MCF7 cells infected with FeLV B was used as a positive control in 
this experiment. Uninfected 293T cells were used as a negative control. 
The Figure 5.2 shows that 293T cells are susceptible to FeLV B infection. 
5.3.3 Infection of THP-1 cells with FeLV B 
THP-1 cells were also infected with FeLV B at MOI=1 (5x105 THP-1 cells infected 
with 1 ml of FeLV B supernatant). MCF7 cells were used as control. FeLV B 
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infection was confirmed by PCR using primers specific for FeLV B as shown in 
Figure 5.3. 
Figure 5.3 PCR for FeLV B infection of THP-1 cells 
 
Figure 5.3 PCR using env primers specific for FeLV B and human GAPDH primers as an 
internal control. Uninfected MCF7 and THP-1 cells were used as a negative control. 
Figure 5.3 shows that THP-1 cells are not as susceptible to FeLV B infection as 
the MCF7 cells.  
5.3.4 Infection of Raji cells with FeLV B 
 Raji cells were also infected with FeLV B at MOI = 1 (5x105 Raji cells infected 
with 1 ml of FeLV B supernatant). The FeLV B infection was confirmed by PCR 
using primers specific for FeLV B as shown in Figure 5.4. 
Figure 5.4 PCR for FeLV B infection of Raji cells 
 
Figure 5.4 PCR using env primers specific for FeLV B and human MYC primers as an 
internal control. FeLV B infected 293 cell-DNA was used as positive control.  
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Figure 5.4 shows that Raji cells (in triplicate) are highly susceptible to FeLV B 
infection.  
5.3.5 Infection of human breast cancer cells with FeLV B 
An invasive breast cancer cell line, MDA MB 231 was next infected with FeLV B at 
MOI=1 (1x106 MDA MB 231 cells infected with 2 ml of FeLV B supernatant). This 
experiment was repeated three times. The FeLV B infection was confirmed by 
PCR using primers specific for FeLV B infection as shown in Figure 5.5. 
Figure 5.5 PCR for FeLV B infection of breast cancer cells 
 
Figure 5.5 PCR using env primers specific for FeLV B and human GAPDH primers as an 
internal control. FeLV B infected MCF7 cell DNA was used as a positive control.  
Figure 5.5 shows MDA MB 231 cells are also susceptible to FeLV B infection but at 
lower level than MCF7 cells.  
5.3.6 Infection of human PBMCs with FeLV B 
PHA treated human peripheral blood mononuclear cells (PBMCs) were infected 
with FeLV B at MOI=0.5 (1x106 PBMCs infected with 1 ml of FeLV B supernatant). 
This experiment was repeated three times. PCR carried out using DNA extracted 
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on 14th day of FeLV B infection (Figure 5.6) shows that PBMCs can get infected 
with FeLV B. 
Figure 5.6 PCR for FeLV B infection of PBMCs 
 
Figure 5.6 PCR using env primers specific for FeLV B and human MYC primers as an 
internal control. FeLV B infected 293 cell-DNA was used as a positive control. 
5.3.7 Infection of CD34+ human cord cells with FeLV B 
Human CD34+ cells were also infected with FeLV B at MOI=1. This infection was 
carried out by Anne Terry. PCR was carried out on the DNA extracted from the 
infected and uninfected CD 34+ cells showed that CD34+ cells can get infected 
with FeLV B as shown in Figure 5.7. 
Figure 5.7 PCR for FeLV B infection of CD34+ cells 
 
Figure 5.7 PCR using env primers specific for FeLV B and human MYC primers as an 
internal control. Water was used as a “non-DNA” control.  
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5.3.8 Infection of MCF7 cells with FeLV B and XMLV 
simultaneously 
FeLV B and XMLV both use different cell surface receptors for infection. XPR1, 
the receptor used by XMLV, is a phosphate exporter37, while PiT1, the receptor 
used by FeLV B, is a phosphate transporter246 and it is responsible for uptake of 
phosphate into the cells from the surroundings. I was interested to see if dual 
infection could be tolerated in the same cell line. For this purpose, MCF7 cells 
were infected simultaneously with filtered XMLV and FeLV supernatants. The 
FeLV B and XMLV infection was confirmed by PCR using primers specific for FeLV 
B and XMLV respectively as shown in Figure 5.8. 
Figure 5.8 PCR for simultaneous FeLV B and XMLV infection of MCF7 cells 
 
Figure 5.8 PCR using env primers specific for FeLV B and XMLV and human GAPDH primers 
as an internal control. MCF7 cells infected with FeLV B alone and MCF7 cells infected with 
XMLV alone were used as positive control for the respective primers. 
In Figure 5.8, we can see that MCF7 cells exposed simultaneously to XMLV and 
FeLV B get infected with both viruses. This shows that the two viruses FeLV B 
and XMLV can coexist in the same cells without obvious cytopathic effect. This 
experiment was carried out once. 
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5.3.9 Specific infectivity of FeLV B in human cell lines 
I have already shown that different cell lines vary in their susceptibility to FeLV 
B infection. I next wished to determine whether cell lines showed any 
differences in virus processing and release and whether these variations affected 
the quality and/or quantity of released virus. In order to find the specific 
infectivity of FeLV B in different cell lines, CEM, CEMSS, Reh, Kyo1, THP-1 and 
AH927 cells were infected with FeLV B. The cells were re-infected with FeLV B 
on the Day 3 to ensure saturation and grown for 2 weeks before harvesting. The 
cell lines were cultured until Day 14 to ensure replication. The FeLV B specific 
infectivity experiment was carried out twice. The supernatant from the cell lines 
on the Day 14 was titrated and added to QN10 cells. The results of the titration 
experiments are shown in Table 5.2. 
Table 5.2 FeLV B titre from different cell lines using the QN10 assay 
 
 
Table 5.2 Titration on QN10 cells shows the yield of infectious virus units capable of 
forming foci. 
Table 5.2 shows that the greatest titre of infectious FeLV B was obtained from 
the feline AH927 cells. Among the human cell lines, the production of infectious 
particles was comparable between the CEM and CEMSS cell lines. THP-1 and Kyo1 
both showed a moderate production of infectious particles while the Reh showed 
the least production of infectious particles. The next step was to quantify the 
total virus particle-related protein released by each cell line. 
To determine the total virus particle-related protein released in the supernatant 
by each cell line, the Day 14 supernatant from FeLV B infected cells was used to 
prepare viral lysate and western blotting was carried out on the virus lysate as 
shown in Figure 5.9.  
Cell line Titre 
CEM 4.43 x104 
CEMSS 6.26 x104 
Kyo1 3.6 x103 
Reh 3.87 x102 
THP-1 5.4 x 103 
AH927  3.67 x 105 
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Figure 5.9 Western blot FeLV B virus proteins and specific infectivity 
 
Figure 5.9 (a) Western blot for virion proteins using anti p27
Gag
 antibody. (b) Densitometry of 
virion CA p27
Gag
 western blot. (c) Specific infectivity of FeLV B calculated by dividing FeLV 
B titre (Table 5.2) by the virion particle-related protein values (Figure 5.9b). ND refers to 
calculations not done due to undetectable virion particle-related proteins in the western 
blot. 
Figure 5.9 shows that the greatest quantity of FeLV B protein was produced by 
the AH927, followed by CEM and CEMSS cells. A large quantity of virion protein 
was shed by Kyo1 cells. Virion capsid protein was below detectable levels for 
Reh and THP-1 cells in this western blot analysis. This shows that the titre of 
infectious FeLV B particles produced by AH927, CEM and CEMSS correlates to 
some extent with the total quantity of virus released in the supernatant. On the 
other hand Kyo1 cells shed a significant quantity of virus particle-related protein 
but subsequent infectivity appeared to be low indicating that the virus particles 
released by Kyo1 cells were of reduced infectivity. The next step was to 
examine the intracellular levels of virus-specific protein being processed within 
different cell lines.  
To examine virus protein processing within each infected cell line, the Day 14 
FeLV B infected cell-pellet from each cell line was used to prepare cellular 
protein extracts and western blotting was carried out with Anne Terry’s help. As 
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described in Chapter 1, The FeLV B Gag precursor protein (Pr65Gag) is cleaved by 
protease enzymes to produce viral proteins that make up the matrix (MA, p15), 
capsid, (CA, p27) and virus nucleocapsid, (NC, p10)8.The quantity of Pr65Gag and 
cell-associated p27 capsid protein, for each cell line was analysed here. The 
results are shown in the Figure 5.10. 
Figure 5.10 Western blot FeLV B infected cell proteins 
 
Figure 5.10 (a) Western blot of cellular proteins from the FeLV B infected cell lines using 
anti p27
Gag 
antibody. (b) Densitometry of FeLV B intracellular Pr65
Gag
 western blot. (c) 
Densitometry of FeLV B intracellular p27
Gag 
western blot. The densitometry of the cellular 
proteins was determined after normalising for the actin loading control.  
Figure 5.10 shows that unprocessed FeLV B Pr65Gag was seen in greatest quantity 
in Kyo1 cells, followed by AH927, CEM, and then CEMSS. Lower quantities of 
unprocessed FeLV B Pr65Gag were seen in THP-1 and undetectably low levels in 
Reh cells. The level of p27Gag followed a similar pattern with the exception of 
THP-1, where no processed p27Gag could be seen. This suggested a block to 
processing of Pr65Gag in these cells. In the case of Kyo1 cells, the relatively low 
infectivity of virions compared to those produced by AH927 feline fibroblasts was 
not simply due to lower production and processing of Gag gene products. The 
ratio of cell associated p27Gag to Pr65Gag was also higher for CEM and CEMSS as 
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compared to that in the AH927. The possible explanation for this could be that 
the particles are released easily in AH927 cells while there may be a restriction 
to release from Kyo1, CEM and CEMSS resulting in higher levels of processed 
virion proteins in these cells. The Reh cell line was consistent in having 
undetectably low levels of intracellular and released virion proteins, and a low 
titre of released virus. It was concluded that there is a block to FeLV B 
replication in Reh cells affecting earlier stages of the growth cycle.    
5.3.10 Specific infectivity of FeLV B in human PBMCs 
The above experiments show how the specific infectivity of FeLV B differed in 
established human cell lines. As these cell lines may have acquired defects in 
the course of transformation and establishment, I also wanted to test the 
susceptibility of primary human blood cells as this might be more informative 
with regard to resistance to zoonotic spread. For this purpose, PBMCs were 
infected with FeLV B in two different experiments. In the first experiment the 
CEM cell line was used as a control. Both CEM and PBMCs were infected with 
supernatant from FeLV B infected AH927 cells at MOI=0.08 (6x106 cells infected 
with 1 ml of FeLV B supernatant). Cells were harvested on Day 14, and were 
used to prepare pellets for DNA, RNA and protein extraction. FeLV B infection of 
PBMCs was confirmed by PCR and is shown in Figure 5.6. Day 14 supernatant 
from PBMCs was used for titration on QN10 cells and also for preparing cell free 
virus pellets. No infectious FeLV titre was detected in infected PBMC 
supernatant. The total virus particle-related protein released by PBMCs was also 
investigated by western blot analysis of the cell free viral pellet obtained from 
the supernatant as described later (Figure 5.13). 
In a second experiment, I examined proviral DNA levels soon after exposure of 
cells to FeLV B to confirm that the PCR product detected in PBMCs was due to 
newly synthesised proviral DNA rather than contaminating DNA in the infecting 
virus stock. Reh and Kyo1 cells were used as controls for PBMCs infection. 
PBMCs, Reh and Kyo1 cells were infected with filtered (0.45m) supernatant 
from AH927 cells infected with FeLV B at MOI=0.08 (6x106 cells infected with 1 
ml of FeLV B supernatant). Samples were obtained at 30 minutes, 6 hours and 72 
hours after FeLV B infection and used to prepare DNA. PCR was carried out to 
follow FeLV B infection and is shown in Figure 5.11. 
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Figure 5.11 PCR for FeLV B infection of PBMCs, Reh and Kyo1 cells 
 
Figure 5.11 PCR carried out using env primers specific for FeLV B and human GAPDH 
primers used as an internal control. The infection of FeLV B in PBMCs, Reh and Kyo1 cells 
was checked at 30 minutes, 6 hours and 72 hours. DNA of 293T cells infected with FeLV B 
was used as a positive control. 
 This analysis showed that, with the possible exception of Reh, there was very 
little proviral DNA detectable in newly infected cells (30 minutes after exposure) 
and that levels increased in all cases by 6-72 hours. This suggested that the virus 
was successfully entering PBMCs and Reh cells at levels comparable to the more 
permissive Kyo1 cells. Since this analysis was carried out by standard 
semiquantitative PCR, the next step was to measure viral DNA more accurately 
by Real Time PCR. The results are shown in Figure 5.12. 
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Figure 5.12 FeLV B copy number in PBMCs, Kyo1 and Reh at different times 
 
Figure 5.12 FeLV B copy number in PBMCs, Kyo1 and Reh cells at different time points 
determined by real time PCR using FeLV B env primers. All the values were normalised 
against the PBMC 6-hour FeLV B copy number. Error bars represent standard deviation. 
As can be seen, these analyses confirmed the very low levels of proviral DNA 
detectable at the 30 minute time point, and the 10-20-fold amplification by 6 
hours. However, there was a marked difference in the Kyo1 cells, where levels 
of proviral DNA continued to amplify to 3 days and 14 days after infection, while 
levels reached a plateau in the PBMCs and Reh cells. In order to further confirm 
this observation, titration experiments were carried out to calculate the number 
of infectious particles released by Reh, Kyo1 and PBMCs.  
Day 14 supernatant from PBMCs, Reh and Kyo1 cells was titrated on QN10 cells. 
The titre is given in Table 5.3. 
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Table 5.3 FeLV B titre from PBMCs, Kyo1 and Reh supernatant 
Cell line  Titre 
PBMC 0 
Reh 2 
Kyo1 47 
AH927 3.3x105 
 
Table 5.3 Titration on QN10 cells shows the yield of infectious virus units capable of 
forming foci. 
As shown in Table 5.3, no infectious FeLV B was detected in day 14 supernatants 
of the PBMCs, while a very low titre was noted from the Reh cells. The titre 
from Kyo1 was 47, consistent with the relatively low infectivity of virions 
released from these cells. AH927 was used as a positive control for the titration 
experiments. The titre of FeLV B released from AH927 cells was 3.3x105. I also 
investigated the levels of virion-related protein released by PBMCs in both 
experiments along with the Reh and Kyo1 cells in the second experiment. 
To investigate virion-related proteins released in the two experiments involving 
PBMCs, cell free virus pellet was obtained from Day 14 supernatant from the 
infected PBMCs, Reh and Kyo1 cells (2nd experiment) and PBMCs and CEM cells 
(1st experiment). Virion protein lysates were prepared and analysed by western 
blotting for the presence of FeLV B as shown in the Figure 5.13. 
Figure 5.13 FeLV B virion proteins produced by infected cells 
 
Figure 5.13 Western blot for virion proteins using anti p27
Gag
 antibody. FeLV B infected 
AH927 cell supernatant was used as a positive control for FeLV B viral protein. 
Figure 5.13 shows that supernatant from the PBMCs did not release any 
detectable FeLV proteins. Levels of protein released by Reh cells were also 
below detection by western blot, despite the presence of low levels of infectious 
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virus. In conclusion, the early stages of FeLV replication occur with similar 
efficiency in Kyo1, Reh and PBMCs, but only Kyo1 cells support production of 
viral protein and significant levels of virus particle production.  
5.4 Discussion 
In this chapter, I have demonstrated that different human cell lines and primary 
cells are susceptible to FeLV B infection but to a variable extent. I have 
identified three broad phenotypes: highly susceptible (293T, MCF7), partially 
susceptible (CEM, CEMSS, Kyo1, THP-1) and highly resistant (PBMC, Reh). These 
findings confirm and extend previous reports of human cells susceptibility to 
FeLV B infection in vitro140. 
FeLV B uses PiT1 or PiT2 phosphate transport receptors to enter human cells142. 
A complete absence of PiT1 and PiT2 receptors may make the cells resistant to 
FeLV B infection. The expression of PiT1 receptor mRNA (Anne Terry’s 
unpublished results) showed no correlation with the susceptibility of various cell-
types to FeLV B infection. This is also supported by the fact that 
gammaretroviruses like GaLV and amphotropic MLV using PiT1 and PiT2 
respectively do not show a correlation between level of receptor mRNA 
expression and degree of susceptibility of human cells to infection by these 
viruses247, suggesting that other mechanisms may be involved in resistance. 
As observed for XMLV, the lineage and origin of the cell lines showed little or no 
correlation with the susceptibility to FeLV B infection. For example the two 
breast epithelial cancer cell lines e.g. MCF7 and MDA MB 231 showed a marked 
difference in susceptibility. THP-1 cells (undifferentiated monocyte cell line) 
showed a unique block at the level of Gag precursor processing, although it is 
conceivable that the lower levels of Pr65Gag produced in these cells was below 
the threshold required to initiate budding and activation of the viral protease as 
has been suggested for some retroviruses248. PBMCs were found to be resistant to 
XMLV infection but perhaps more susceptible to entry of FeLV B. CD34+ human 
cord cells showed more or less similar susceptibilities to both XMLV and FeLV B.  
I have also demonstrated that in different cell lines the barrier to virus 
replication was not present at the same stage of replication. These experiments 
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also indicated that the virus released from different cell lines not only varied in 
quantity but also in infectivity. AH927 produced the greatest levels of total virus 
particle-related proteins and the highest titre of infectious virus released into 
culture supernatant and was used as the primary source of FeLV B and the 
standard for comparison in the specific infectivity experiments. The relatively 
low levels of unprocessed and processed intracellular FeLV proteins in AH927 
cells indicate efficient virus processing and release. Several human leukaemia 
cell lines, (Kyo1, CEM and CEMSS) showed high levels of unprocessed and 
processed intracellular viral proteins but slightly lower levels of released virion 
particle-related protein and significantly lower infectious virus titres. These 
results suggest that virus particle release is somewhat delayed in the human 
leukaemia cell lines compared to the highly productive feline fibroblasts. 
However, the four to fifty-fold reduction in specific infectivity of the released 
virus particles appeared to be a more significant finding as a potential barrier to 
cross-species infection. The Reh cells on the other hand did not show any 
detectable intracellular or virus particle-related protein by western blot. The 
titre of infectious virus released by Reh cells was also very low. It appeared that 
the block to Reh infection might be at an early stage of infection after reverse 
transcription but before proviral integration or transcription. 
PBMCs were found to be the least susceptible although, as in Reh cells, the early 
steps of proviral DNA synthesis appeared to proceed normally. Provirus persisted 
in PBMC cultures but PBMCs did not produce any detectable level of virus 
particle-related protein released into the supernatant or infectious virus titre. 
These observations were confirmed and extended by quantitative DNA PCR 
analyses that showed a clear difference between cells in which FeLV B infection 
was blocked at an early stage (PBMC, Reh) and those in which productive 
infection occurred (Kyo1).   
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6 Mechanisms of resistance of human cells to 
FeLV  
6.1 Introduction 
In the previous chapters, different cell lines and primary cells were investigated 
for susceptibility to XMLV and FeLV infection. It has also been demonstrated that 
human cell lines varied in terms of their susceptibility to FeLV B, and that the 
FeLV B was able to infect PBMCs but was not capable of replicating successfully. 
I wished to explore the mechanism for this resistance in PBMCs and the less 
susceptible cell lines further for potential relevant resistance to zoonotic 
infection of FeLV, which is still not well understood.  
The main aim of the studies described in this chapter was to explore the barriers 
to replication of FeLV B, in human cells. Towards this aim, I sequenced FeLV B 
propagated in human cells to screen for mutations indicative of APOBEC3 
activity which has been reported to restrict gammaretrovirus infectivity by 
mechanisms including G to A hypermutation of the viral genome234. I also 
examined the level of mRNA expression of APOBEC3 genes and other established 
retroviral restriction factors in different cell lines to see if the mutations and 
differential susceptibility correlated with restriction factor gene expression. I 
also explored the role of the glycoGag precursor protein, which is known to play 
an important role in virus release, infectivity and spread93 and has been reported 
to counteract APOBEC3 activity in MLV91. FeLV also encodes a glycoGag 
precursor3 but this had not been examined for its effects on FeLV replication and 
APOBEC resistance in human cells. 
6.2 Materials and methods 
Materials and methods have been discussed in Chapter 2. 
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6.3 Results 
6.3.1 FeLV B mutation analysis 
To get a better understanding of differences in susceptibility of human cells to 
gammaretrovirus replication, I decided to look for G to A hypermutation in the 
pol region of FeLV B in cells infected with FeLV B. For this purpose primers 
capable of amplifying the pol region of FeLV B were used (given in Appendix 1). 
The cell lines checked for hypermutation included FeLV B infected 293 cells, 
THP-1 cells, Kyo1 cells, CEM cells, CEMSS cells, Reh cells and PBMCs. The details 
of the hypermutation analysis are summarised in the Table 6.1.  
While no mutations were detected in the highly susceptible 293 cells (Table 6.1), 
all the leukaemia cell lines displayed evidence of G->A mutations at rates 
ranging from 0.4 to 6.2 per kilobase of FeLV genome sequenced. A small number 
of other mutations were also seen. Notably, the CEMSS cell lines, which is 
permissive for Vif defective HIV due to its low expression of APOBEC3G86, 
displayed a higher mutation rate than the parental CEM cell line. Despite the 
early block and low virus output from Reh cells, it was possible to obtain 
sequence that indicated virus replication with G->A mutations at similar levels to 
the more permissive cell lines. 
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Table 6.1 Mutations in FeLV B pol region in different cell lines 
Cell line Total 
nucleotides 
sequenced 
No. of 
clones 
sequenced 
G to A 
mutation 
G to A mutation 
rate  
(mutation/kb) 
Non G to A 
mutation 
293 3600 3 0 0 0 
THP-1 6000 5 37 6.17 1 
Kyo1 10800 9 43 3.98 1 
CEM 7200 6 3 0.42 1 
CEMSS 9600 8 8 0.83 1 
Reh 1200 1 3 2.5 1 
 
 
Table 6.1 Showing mutations in FeLV B pol region in different cell lines infected with FeLV B 
(above) and showing the nature of non G to A mutations (below). 
As the human APOBEC3 enzymes have been shown to have subtle differences in 
mutational target sequence preference, I wished to see how the mutations in 
FeLV compared and determine whether any prediction could be made about the 
family member responsible for the mutations. An online tool for hypermutation 
analysis218 was used to display the mutations in graphical form with a colour 
code according to the dinucleotide at the target site as shown in Figure 6.1.  
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Figure 6.1 Graphical representation of hypermutation in the FeLV B 
 
Red=GG>AG, Cyan=GA>AA, Green=GC>AC, Magenta=GT>AT, Other Non G>A 
Figure 6.1 shows graphical representation of hypermutation in FeLV B pol region. In THP-1 
cell line, out of 37 G to A mutations, 34 were GG to AG (red lines) and only 3 were GA to AA 
(cyan lines). In Kyo1 cells, out of 43 G to A mutations, only 14 were GG to AG (red lines), 
while 28 were GA to AA (cyan lines) and one was GC to AC mutation (green line). In CEM 
cells, out of 3 G to A mutations, 1 was GG to AG (red line) and 2 were GT to AT (magenta 
lines). In the CEMSS cells, out of 8 G to A mutations, 6 were GG to AG (red lines), 1 was GC 
to AC (green line), and 1 was GT to AT mutation (magenta line). In the Reh cell line, out of 3 
G to A mutations, only one was GG to AG (red line), while the remaining 2 were GC to AC 
(green lines) mutations.  
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GG to AG mutation is the most likely effect of APOBEC3G or, with a lesser 
preference, APOBEC3C activity69. GA to AA could also arise as a result of 
APOBEC3G (though less frequently as compared to GG to AG) but is the 
preferential change induced by APOBEC3F, APOBEC3B or APOBEC3C activity. 
While these overlapping dinucleotide preferences don’t allow definitive 
identification of the enzymes responsible, the predominance of GG to GA 
changes in THP-1 was suggestive of APOBEC3G activity, while Kyo1 cells showed 
a more complex pattern that was unlikely to be created by APOBEC3G alone. 
Surprisingly, G->A changes were also most frequent in CEMSS cells, despite their 
anticipated low levels of APOBEC3G mRNA.   
In order to have a deeper look into the preference sequence for deamination and 
the APOBEC3 enzymes responsible for it, analysis of the nucleotides upstream 
and downstream of the deaminated nucleotide was carried out as shown in the 
Table 6.2. 
Table 6.2 Preferred sequence context for deamination by APOBEC3 enzymes 
 
Table 6.2 Preferred sequence context for deamination by APOBEC3 enzymes of the different 
cell lines. Position zero “0” indicates deaminated nucleotide on the virus negative strand. -1 
, -2 and +1, +2 indicate adjacent nucleotides upstream and downstream of the deaminated 
(zero position) nucleotide respectively. “n” denotes the total number of nucleotide 
mutations analysed. Letters at the bottom of each table show the preferred sequence 
context for deamination by the respective cell line’s APOBEC3 machinery. 
In most cases, the preferred site for deamination is dC (deoxycytidine) in the 
minus virus DNA strand resulting in G to A hypermutation in the plus virus DNA 
strand. The preferred sequence context for deamination of nucleotides in the 
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pol region of FeLV B in the THP-1 cells was CCC. In Kyo1 cells, CTC appeared to 
be preferred sequence for deamination. In CEM cells, TAC appeared to be the 
preferred sequence for deamination while in CEMSS cells TCC was the preferred 
sequence for deamination. Reh cells showed an equal preference for 
deamination for CCC and CGC (The underlined nucleotide indicates the 
deaminated nucleotide, the ones written before it are -1 and -2 respectively). 
APOBEC3G is known to show a preference for CCC nucleotide sequence66,70 while 
APOBEC3F shows a preference for CTC70 and APOBEC3B prefers GTC or CTC70. 
This indicates that THP-1 show an APOBEC3G hypermutation signature while 
Kyo1 cells show an APOBEC3F preference. 
PBMCs infected with FeLV B were also checked for mutations. Amplification of 
the pol fragment from Day 3 infected PBMCs generated 2 clones but repeated 
efforts were required to generate these clones. The 2 clones were free of 
mutations. No clones could be amplified or sequenced from Day 14 infected 
PBMC cells. The basis of this difficulty in cloning PCR products from the FeLV 
infected PBMCs has not been established. 
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6.3.2 Restriction factor expression analysis 
The next step was to compare the mRNA expression of different restriction 
factors in the panel of cell lines. The expression was investigated by qRT-PCR as 
described in Chapter 2. All expression analyses were normalised and compared 
against a baseline of the permissive 293 cell line. The expression of different 
restriction factors is described below. 
6.3.2.1 APOBEC3 expression 
The expression of different APOBEC3 gene mRNAs in a panel of cells is shown in 
Figure 6.2. 
Expression levels of APOBEC3A, 3D, 3F and 3G were markedly higher in PBMCs 
than in the other cell lines in line with a published analysis of these genes across 
multiple tissues and cell lines61, the most extreme differences were noted for 
APOBEC3A and APOBEC3G which displayed 170-200-fold increased expression 
over the 293 cell baseline (Figure 6.2). My results also recapitulated observations 
on the CEMSS subline, showing reduced levels of all APOBEC family members 
compared to the CEM parental line apart from 3C and 3F. APOBEC3B expression 
was highest in THP-1 cells, close to 20-fold higher than baseline, while 
APOBEC3C was highest in PBMCs and Kyo1 cells (Figure 6.2).  
Taking these data together, it is not easy to correlate expression levels with 
hypermutation activity or the early blocks to FeLV infection seen in PBMCs and 
Reh cells. However, the levels of 3G and 3B show some inverse association with 
specific infectivity of virus released from several lines (CEM>Kyo,THP-1) and it is 
notable that both of these enzymes have been reported to be encapsidated.    
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Figure 6.2 Expression of APOBEC3 mRNAs relative to permissive 293 cells  
 
Figure 6.2 Expression of different APOBEC3 restriction enzyme mRNAs in different cells by 
qRT-PCR. All expression analyses were normalised and compared against 293 cell line. 
Error bars represent standard deviation. 
While APOBEC3G appears to be the best candidate for the predominant 
mutational activity against FeLV B, the activity detected in CEMSS cells despite 
low expression levels of all family members suggests that mRNA levels alone 
cannot account for the differences in activity and the lack of mutations seen in 
permissive 293 cells. The possibility that APOBEC activity underlies the early 
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block to infection in PBMCs despite the low level of mutations might also be 
suggested by the extremely high levels of APOBEC3A and APOBEC3G, and it is 
notable that Reh are the next highest expressers of both genes. The relatively 
strong mutational activity in Kyo1 cells is also correlated with higher APOBEC3G 
expression compared to baseline, although the strong expression of several other 
family members (APOBEC3B, APOBEC3C and APOBEC3D) precludes any firm 
conclusion (Figure 6.2). 
6.3.2.2 SAMHD1 expression 
I examined the expression of other candidate restriction factors including 
SAMHD1 as shown in Figure 6.3. SAMHD1 was highly expressed in the THP-1 
monocytic leukaemia cell lines, and was also higher in PBMCs compared to 
baseline. Very low expression was observed in CEM and CEMSS cells. The SAMHD1 
gene did not appear to be a likely candidate for the early block in Reh cells.  
Figure 6.3 Expression of SAMHD1 mRNA in different cells 
 
Figure 6.3 Expression of SAMHD1 in different cells by qRT-PCR. The expression was 
normalised and compared against 293 cell line. Error bars represent standard deviation. 
THP-1 cells show a defect in processing intracellular virion protein which cannot 
be attributed to SAMDH1 expression on the basis of its reported mode and site of 
action. The expression of SAMHD1 was checked thrice for each sample in 
triplicate. 
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6.3.2.3 TRIM5
The expression of TRIM5in different cells is shown in Figure 6.4. Although 
TRIM5 has not been shown to restrict gammaretroviruses, I found that its 
expression was markedly higher than the 293 cell baseline in all case. Expression 
was observed to be highest in Reh followed by Kyo1 cells.  
Figure 6.4 Expression of TRIM5 mRNA in different cells 
 
Figure 6.4 Expression TRIM5 in different cells by qRT-PCR. The expression was 
normalised and compared against 293 cell line. Error bars represent standard deviation. 
The lowest expression in leukaemia cell lines was in CEM which had comparable 
levels to the CEMSS subline. The level of expression was also comparable in 
PBMCs and THP-1 cells though it was slightly lower in PBMCs. As TRIM5 typically 
acts at before reverse transcription96 it appears unlikely as a candidate for the 
early block to replication in Reh and PBMCs. Also, Kyo1 cells which do not 
display the early block expressed quite high levels of TRIM5 The expression of 
TRIM5 was checked thrice for each cell line in triplicate.  
6.3.2.4 Tetherin 
The expression of Tetherin in different cells is shown in Figure 6.5. The 
expression of Tetherin was high in THP-1, CEM and PBMCs. 
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Figure 6.5 Expression of Tetherin mRNA in different cells 
 
 Figure 6.5 Expression Tetherin in different cells by qRT-PCR. The expression was 
normalised and compared against 293 cell line. Error bars represent standard deviation. 
The expression of Tetherin was higher in CEMSS as compared to Kyo1 and Reh 
cell lines. This showed that Tetherin expression did not correlate with FeLV B 
titre or virion-related protein released by the infected cells in general. Tetherin 
expression was checked twice for each cell line in triplicate. 
6.3.3 The role of glycoGag in FeLV B 
As described in Chapter 1, simple gammaretroviruses like MLV and FeLV also 
encode an alternative type of Gag known as glycosylated Gag in addition to the 
normal Gag protein. Glycosylated Gag in MLV assists in viral budding and has also 
been reported to counter APOBEC3-mediated restriction91,93. I wanted to 
investigate whether glycoGag is able to affect FeLV B specific infectivity. I 
received two relevant plasmids PENHF and PENHFX from Anne Terry. PENHF is a 
clone of wild-type FeLV B capable of producing glycosylated Gag, while the 
PENHFX has a mutation in the glycoGag start codon region, and is unable to 
synthesise glycoGag. The first important step was to confirm the difference 
between PENHF and PENHFX FeLV B plasmids in terms of the glycoGag start 
codon region. I designed primers (FeLV B gag, given in Appendix 1) to sequence 
the gag region from the PENHF and PENHFX FeLV B plasmids. The sequence of 
PENHF and PENHFX in the glycoGag start codon region is shown in the Figure 6.6. 
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Figure 6.6 gPr80
Gag
 start codon sequence of PENHF and PENHFX transcripts 
 
Figure 6.6 Sequences of PENHF and PENHFX in the glycoGag start codon region upstream 
of the normal Pr65
Gag
 start codon showing the presence of AUG start codon in both 
sequences and the presence of UAG stop codon only in PENHFX due to addition of 4 
nucleotides in PENHFX which results in a frame shift mutation after the start codon region, 
resulting in termination of glycoGag translation in PENHFX. The normal Gag precursor 
could however be translated in PENHFX as its initiation site is unaffected. 
Figure 6.6 shows that PENHFX is a glycoGag mutant form of FeLV B. I wanted to 
see if a partially susceptible cell line like Kyo1 would replicate the wild-type 
(PENHF) and the glycoGag mutant FeLV B (PENHFX) in a different or similar 
manner. For this purpose I first transfected 293T cells with FeLV B (PENHF) and 
the glycoGag mutant FeLV B (PENHFX) plasmids using the Lipofectamine 
transfection reagent (Invitrogen) according to manufacturer’s protocol as 
described in Chapter 2. DNA was extracted from the transfected 293T cells on 
Day 14 and PCR carried out using primers specific for FeLV B as shown in the 
Figure 6.7. 
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Figure 6.7 Transfection of 293T cells with PENHF and PENHFX 
 
Figure 6.7 PCR carried out using LTR primers specific for FeLV B and human GAPDH 
primers used as an internal control. DNA of MCF7 cells infected with FeLV B was used as a 
positive control.  
Figure 6.7 shows that the 293T cells were successfully transfected with PENHF 
(wild-type FeLV B) and PENHFX (glycoGag mutant FeLV B) plasmids. The next 
step was to infect Kyo1 cells using the supernatant from the PENHF and PENHFX 
transfected 293T cells. For this purpose 5x105 Kyo1 cells were infected with 
filtered (0.45m) supernatant from the PENHF and PENHFX transfected 293T 
cells. The cells were saturated by a repeated infection on the Day 3, again using 
the supernatant from the PENHF and PENHFX transfected 293T cells. On Day 14 
of infection, cell pellets were made and DNA was extracted. The DNA was used 
for PCR to confirm infection of Kyo1 cells using specific primers as shown in 
Figure 6.8. 
Figure 6.8 Infection of Kyo1 with PENHF and PENHFX 
 
Figure 6.8 PCR carried out using LTR primers specific for FeLV B and human GAPDH 
primers used as an internal control. DNA of MCF7 cells infected with FeLV B was used as a 
positive control.  
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Figure 6.8 shows that Kyo1 cells were infected with PENHF and PENHFX. The 
supernatants from Day 14 PENHF and PENHFX infected Kyo1 cells were used to 
perform a QN10 titration assay. The results of the QN10 titration assay are 
shown in the Table 6.3. 
Table 6.3 PENHF and PENHFX QN10 titration 
Cells Titre 
Kyo1 PENHF 1.52 x102 
Kyo1 PENHFX 1.5 X102 
AH927 FeLV B 4.2x105 
 
Table 6.3 Titration on QN10 cells shows the yield of infectious virus units capable of 
forming foci from the different infected cell lines. 
The Table 6.3 shows that the titre released from the Kyo1 cells was equivalent 
for glycoGag mutant (PENHFX) and wild-type (PENHF) FeLV B. Supernatant from 
AH927 cells infected with FeLV B was used as positive control for titration. This 
analysis suggests that both the wild-type and glycoGag mutant FeLV B have 
similar specific infectivities when grown in the partially susceptible cell line 
Kyo1.  
The next step was to see if the glycoGag mutant was impaired in human PBMCs. 
PBMCs were infected with filtered (0.45m) supernatant from the PENHF and 
PENHFX transfected 293T cells. Cells were harvested on Day 14, and were used 
to prepare pellets for DNA. Confirmation of FeLV B infection of PBMCs was 
carried out by PCR and is shown in the Figure 6.9. 
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Figure 6.9 PCR for PENHF and PENHFX infection of PBMCs 
 
Figure 6.9 PCR carried out using LTR primers specific for FeLV B and human MYC primers 
used as an internal control. DNA from 293 cells infected with FeLV B was used as a positive 
control. 
Figure 6.9 shows that PBMCs can became infected with both PENHF and the 
PENHFX. Day 14 supernatant from PBMCs was used for titration on QN10 cells. No 
titre was obtained from PENHF or PENHFX infected PBMC supernatant indicating 
that PBMCs do not release any infectious virus from either the wild-type or 
glycoGag mutant infected cells. 
6.4 Discussion 
In this chapter, I demonstrated the expression of restriction factors in different 
cells and the mutations induced in FeLV B after infecting these cells. This was 
carried out to seek mechanistic insight into the difference in susceptibility and 
processing of virus by these cells and the production of infectious particles and 
is summarised in the Table 6.4.  
No evidence of hypermutation in FeLV B was observed in the highly susceptible 
293 cell line which is also susceptible to rapidly spreading infection with FeLV, 
presumably due to the negligible levels of restriction factor activity in this cell 
line. All other cell lines examined showed evidence of APOBEC3-induced 
mutations and reduced specific infectivity of virions, although the identity of the 
APOBEC3 genes responsible for FeLV mutations could not be fully elucidated 
from the spectrum observed. The THP-1 cell line showed a predominance of GG 
target sites suggestive of APOBEC3G activity, while Kyo1 cells showed a 
predominance of GA targets, suggestive of A3F or other family members.  
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Table 6.4 Summary of restriction factor expression, PiT1 expression, mutations and susceptibility of FeLV B 
Cells A3A A3B A3C A3D A3F A3G SAMHD1 TRIM5 Tetherin PiT1 Total 
mutation/ 
bp 
sequenced 
G to A 
mutation 
(%) 
FeLV B 
entry 
FeLV B 
titre 
FeLV B 
Intra cellular 
Pr65
Gag
 
FeLV B 
Intracellular 
p27
Gag
 
FeLV B 
Virion 
p27
Gag
 
293 1 1 1 1 1 1 1 1 1 1 0/3600 0 + ND ND ND ND 
Kyo1 2.4 9.2 6.6 7.5 2.3 13.7 0.8 11.3 1.9 1.8 44/10800 97.7 + ++ ++ ++ ++ 
THP-1 1 18.8 3.3 0.1 0.2 15.4 16.8 7.7 4.5 1.4 38/6000 97.4 + + + 0 0 
Reh 5.5 0.4 1.7 1.6 1.5 16 0.2 15.7 2.2 3.5 4/1200 75 + + 0 0 0 
CEM 3.1 2.4 0.8 6.5 1 4.8 0.01 3.2 4.1 1.6 4/7200 75 + +++ ++ ++ ++ 
CEMSS 0.8 1 0.6 0.8 1.4 0.6 0.01 3 2.8 1.5 9/9600 89 + +++ ++ ++ ++ 
PBMC 196.4 7.7 7.2 29.3 10 178 3.3 6.6 3.4 1 3/13200 100 + 0 ND ND 0 
 
Table 6.4 Summary of restriction factor expression in a panel of cells compared with FeLV B susceptibility, processing, infectious virus titre, PiT1 receptor 
expression and mutations in FeLV B pol region. The restriction factor expression and PiT1 expression have been compared to corresponding expressions 
in 293 cells.
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While most studies on restriction factor activity for the APOBEC3 genes have 
focused on HIV as a target, extrapolation to FeLV is not straightforward as HIV 
encodes a potent counter-measure by expression of the Vif accessory protein 
that can degrade some APOBEC3 family members71. It has been reported that 
Moloney murine leukaemia virus is specifically susceptible to A3B and A3G due to 
the ability of these proteins to become encapsidated via binding to MLV Gag249. 
However, this report is not consistent with recent evidence that APOBEC 
encapsidation occurs quite non-specifically via broadly specific RNA binding250.  
THP-1 cells also expressed high levels of SAMHD1. SAMHD1 is known to inhibit 
HIV-1 infection in non-dividing macrophages and dendritic cells, primarily by 
depleting nucleotide pools111 and it high expression in THP-1 cells is not 
surprising. The fact that THP-1 are dividing suggests that SAMHD1 restriction will 
not be operative in these cells. TRIM5is another restriction factor known to 
inhibit HIV infection251 and is known to be operative against some murine 
leukaemia virus strains (N-tropic, but not B-tropic)252. It is expressed more highly 
in Reh cells but as this factor appears to act at a stage prior to reverse 
transcription it seems unlikely as a candidate for the block after proviral DNA 
synthesis that I observed. The occurrence of G to A mutations in CEMSS cells 
despite low levels of APOBEC3 gene expression is hard to account for and merits 
further study. It is possible that the levels of mRNA expression are not fully 
representative of protein levels or functional activity. 
I did not check the restriction factor protein levels in different cells and also 
whether all cell lines were expressing same restriction factor proteins or their 
variants or mutant forms were not confirmed. The variant or mutant forms of 
these restriction factor proteins could have a great impact on the antiviral 
properties of these restriction factors. It is also likely that host resistance does 
not depend on any single restriction factor activity and may be due to an inter 
play between different restriction factors, and the combined effect resulted in 
the observed differences in the specific infectivity of the virus released. 
It has been shown that XMRV used to infect macaques showed an initial rise in 
plasma levels, which later on disappeared from the plasma after 4 weeks, 
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though XMRV DNA was still detectable in PBMCs up to 119 days after infection253 
suggesting a limited gammaretrovirus replication in vivo. XMRV was efficiently 
restricted by the host restriction factors, with APOBEC3 playing a significant 
role, shown by the increasing G to A mutation, thus highlighting one of the 
mechanisms why gammaretrovirus do not infect humans despite high levels of 
human exposure to these agents253. The expression of APOBEC3A, APOBEC3D and 
APOBEC3G was very high in PBMCs which may conceivably be responsible for the 
undetectably low infectious titre and virion particle release. I was able to clone 
and sequence only 2 templates of FeLV from the PBMCs in spite of repeated 
efforts. These efforts were repeated later by Nancy Mackay who used an 
alternative PCR protocol (unpublished results) and obtained 9 clones which 
showed only 3 G to A mutations despite the high level of APOBEC3 expression in 
PBMCs. It seems likely that this reflects the lack of replication and the inability 
of APOBEC to mutate incoming viral DNA. APOBEC3 is also known to inhibit 
retrovirus infection by mechanisms other than G to A mutations e.g. by 
interfering with reverse transcription or integration of the retroviral DNA into 
the cell76,77. Therefore a cytidine deaminase independent mechanism can be a 
possible explanation in this case which needs to be investigated further. 
Tetherin is known for restricting HIV particle release100 but no correlation was 
observed between expression of Tetherin and virion particle-related protein 
released into the supernatant.  
I also found no difference in the infectious titre of wild-type and glycoGag 
mutant FeLV B released from infected Kyo1 cells. The glycoGag protein has been 
described to play a role in MLV budding or release from cells93. MLV glycoGag has 
also been described to counteract mouse APOBEC3 activity91. Repairing the 
defective glycoGag of XMRV has also been shown to increase its infectivity92. I 
confirmed the presence of mutation in the glycoGag start codon region in the 
FeLV B mutant (PENHFX) plasmid as compared to the wild-type FeLV B which 
could result in a stop codon in the glycoGag transcript but found no difference in 
its ability to replicate or evade APOBEC activity in Kyo1 cells or human PBMCs.    
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7 Phenotypic effects of gammaretrovirus infection 
on human cells 
7.1 Introduction 
In the previous chapters, it has been shown that many human cell lines are 
susceptible to XMLV infection. Therefore the cell lines developed by 
xenografting or used in xenograft experiments or kept in the same laboratory 
may get infected with XMLV173. The presence of XMLV contamination may affect 
human cell biology and thus act as a confounding factor for experimental 
results.  
The main aim of studies described in this chapter was to investigate whether 
gammaretroviral infection/contamination of samples (especially XMLV) could 
affect the behaviour of cells.  
7.2 Materials and methods 
Materials and methods have been discussed in detail in Chapter 2. 
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7.3 Results 
7.3.1 XMLV and FeLV B infected MCF7 cells show accelerated 
wound healing compared to uninfected MCF7 cells 
As shown in Chapter 4 that XMLV can successfully infect MCF7 cells and integrate 
at multiple sites in the MCF7 genome. As retroviruses can exert their oncogenic 
action by disrupting host gene expression or coding sequences15, ongoing 
integration of XMLV provirus could affect the behaviour of the cell line by 
activating/deactivating adjacent genes. In addition to the risk of insertional 
mutagenesis there are other mechanisms by which XMLV may conceivably affect 
cell behaviour, including effects mediated by ligation of entry receptors and 
expression of viral proteins that may affect cell function. The aim of these 
experiments was to investigate whether gammaretrovirus infection of MCF7 cells 
could affect their migratory properties, determined by their ability to migrate 
across an artificially created wound in a confluent layer of cells. Wound assays 
were carried out on MCF7 cells that had been infected with either XMLV or FeLV 
B for at least 14 days, as described in Chapter 2. The experiments were 
repeated three times and in each experiment 5-6 wounds were made. From 
these, wounds with comparable size and shape were selected resulting in the 
measurement of three wounds per sample in experiments 1 and 2, and five 
wounds per sample in experiment 3. Wound healing was monitored using Image J 
software and serial images recorded at regular intervals. The results are shown 
in Figure 7.1 and demonstrate that viral infection, with either FeLV or XMLV, 
modestly influenced the rate of wound healing as discussed below. 
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Figure 7.1 Wound healing assay 
 
 
 
Figure 7.1 Wound healing assay. (a) Images of wounds at time zero. (b) Images of partially 
healed wounds at 34 hours. (c) Percentage of open wound at different time intervals. Error 
bars represent standard deviation. (d) Percentage of open and closed wound after 34 hours. 
Figure 7.1 (a & b) shows that at 34 hours the wound size in XMLV and FeLV B 
infected MCF7 cells is reduced compared to uninfected controls. At this time 
point the wound had closed by 67% (±7.7%) and 59% (±10.3%) in MCF7 FeLV B and 
MCF7 XMLV infected cells respectively. By contrast the wound had only closed by 
36% (±6%) in uninfected MCF7 cells (Figure 7.1d). T-test was applied to the data 
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obtained for the three different experiments separately at the 34-hour time 
point. These results are shown in Table 7.1. 
Table 7.1 Analysis of wound assay 
  T-test (p value) 
 
1st Experiment 
(3 wound per sample) 
MCF7/MCF7B 0.009* 
MCF7/MCF7X 0.02* 
MCF7B/MCF7X 0.72 
 
2nd Experiment 
(3 wound per sample) 
MCF7/MCF7B 0.001* 
MCF7/MCF7X 0.007* 
MCF7B/MCF7X 0.121 
 
3rd Experiment 
(5 wound per sample) 
MCF7/MCF7B 0.001* 
MCF7/MCF7X 0.011* 
MCF7B/MCF7X 0.485 
 
Table 7.1 Statistical analysis of wound assay using Student T-test. MCF7B and MCF7X 
denote MCF7 cells infected with FeLV B and XMLV respectively. *p value <0.05 has been 
taken as significant. 
The foregoing results demonstrate that in all three experiments wound healing 
was significantly accelerated in FeLV B and XMLV cells compared to control cells. 
Although statistically significant, the difference between infected and control 
cells was relatively modest. The results suggest that both viruses can alter 
wound healing while there was no significant difference between FeLV B and 
XMLV infected cells. These data should be considered preliminary due to 
relatively small sample size and the conclusions drawn would benefit from 
further repeat experiments. 
As the cells were chronically infected with XMLV or FeLV B there is a possibility 
that the effects on would healing were due to evolution of the infected cell 
lines, perhaps due to insertional effects. To explore this further these 
experiments were repeated in cells freshly infected with FeLV B as shown in 
Figure 7.2. 
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Figure 7.2 Wound assay for freshly infected MCF7 cells 
 
Figure 7.2 Wound healing in fresh FeLV B infected MCF7 cells and the uninfected MCF7 
cells. 
In contrast to the results observed in cells that had been infected for greater 
than 14 days before carrying out the wound healing assays, no difference was 
seen in the rate of wound closure between MCF7 cells freshly infected with FeLV 
B and uninfected cells. This experiment was only carried out once with five 
wounds per sample but, the discordant result suggests that longer term infection 
may be required to alter cell behaviour, perhaps driven by clonal expansion 
following insertional mutagenesis.  
7.3.2 THP-1 cells differentiate when exposed to XMLV supernatant 
In the above experiments, it has been shown that gammaretrovirus infection can 
alter the behaviour of infected MCF7 cells, although the effect is modest. To 
investigate whether infection had a discernible effect in other susceptible cells I 
infected THP-1 cells with XMLV as described in Chapter 2 and as shown in Figure 
7.3.  
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Figure 7.3 Altered morphology and cell number in XMLV treated THP-1 cells 
 
 
 
 
Figure 7.3 (a) & (b) THP-1 cells before and 48 hours after XMLV infection respectively. (c) 
Total number of THP-1 cells 96 hours after infection with XMLV. (d) Number of live cells 96 
hours after infection. (e) Number of dead cells 96 hours after infection. 
Supernatant treated cells showed rapid morphological changes not observed in 
control cells. The phenotype is shown in Figure 7.3 (a & b) and was 
characterised by an obvious change in cell number, cell appearance and an 
increased tendency to adhere to the surface of the tissue culture plate. In 
addition Figure 7.3 (a & b) also shows that the THP-1 cells became spindle 
shaped after exposure to XMLV-infected cell supernatant. The cells also 
appeared to be enlarged and were adherent to the flask. To investigate whether 
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the growth of THP-1 cells was affected, the cells were counted 96 hours after 
XMLV infection at which point cells exposed to viral supernatant showed a 
greater than two-fold reduction in total cell number (1.5x106) compared to non-
infected cells (3.9x106) (Figure 7.3c). Among the uninfected THP-1 cells the 
majority of cells (3.3x106) were alive and in suspension with only a small number 
of live adherent cells (6.3x104), moreover a relatively small proportion of cells 
were dead (5.1x105) as shown in Figure 7.3 (d & e). In contrast, the majority of 
live XMLV infected cells were adherent (7.3x105 were adherent, 5x105 in 
suspension) as shown in Figure 7.3d. Among XMLV infected THP-1 cells, the total 
number of dead cells was 2.7x105 as shown in Figure 7.3e. Thus XMLV infection 
of THP-1 cells seemed to have a dual effect; it reduced their viability and 
changed their properties making them more prone to adhere to the surface of 
the plate. This experiment was repeated three times in triplicate. 
The next step was to see whether the THP-1 cells exposed to the XMLV 
supernatant were differentiated or not. For this purpose the expression of CD14, 
a surface marker upregulated during macrophage differentiation, was assayed by 
PCR. THP-1 cells were exposed to supernatant from XMLV infected MCF7 cells 
and grown for 48 hours before RNA was harvested using the RNeasy kit (Qiagen) 
as described in Chapter 2. This experiment was performed in duplicate. The 
primer design as well as the thermal cycling conditions were as described by 
Park et al254 and the results are shown in Figure 7.4. 
Figure 7.4 PCR for CD14 expression 
 
Figure 7.4 CD14 expression in THP-1 cells infected with XMLV using CD14 specific primers. 
Human Actin primers were used as an internal control. 
  151 
 
Figure 7.4 shows that both samples of THP-1 cells exposed to XMLV expressed 
slightly more CD14 compared to uninfected THP-1 control cells. This result 
suggested that the infected THP-1 cells were undergoing differentiation.  
To further demonstrate differentiation in XMLV infected THP-1 cells, flow 
cytometry was carried out using anti-human CD54 antibodies. CD54, also known 
as intracellular adhesion molecule 1 (ICAM1), is another surface marker for 
macrophages. CD54 expression is known to be higher in natural and PMA 
stimulated macrophages compared to monocytes255. The THP-1 cells were 
exposed to supernatant from XMLV infected MCF7 cells and were grown for 2 
days before analysing CD54 cell surface expression by flow cytometry using APC 
mouse anti-human CD54 (559771, BD Biosciences) antibody shown in the Figure 
7.5. 
Figure 7.5 Flow cytometry for CD54 expression 
 
Figure 7.5 Flow cytometry using anti-human CD54 antibody in uninfected THP-1* and XMLV 
infected THP-1 cells**. 
Figure 7.5 shows that THP-1 cells infected with XMLV show higher levels of CD54 
expression compared to the uninfected THP-1 cells. This shows that the THP-1 
cells exposed to supernatant from the XMLV infected MCF7 cells showed changes 
consistent with increased differentiation towards a macrophage phenotype.  
These results suggested that XMLV could induce the THP-1 cells to differentiate 
but other factors present in supernatant of XMLV infected THP-1 cells could be 
responsible for this phenotypic change. To ensure the effects were XMLV 
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mediated I assayed the XMLV infected MCF7 cells, and 293T cells, for 
Mycoplasma contamination using PCR, by designing and ordering primers used by 
Zakharova et al256. The results of the PCR are shown in the Figure 7.6. 
Figure 7.6 PCR to detect Mycoplasma 
 
Figure 7.6 PCR carried out using Mycoplasma specific primers and human GAPDH primers 
as an internal control. 
XMLV infected MCF7 cells and XMLV infected 293T cells were positive for 
Mycoplasma using 280 Myco primers (Figure 7.6). The uninfected 293T cells were 
negative. A positive control for Mycoplasma was not available at this point but 
these results were later confirmed by my colleague Nancy Mackay using a 
commercial Mycoplasma detection kit (Venor-Gen, Minerva Biolabs).  
The next step was to see the effect of XMLV-free Mycoplasma, Mycoplasma-free 
XMLV, and both XMLV and Mycoplasma-free MCF7 supernatant on THP-1 cells. In 
performing this experiment I was fortunate in having two sources of MCF7 cells, 
the original potentially contaminated cells and a clean source thought to be 
Mycoplasma free. THP-1 cells were exposed to Mycoplasma-contaminated but 
XMLV-negative MCF7 cell supernatant, Mycoplasma-negative MCF7 cell 
supernatant and supernatant from XMLV infected Mycoplasma-negative MCF7 
cells. All supernatant were filtered using 0.45m filter. Fresh medium was added 
after 2 hours. Both suspension and adherent cells were counted after 24 hours 
using a haemocytometer. These experiments were carried out in triplicate and 
the results are summarised in Figure 7.7. 
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Figure 7.7 THP-1 differentiation by XMLV free Mycoplasma 
 
Figure 7.7 Comparison of the effects of XMLV and Mycoplasma (separately) containing 
MCF7 cell supernatant on THP-1 cells. Uninfected MCF7 cell supernatant was used as 
negative control. 
Figure 7.7 shows that THP-1 cells exposed to Mycoplasma free MCF7 cell 
supernatant and Mycoplasma-free XMLV infected MCF7 cell supernatant had a 
similar number of suspension cells. In the case of Mycoplasma free MCF7 cell 
supernatant, 1x106 THP-1 cells (±5.3 x104) were found to be in suspension, but 
only 7.5 x104 (±1.5 x104) were found to be adherent. In the case of THP-1 cells 
exposed to XMLV infected (Mycoplasma free) MCF7 cell supernatant, 9.6x105cells 
(±8.1 x104) were found to be in suspension while only 6.5 x104 (±8.6x103) cells 
were found to be adherent. By contrast THP-1 cells exposed to the Mycoplasma 
contaminated XMLV-free MCF7 cell supernatant showed a change in their 
morphology and a greater proportion of the THP-1 cells (5x105 ±5.3 x104) were 
found to be adherent to the flask while only 2.9x105cells (±8.8x104) were in 
suspension This shows that XMLV infected MCF7 cells and uninfected MCF7 cell-
supernatant had very little effect on the THP-1 cells, but the Mycoplasma 
contaminated MCF7 cell supernatant induced significant changes in the THP-1 
cultures. Thus the changes observed earlier were most possibly due to 
Mycoplasma. The CD14 and CD54 differentiation experiments were not repeated 
for XMLV free Mycoplasma infected THP-1 cells, because of the concern of 
potentially spreading the contamination to other colleagues using the same 
laboratory facility.  
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After detecting Mycoplasma in my samples, it was very important to detect the 
source of Mycoplasma. For this purpose, PCR was carried out for Mycoplasma 
using original MCF7 cell DNA, from cells that were received from Beatson and 
used for xenografting, the MCF7 primary tumour explants from these cells, and 
also MCF7 gifted by Anne Terry (University of Glasgow) were used. The PCR 
results are shown in the Figure 7.8. 
Figure 7.8 PCR for detecting source of Mycoplasma 
 
Figure 7.8 PCR carried out using Mycoplasma specific primers and human GAPDH primers 
as an internal control. 
These results confirm MCF7 cells received from Beatson (Figure 7.8) were 
contaminated with Mycoplasma. These were the cells used for xenografting 
experiments, however MCF7 cells recovered from explants showed no evidence 
of Mycoplasma infection. This observation suggests that passage through the 
mouse had cleared the cells of Mycoplasma infection.  
7.3.3 Raji cells infected with XMLV do not differentiate 
An interesting observation was made by Sturzel et al257. They claimed that Raji 
cells (Burkitt’s lymphoma cell line) undergo syncytium formation when infected 
with XMRV. As described earlier, XMRV shares 93% sequence similarity with XMLV 
and also uses the same receptor XPR1 to enter cells, therefore I decided to 
check the effects of XMLV infection on Raji cells. Any change in behaviour would 
mean significant implications for the study of lymphoma cells when used for 
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xenografting. For this experiment, Raji cells were infected with filtered 
supernatant from MCF7 cells infected with XMLV as described in Chapter 2. 
Despite evidence of infection no discernible change was observed in the 
morphology of XMLV infected Raji cells, nor was there any evidence of syncytium 
formation. This experiment was repeated three times. The supernatant used to 
infect Raji cells was free of Mycoplasma contamination. The effects of 
Mycoplasma on Raji cell behaviour were not determined. 
7.4 Discussion 
In this chapter I have demonstrated that gammaretrovirus particularly XMLV, 
could affect the behaviour of cancer cells. The wound-healing assay was carried 
out to see if there are any effects of XMLV and FeLV B infection on the 
properties or behaviour of MCF7 cells. It was found that the gammaretroviral 
(XMLV and FeLV B) infected MCF7 cells showed a slightly increased rate of wound 
healing compared to the uninfected MCF7 cells. The starting size of the wound 
was very important for wound healing. It was found that narrow wounds healed 
rapidly as compared to wide wounds of the same sample of cells. To overcome 
this confounding factor, only wounds of comparable starting sizes were selected 
for analysis. It was also found that when very recently infected MCF7 cells were 
used for the wound-healing assay, no difference was seen between the rate of 
wound healing in the infected and uninfected MCF7 cells. Only the MCF7 cells 
chronically infected with XMLV and FeLV B showed a difference in wound 
healing. The mechanism by which infected MCF7 cells healed more quickly 
compared to uninfected MCF7 cells is not known but the possibility of insertional 
mutagenesis and clonal expansion cannot be ruled out. There have been similar 
claims that XMRV infection can increase the in vitro migration rate of LNCaP 
prostate cancer cells189,258. Whether the effects in the case of XMLV are due to 
the direct action of viral proteins or the consequences of insertional activation 
of key cellular genes is unknown as yet. Whatever the exact explanation is, 
XMLV/FeLV B affects the migratory properties of cells, although in the context 
of these experiments, the effect is a relatively minor one. These results 
demonstrate that XMLV infection of xenografts or through horizontal 
contamination of other samples in the laboratory may potentially alter the 
results of the experiments under consideration. These results emphasise the 
need for investigators to be more widely aware of these potential confounding 
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factors. Other gammaretroviruses with the capacity to infect human cells may 
also present a risk, e.g. GaLV has been reported as an in vitro contaminant, 
highlighting the need for precautions and thorough testing of cell lines for 
adventitious infection178.  
I have also demonstrated that infection of THP-1 cells, a monocytic leukaemia 
cell line with Mycoplasma resulted in a change of phenotype, inducing adhesion, 
reduced viability and differentiation along the macrophage lineage. These 
effects of Mycoplasma infection on THP-1 cells and human monocytes have 
already been described by others259,260. These results were a potent reminder 
that other factors need to be eliminated when investigating the effects of XMLV 
carried within the supernatant derived from primary virus producing cells. The 
effects of Mycoplasma on Raji cells were never determined. I was not able to 
demonstrate syncytia formation in Raji cells when infected with XMLV. This was 
contrary to the findings of Sturzel et al257 who reported that Raji cells displayed 
syncytia formation following XMRV infection.  
Experiments originally conducted with Mycoplasma contaminated XMLV were 
subsequently repeated with Mycoplasma free XMLV. The results for all the 
experiments were the same as before, specifically accelerated wound healing 
was not related to Mycoplasma infection. Another interesting fact was noticed 
that Mycoplasma infection could be cleared by passaging contaminated cells 
through mice. This result has also been previously reported by Carroll & 
Kennedy261. 
Thus it is very important not only to screen for gammaretrovirus contamination 
in cells grown in laboratories working with viruses; cells should be screened for 
Mycoplasma and other intracellular contaminants as well. Since both 
gammaretroviruses as well as Mycoplasma contamination can affect the cell 
behaviour and thus the overall results of the experiment, it may be worthwhile 
considering specifically reporting that cells used in certain types of experiments 
are free of gammaretrovirus and Mycoplasma.  
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8 Effects of XMLV infection on human cell 
transcriptomes 
8.1 Introduction 
In the previous chapters, I have shown that a number of human cell lines are 
susceptible to XMLV infection. I have also shown that XMLV (and FeLV B) can 
affect the behaviour of human cells. I have also shown that XMLV susceptible 
cell lines MCF7 and Raji cells behaved differently when used for xenografting. 
MCF7 cells formed tumour nodules and the MCF7-BALB/c tumour explants 
released infectious XMLV. Raji cells, on the other hand, when used for 
xenografting into BALB/c mice initially formed lumps, which later regressed 
(Chapter 3). Thus it was interesting to determine whether XMLV infection of 
human cells could result in a significant change in the cell transcriptome that 
might explain changes in cell behaviour. 
The main aim of the studies described in this chapter was to investigate whether 
persistent XMLV infection affects the expression pattern of human cellular genes 
and whether the altered expression pattern could be correlated with any known 
host genetic pathway or function. It was also of interest to see whether or not 
the change in expression pattern was cell type or gammaretrovirus specific. Two 
XMLV susceptible cell lines: MCF7 and Raji cells were selected for this purpose.  
 
8.2 Materials and methods 
Materials and methods have been discussed in Chapter 2. 
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8.3 Results 
8.3.1 Changes in gene expression after XMLV infection 
RNA was extracted from MCF7 and Raji cells infected with XMLV as described in 
Chapter 2. The quality and the quantity of this RNA was determined using a 
Nanodrop spectrophotometer (Thermo Scientific) and was confirmed with Anne 
Terry’s help using Agilent 2100 Bioanalyzer and is given in Table 8.1. 
Table 8.1 Quality check of RNA samples 
Sample 
Conc. 
(ng/l) 
OD 
260/280 
OD 
260/230 
MCF7 1 739 2.05 2.19 
MCF7 2 820 2.06 1.38 
MCF7 3 730 2.04 2.11 
MCF7 XMLV 1 640 2.08 1.62 
MCF7 XMLV 2 840 2.06 1.70 
MCF7 XMLV 3 690 2.06 2.10 
Raji 1 270 2.07 2.12 
Raji 2 430 2.10 2.16 
Raji 3 200 2.04 2.13 
Raji XMLV 1 310 2.08 1.88 
Raji XMLV 2 830 2.05 2.23 
Raji XMLV 3 670 2.07 2.21 
 
Table 8.1 Quantity and quality of RNA samples determined by Nanodrop. All the RNA 
samples satisfied the desired quality requirements (OD260/280 > 1.5; OD260/230 >1.0).  
Approximately 500ng of RNA for each sample was submitted for Affymetrix 
human Gene 2.0 ST expression analysis. All the steps needed for the microarray 
including cDNA synthesis and amplification, cDNA purification, fragmentation 
and labelling, hybridization, washing and scanning of appropriate Affymetrix 
Gene Chip and primary data analysis including normalization and calculation of p 
value for each transcript across infected and uninfected triplicate samples and 
calculation of fold change (FC) was performed by the Atlas Biolabs. I confirmed 
fold changes by recalculation and investigated a total number of 48,416 
transcripts/entities to detect differentially expressed genes. A summary of 
transcripts with a differential expression at various levels of significance is 
shown in the Figure 8.1. 
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Figure 8.1 Differential expression of transcripts 
 
Figure 8.1 Number of up regulated and down regulated transcripts for XMLV infected MCF7 
and Raji cells at different levels of significance. 
 Figure 8.1 shows that in the Raji cells infected with XMLV, many more biological 
entities have shown a change in the expression levels when these are sorted by p 
value. A similar difference was noted when the probe sets were sorted by fold 
change (Figure 8.2).  
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Figure 8.2 Differential expression of transcripts in terms of fold change 
 
Figure 8.2 Number of up regulated and down regulated transcripts for XMLV infected MCF7 
and Raji cells at different levels of fold change. 
It is generally recommended to use multiple testing corrections for large data 
sets to exclude false positives. The Benjamini and Hochberg False Discovery Rate 
(BH FDR) which is known to be high in terms of stringency, was applied using the 
formula “FDR = p value x (n/rank of the entity), significant if < 0.05” 262. Where 
“n” is the total number of entities and “rank of an entity” is its serial number 
when entities are arranged in ascending order of their p values. Applying this 
stringent test left only 99 probe sets with a FDR of <0.05 in the Raji set and none 
from the MCF7 array. However, while this very stringent statistical test is robust 
for elimination of false positives, it can lead to exclusion of genuine 
differences263. I noticed that many of the highly significant changes by FDR 
represented very small fold changes while some genes with larger fold changes 
fell just short of the stringent cut-off. Also, some of these genes and transcripts 
just under the threshold were represented by more than one probe set or by 
orthologues with similar changes in expression level, indicating the likelihood 
that the stringent FDR cut-off was eliminating real differences. I therefore 
decided to analyse the dataset using a compromise threshold of standard p value 
<0.05 and fold change ≥ 1.5. These provisional datasets were subjected to 
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further analysis and validation of selected genes that appeared likely to be 
biologically significant.  
The entities from both the XMLV infected MCF7 and Raji cells that have shown a 
fold change (FC) ≥1.5 in expression level were analysed by Ingenuity Pathway 
Analysis (IPA) software. The total number of genes selected for analysis is 
summarised in Figure 8.3. 
Figure 8.3 Differentially expressed genes with fold change ≥ 1.5 
 
Figure 8.3 117 well-annotated genes were up regulated and 201 well-annotated genes were 
down regulated with a fold change of 1.5 or more in XMLV infected Raji cells. In XMLV 
infected MCF7 cells, 22 well-annotated genes were up regulated and 24 well-annotated 
genes were down regulated with a FC of 1.5 or more.  
The heat map for the top 50 genes with FC≥1.5 and p value <0.05 is given in the 
Figure 8.4.  
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Figure 8.4 Heat map for signal intensity of top 50 individual gene entities 
 
Figure 8.4 Relative signal intensities of top 50 gene entities, differentially expressed in 
XMLV infected MCF7 and Raji cells versus the respective uninfected ones. All the entities 
have been assigned a colour based on their expression relative to the baseline. The green 
and red colours indicate the maximum and minimum expression values respectively with 
yellow colour indicating a borderline expression. 
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The complete list of these genes is given in the Appendix 5 along with functional 
annotations in the IPA listings. The results are summarized briefly in the Table 
8.2. 
Table 8.2 Functional summary of entities with ≥ 1.5 fold change expression 
 Categories on basis of function 
Up regulated 
Entities  
Down regulated 
Entities 
Raji MCF7 Raji MCF7 
Cytokine 2 0 3 1 
Enzyme 19 1 23 1 
G protein coupled receptor 4 1 6 2 
Growth factor 2 0 0 0 
Ion channel 1 0 5 0 
Kinase 7 0 8 0 
Ligand dependent nuclear receptor 1 0 1 0 
miRNA 7 1 4 7 
Other 65 12 121 11 
Peptidase 5 1 2 0 
Phosphatase 2 0 0 1 
Transcription regulator 0 6 14 0 
Translation regulator 0 0 0 0 
Transmembrane receptor 0 0 6 0 
Transporter 2 0 8 1 
Total Genes 117 22 201 24 
 
Table 8.2 Different categories in which the differentially expressed genes can be grouped by 
function.  
As can be seen, most of the changes affect entities of unknown function 
(“Other”). Enzymes was the next most frequent category in the Raji cells with 
kinases as an abundant subset.   
The only differentially expressed gene common to both XMLV infected Raji and 
MCF7 cells was zinc finger protein 826, pseudogene (ZNF826P) which was up- 
regulated in Raji cells (1.87 FC, p= 0.007) and in MCF7 cells (1.76 FC, p= 0.002).   
The differentially expressed well-annotated genes in the XMLV infected Raji and 
XMLV infected MCF7 cells with a FC≥1.5 were further analysed using the IPA 
software. The IPA analyses include assessments of the relationship between the 
proteins encoded by the list of genes on the basis of their annotated functions 
and interactions. This analysis is based on reports in the scientific literature. 
The IPA software then groups the genes into networks according to host 
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functions affected. Fisher’s exact test is used to determine statistical 
significance of any associations discovered. The different host functions altered 
in XMLV infected Raji and MCF7 cells as determined by IPA are summarized in 
the Figure 8.5.  
Figure 8.5 Host functions affected in XMLV infected Raji and MCF7 cells 
 
Figure 8.5 Host functions affected in XMLV infected Raji cells and XMLV infected MCF7 cells 
as compared to the respective uninfected cells. The horizontal axis shows –log of p value of 
overlap of the differentially expressed genes related to host functions affected.  
It should be noted that the functional grouping of genes by IPA software is based 
on the current literature related to the genes and cannot be regarded with the 
same rigour as, for example, biochemical pathway analysis. However, it can be 
useful in formulating hypotheses. IPA mapping of the differentially expressed 
genes to canonical pathways showed a number of interesting associations. 
Fisher’s exact test was used to determine significance. No canonical pathway 
with a gene overlap having a significance of less 10-5 was observed in MCF7 cells 
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but in Raji cells two canonical pathways were found to be significant. These are 
illustrated in Figure 8.6. 
Figure 8.6 Significant canonical pathways 
 
Figure 8.6 Two canonical pathways with genes overlapping with that of the differentially 
expressed genes in Raji cells infected with XMLV with a significance of p value <10
-5
. Black 
line with dots represents ratio of differentially expressed genes in XMLV Raji cells that 
belong to the respective pathway to total number of genes in the respective pathway.  
The first pathway affected (Figure 8.6) was the G2/M DNA damage checkpoint 
regulation pathway. A total number of 8 genes out of 49 genes (16.3%) of this 
pathway was differentially expressed in XMLV infected Raji cells. The p value of 
overlap for this pathway was 1.28 x10-7 .The second significant observation was 
for the ATM signalling pathway. The p value of overlap for this pathway was 
7.35x10-6, with seven out of 59 pathway genes (11.9%) differentially expressed in 
XMLV infected Raji cells. The ATM signalling pathway is normally activated as a 
result of double strand DNA damage and in turn activates the G2/M DNA damage 
check point, to arrest the cell cycle and repair the damaged DNA 264. This 
analysis did not take into account the direction of change in expression. 
Therefore the next step was to determine whether the genes mapped to the 
pathway were would be predicted to stimulate or inhibit. The following genes 
were mapped to the canonical pathways: Cyclin dependent kinase 1(CDK1), 
Cyclin B1 (CCNB1), Cyclin B2 (CCNB2), Growth arrest and DNA-damage-inducible 
alpha (GADD45A), Cell division cycle 25C (CDC25C), CDC28 protein kinase 
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regulatory subunit 2 (CKS2), Polo-like kinase 1 (PLK1), Aurora kinase A (AURKA), 
Growth arrest and DNA-damage-inducible beta (GADD45B) and Fanconi anaemia 
complementation group D2 (FANCD2). The first 5 genes were common to both 
pathways. The G2/M DNA damage checkpoint regulation pathway included the 
first 8 genes, while the ATM signalling pathway included the first 5 and the last 
two genes. Among these genes, CDK1, CCNB1, CCNB2, CDC25C, PLK1, CKS2, 
FANCD2 and AURKA were up regulated in Raji cells infected with XMLV (see 
Appendix 5 for further details), while only GADD45A and GADD45B were down 
regulated. The pattern of gene expression in Raji cells favours cell cycle 
progression, and not cell cycle arrest. In fact up regulation of CCNB1, CDK1, 
PLK1 and CDC25C all favour the entry of cells into mitosis265. The effect of these 
differentially expressed genes in Raji cells need to be confirmed experimentally. 
For this purpose, the expression of genes should be compared with the 
respective translated proteins and then the functional effects of any 
differentially expressed proteins on Raji cell behaviour should be investigated. 
8.3.2 Validation of microarray by qRT-PCR 
The microarray gene data were validated to ensure that expression changes 
were not due to false discovery in the large dataset. A panel of 7 genes of 
biological interest, including both up regulated and down regulated genes was 
selected for validation by qRT-PCR. The results are summarised in Figure 8.7. 
Figure 8.7 Validation of microarray results by qRT-PCR 
 
Figure 8.7 Comparison between the results of validation by qRT-PCR and the results of the 
Raji microarray.  
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Figure 8.7 shows that each of the differentially expressed genes on the 
microarray was validated by qRT-PCR, reinforcing the results of the microarray. 
This shows that the changes in gene expression predicted by the microarray are 
genuine.  
  
8.3.2.1 Validation of Early Growth response-1 (EGR1) gene expression in 
MCF7 XMLV by qRT-PCR 
In the MCF7 XMLV microarray, the expression of two different EGR1 gene probe 
sets was found to be up regulated in the XMLV infected MCF7 cells with 2.2 and 
2.16 fold change and with p values of 0.0211 and 0.0218 respectively. The 
expression of EGR1 was validated in MCF7 cells infected with XMLV by qRT-PCR. 
The result is shown in the Figure 8.8. 
Figure 8.8 Validation of EGR1 gene 
 
Figure 8.8 EGR1 shows a fold change of 1.97 by qRT-PCR. This validates the gene 
expression of EGR1 in MCF7 XMLV microarray, which shows a fold change of 2.2 and 2.16.  
The differential expression of EGR1 predicted by the microarray analysis is 
therefore a genuine change that may be of biological significance in MCF7 cells 
infected with XMLV. 
8.3.3 Comparison of change in miRNA expression 
Visual inspection of the microarray lists showed an interesting phenomenon as 
many of the small changes observed in XMLV infected MCF7 cells affected 
miRNAs. I explored this further and all of the miRNAs which showed differential 
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expression at significance of p<0.05 are listed in Table 8.3 and illustrated in 
Figure 8.9 (The cut-off of FC ≥1.5 was not applied here). 
Figure 8.9 Differentially expressed miRNAs 
 
Figure 8.9 In contrast to the coding gene changes, the numbers of miRNAs displaying 
differential expression was greater in XMLV infected MCF7 cells than Raji cells. 
 
Table 8.3 Differentially expressed miRNAs 
 
Table 8.3 Differentially expressed miRNAs in MCF7 and Raji cells infected with XMLV. Three 
miRNAs were common between MCF7 and Raji cells (underlined).  
 Down regulated miRNA Up regulated miRNA 
MCF7 cells 
MIR16-2, MIR619, MIR3184, MIR423, 
MIR3685, MIR1293, MIR4794, 
MIR554, MIR584, MIR3911,  
MIR1289-1, MIR1253, MIR3684, 
MIR15B, MIR631, MIR3148, MIR4718, 
MIR31, MIR4705, MIR4433, MIR4280, 
MIR4680, MIR1304, MIR627, MIR454, 
MIR632 
 
MIR1236, MIR3672, MIR613, MIR1324 
MIR1324, MIR1184-1, MIR1184-2, 
MIR1184-3, MIR3661, MIR518F, 
MIR4765, MIR4744, MIR3910-1, 
MIR3910-2, MIR4803, MIR153-1, 
MIR106B, MIR4776-1, MIR4776-2, 
MIR1234, MIR939, MIR3606, MIR132, 
MIR1976, MIR214, MIR3120, 
MIR4689, MIR4770, MIR1185-2, 
MIR4638, MIR431, MIR4791,  
MIR511-1, MIR511-2, MIR3116-1 
MIR3116-2, MIR4752, MIR934, 
MIR744, MIR1322, MIR3150A, 
MIR3150B, MIR548M, MIR770, MIR140 
Raji cells 
MIR944, MIR1204, MIR4477A, 
MIR1302-3, MIR23C, MIR103A2, 
MIR103A2, MIR320B2, MIR15B, 
MIR378I, MIR376C, MIR155, MIR3146, 
MIR411, MIR1913, MIR329-2, 
MIR1245A 
 
MIR4495, MIR193A, MIR4288, 
MIR1295A, MIR148A, MIR24-2, 
MIR574, MIR574, MIR4640, MIR576, 
MIR943, MIR130B, MIR1253, 
MIR3689F, MIR1205, MIR193B, 
MIR613, MIR4732, MIR181C, MIR661, 
MIR4442, MIR346, MIR372, MIR548I3, 
MIR4478, MIR3972, MIR345, MIR150, 
MIR603, MIR382, MIR2909, MIR548T, 
MIR4254 
  169 
 
Very few miRNA changes were common between MCF7 and Raji cells and only 
two (MIR15B, MIR613) showed regulation in the same direction in both cell lines. 
Nevertheless, the miRNAs were analysed by IPA to see if they could be clustered 
into groups according to host functions altered. The host functions which 
correlated with the miRNA clustering with significance included developmental 
disorders, hereditary disorders, skeletal and muscle disorders, dermatological 
diseases, inflammatory diseases, cellular development, cellular growth and 
proliferation, cancer, cell death and survival. While the biological significance of 
these changes has not been established, it would be interesting to explore 
further to establish whether the marked differences between Raji and MCF7 
miRNA changes represent tissue-specific responses to XMLV. It will also be 
important to learn whether it represents a general effect of gammaretrovirus 
infection or a more specific response due, for example, to occupation of the 
XPR1 receptor by XMLV env gene products. 
8.3.4 Comparison of FeLV B versus XMLV gene expression 
In order to see if the differential expression of selected genes in Raji cells was 
specific for XMLV or a general response to gammaretroviruses, the expression of 
validated genes was also checked by qRT-PCR in Raji cells infected with FeLV B 
in triplicates. The results are summarized in Figure 8.10. 
Figure 8.10 Gene expression in XMLV vs FeLV B infected Raji cells 
 
Figure 8.10 Comparison of differential expression of genes in Raji cells infected with XMLV 
with that in Raji cells infected with FeLV B determined by qRT-PCR.  
Figure 8.10 shows that changes in the expression of IFI44, CCL4 and IL7R were 
comparable for FeLV B and XMLV infected Raji cells. However the expression of 
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PCOLCE2, CCNB1, and SLC30A4 were oppositely regulated in the XMLV and FeLV 
B infected Raji cells.  
 
8.4 Discussion 
In this chapter I have demonstrated that XMLV infection of cells can result in 
differential expression of genes, with a more pronounced effect in Raji cells as 
compared to MCF7 cells. I also demonstrated that a panel of genes selected for 
functional interest and validated using qRT-PCR showed changes consistent with 
the microarray results. The effect of FeLV B on some of these genes was also 
tested in Raji cells and in other cell lines. Notably, FeLV B infection up regulated 
IFI44 and CCL4 in a similar manner to XMLV suggesting that this might be part of 
a cellular response to chronic retroviral infection. 
Using IPA software, I found that the differentially expressed genes in Raji cells 
infected with XMLV were significantly enriched for two canonical pathways: the 
G2/M DNA damage checkpoint regulation pathway and the Ataxia Telangiectasia 
Mutated (ATM) signalling pathway. Both of these pathways regulate cell cycle 
arrest following any DNA damage264. The gene expression changes I observed 
suggested that these pathways were altered in a manner that would favour cell 
cycle progression. Among these genes, CCNB1 gene, known to play a crucial role 
in regulating cell cycle266,267 was validated by qRT-PCR. The other genes involved 
in these pathways (CDK1, CDC25C, PLK1, AURKA) also showed a change in gene 
expression indicative of progression of cell cycle in Raji cells infected with XMLV 
265,268,269. The expression of CCNB1 has been reported to be up regulated in 
malignancies, especially those with aggressive behaviour and poor 
outcome270,271. In contrast, down regulation of CCNB1 causes cell cycle to arrest 
at G2 phase, inhibiting cell proliferation and induces apoptosis267,272. I did not 
have time to explore the effects of viral infection on growth of Raji cells, but 
these changes in gene expression suggest that growth stimulation is the likely 
outcome. 
The expression of CCL4, also known as macrophage inflammatory protein-1 
(MIP-1), was also validated by qRT-PCR. CCL4 forms a complex with CLL3 (MIP-
1) which serves as a chemoattractant for natural killer cells and monocytes273. 
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Notably, multiple orthologues of these genes (CCL3L1, CCL3L3, CCL4L1, CCL4L2) 
were upregulated in Raji cells (validated by A. Terry), and would be expected to 
act synergistically to evoke biological responses. Raji cells are known to express 
up regulated levels of the chemokine CCL4 due to infection with Epstein-Barr 
virus (EBV)274. CCL4 (in complex with CCL3) attracts helper T cell type 1 (Th-1 
cells) via the CCR5 receptor, a G-protein coupled cell surface receptor275. Th-1 
cells play a very important role in antiviral activity by recruiting cytotoxic T 
cells to remove the virus-infected cells. Raji cells are also known to express high 
levels of CCL17 and CCL20 induced by EBV latent proteins274. Due to expression 
of CCL17 and CCL20, helper T cell type 2 (Th-2 cell) recruitment is favoured as 
compared to Th-1 cells274. Th-2 cells are responsible for humoral or antibody 
mediated immunity. Th-2 recruitment theoretically favours Raji cell-survival in 
vivo274. The XMLV infected Raji cells express 2.9 fold higher levels of CCL4 as 
compared to the uninfected Raji cells. However, I noted no effect on CCL17 and 
CCL20 expression. These findings imply that XMLV infected Raji cells may be 
more potent in attracting Th-1 cells via CCL4 and thus are potential targets of 
cytotoxic T cell mediated removal. However this hypothesis needs to be verified 
experimentally. As described in Chapter 3, when I xenografted Raji cells into 
BALB/c nude mice, Raji tumour nodules were initially formed in the mice but 
they regressed soon thereafter. It is conceivable that the Raji cells xenografted 
into nude mice acquired XMLV from the BALB/c, which could have resulted in 
higher expression levels of CCL4 and their subsequent removal by host immune 
system. BJAB cell line is an EBV-negative human Burkitt’s lymphoma cell line. Up 
regulation of CCL3 and CCL4 by treatment with rituximab is known to cause the 
rejection of xenografted BJAB cell tumours in mice276 showing how these 
chemokines can play a functional role in xenograft rejection. Though BALB/c 
nude mice are depleted in T cells, they are not totally deficient34 and moreover 
harbour natural killer (NK) cells277 that express high levels of CCR5278 and may 
play a role in the Raji cell rejection phenomenon.  
The interferon- inducible protein 44, IFI44 is an interferon stimulated gene 
(ISG)279,280. While ISGs form an important part of the innate immune response281 
IFI44 and IFI44L were the only representatives of this functional group that were 
up regulated in Raji cells. IFI44 has antiviral activity against HIV-1282 and also 
against other viruses e.g. hepatitis C virus280. IFI44 is known to have an 
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antiproliferative activity and has been described to bind to intracellular GTP and 
thus prevent cyclic AMP (cAMP) mediated signalling280. It would be interesting to 
test the status of these pathways in infected cells, but this was beyond the 
scope of my studies. IFI44 was also found to be up regulated 15-fold in FeLV-
infected Kyo1 cells but not in a series of other leukaemia cells lines (A. Terry, 
unpublished results). 
The interleukin 7 receptor (IL7R) was found to be modestly down-regulated in 
Raji cells infected with either XMLV or FeLV B. The effects of this change on 
responses to IL7 have not been tested. 
Solute carrier family 30 gene member 4 (SLC30A4) also known as Zinc 
Transporter-4 (ZnT-4) encodes a zinc transporting protein283. I found that the 
expression of SLC30A4 was down regulated in Raji cells infected with XMLV while 
it was slightly up regulated in Raji cells infected with FeLV B. This variation in 
the expression of SLC30A4 is quite interesting because XPR1, the receptor used 
by XMLV, is a phosphate exporter37, while PiT1, the receptor used by FeLV B, is a 
phosphate transporter246 and it is responsible for uptake of phosphate into the 
cells from the surroundings. A phenomenon of Zinc-Phosphate homeostasis is 
known in plants, where a deficiency of one can lead to the excess of the 
other284. On the other hand in bacteria, phosphate transporters also play a role 
as zinc co-transporters285, thus suggesting there can be a possible connection 
between ligation of receptors by FeLV B and XMLV, and the subsequent effect on 
SLC30A4 expression.  
Differential expression of genes due to gammaretroviral infection has previously 
been noted in the 22Rv1 prostate cancer cell line which is chronically infected 
with XMRV. Suppression of XMRV transcription in 22Rv1 results in reduced 
expression of osteopontin, CXCL14, IL13, and TIMP2189 and leads to altered 
xenograft behaviour, with reduced angiogenesis and tumour size and increased 
necrosis in vivo189. XMRV infection of primary prostatic stromal fibroblasts was 
reported to cause differential expression of cytokines which can increase the 
migratory ability of LNCaP cells and also increase tube formation in human 
mammary epithelial (HMEC) cells in vitro189. Similarly, XMRV was reported to 
increase the proliferation rate of LNCaP but not PC3 cells by p27kip1 down 
regulation258. Thus the differential expression of genes as a result of XMRV 
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infection can vary from cell to cell. As some of these phenomena were reported 
in cells with long established infection, a role for insertional mutagenesis 
followed by clonal selection could not be excluded.  
I found the expression of EGR1 to be up regulated in MCF7 cells infected with 
XMLV with a fold change of approximately 2. This finding was validated using 
qRT-PCR. EGR1 is a zinc finger transcription factor and is known to regulate 
genes for growth factors, hormones, cytokines and adhesion molecules etc.286. 
EGR1 may act as a tumour suppressor or as an oncogene depending on the cell 
type287,288. The expression of EGR1 also varies in different cell types. EGR1 is 
over expressed in prostate cancer cells289 and is considered to be important in 
regulating the transition of prostatic in situ tumours into invasive prostatic 
cancers288,290. EGR1 is down regulated in oestrogen receptor negative breast 
cancers where it acts as a tumour suppressor289,291 but its expression is up 
regulated in oestrogen receptor positive breast cancer cells292. MCF7 is a breast 
cancer cell line positive for oestrogen receptor293,294. Oestrogen is considered to 
be responsible for the increased EGR1 expression in MCF7 cells295. Erythropoietin 
treatment of MCF7 cells also increases cell proliferation by up regulating EGR1 
expression296. Down regulation of EGR1 in MCF7 cells negatively affects the 
migratory ability of cells in vitro297. Thus the ability of XMLV infected MCF7 cells 
to show a mild acceleration in wound healing as described in Chapter 7 may be 
at least partially due to EGR1 up regulation in XMLV infected MCF7 cells.  
miRNA are small RNA molecules comprising 18-25 nucleotides that are known to 
play a role in the post-transcriptional regulation of gene expression298. They may 
also play a role in viral infections by facilitating or inhibiting replication or by 
mediating cellular responses to infection299,300. It was found that 69 miRNAs were 
differentially expressed in XMLV infected MCF7 cells while 50 miRNAs were 
differentially expressed in XMLV infected Raji cells as compared to uninfected 
cells with a significance of p<0.05. The larger number of altered mRNAs in MCF7 
cells compared to Raji cells was surprising in light of the much smaller number 
of changes to coding genes. It appears unlikely that this was due to a global 
change in the miRNA processing machinery in MCF7 cells, as similar numbers of 
miRNAs were up and down regulated, and no significant changes were noted in 
the expression of relevant genes (DICER, DROSHA). Some of the miRNAs (e.g. 
MIR150, MIR372 and MIR106ba) known for their role in controlling or responding 
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to other viruses301,302,303 were differentially expressed in MCF7 and Raji cells 
infected with XMLV. However, other miRNAs (e.g. MIR222 and 221) known to be 
significantly up regulated as a result of XMRV infection of LNCaP prostate cancer 
cells and known to be associated with an increase in cell proliferation, cell 
invasion and transformation activity258 did not show a differential expression in 
Raji cells or MCF7 cells as a result of XMLV infection.  
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9 General discussion 
The main aims of this project were to examine the significance of 
gammaretrovirus infection as a confounding factor for xenograft related 
experiments and as a potential source of zoonosis. I also considered the 
mechanisms of resistance of human cells to gammaretroviral infection, and the 
ways in which persistent infection can affect host cell behaviour including global 
effects on host transcription. 
There have been reports that human cancer cells xenografted into mice may 
acquire XMLV, but these previous reports were unable to exclude in vitro cross 
contamination as the source of most infections with XMLV173. I have studied this 
phenomenon prospectively and have shown that when MCF7 cells are 
xenografted in BALB/c mice, a mouse strain positive for the Bxv1 locus, a 
significant proportion (>40%) of tumour explants released infectious XMLV. I have 
also shown that the newly isolated XMLV was replication competent and on 
sequencing was found to match almost completely (99.96%) to the Bxv1 locus. 
Thus XMLV can not only act as a potential confounding factor for the xenograft 
related experiments but also as source of XMLV contamination in the laboratory. 
Xenograft experiment models are used by researchers throughout the world 
without apparent awareness of the potential presence of infectious XMLV as a 
confounding factor.  
It is recognised that my experiments were conducted under conditions that were 
highly conducive to activation of XMLV and infection of the xenografts. I used 
the BALB/c strain that harbours a replication-competent XMLV provirus at the 
Bxv1 locus which is readily inducible30,304,305. I also used MCF7 cells which are 
unusually susceptible to gammaretroviral infection as like 293 cells, they lack a 
functional APOBEC barrier to spreading infection (Anne Terry, personal 
communication). My findings are reminiscent of early studies that showed a high 
frequency of retroviral activation in xenografts of urogenital tumours171 . 
Moreover, some prostate cancer cell lines have been shown to express low levels 
of APOBEC3G and to be non-restrictive to MLVs79 in a similar manner to MCF7 
cells. To gain a fuller understanding of the risks of acquiring replicating XMLV in 
xenografts, it would be necessary to repeat these studies on a larger scale in 
other commonly used mouse strains that are used for xenograft studies.  
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Another aspect of my thesis work that merits further study is the stage at which 
xenograft cells become infected with XMLV. By cell fractionation I was able to 
confirm that the MCF7 cells within primary explant cultures were infected with 
XMLV, but the presence of actively replicating XMLV in the xenograft in vivo was 
not addressed here. Again, early studies that showed virus production from 
epithelial cells in some xenografts in vivo171 suggesting that at least in some 
cases infection was initiated in vivo and not merely after explanting.  
I also showed that Bxv1 locus was not carried by NOD/SCID/c
null (NSG) mice, 
despite the fact that NSG mice have a breeding history that includes the Bxv1 
positive C57BL/6 strain231. The Bxv1 locus was presumably lost due to repeated 
inbreeding with NOD/Shi-scid mice. When NSG mice were used for xenografting, 
no replication competent virus was detected. I was able to clone and sequence a 
defective virus from the explants that was clearly distinct from XMLV but related 
to endogenous polytropic MLVs. A defective virus capable of even abortive 
infection of xenografts could have direct effects on cell properties even if it 
does not present a risk for horizontal spread. A recent study by Triviai et al235 
showed that NSG mice are not entirely risk-free as they harbour replication 
competent EMLV that can be activated from the endogenous provirus Emv30. 
Triviai et al235 also showed that the EMLV contributed as a mutagenic cofactor in 
the development of mouse myeloid neoplasms that were in part driven by 
paracrine stimulation from the human xenograft cells. This finding also raises 
the possibility that EMLV could undergo further recombination with endogenous 
retroviruses to generate polytropic murine leukaemia virus (PMLV) capable of 
infecting human cells. For example C57BL/6 is a strain of mice that lacks 
replication competent EMLV, but it was found that EMLV was generated in 
immune deficient C57BL/6 mice as a result of recombination306. The 
recombinant EMLV was capable of infecting mouse cells and capable of giving 
rise to lymphomas306. It will be important to continue to investigate laboratory 
mouse strains for their capacity to activate MLV of all types that may act as 
confounding factors in xenografts and in other experimental settings. 
I found that cultured human cells varied in their susceptibility to infection with 
XMLV and FeLV B. The susceptibility presented by most cell lines was very 
similar for both viruses suggesting that factors affecting gammaretroviruses in 
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general predominated over virus-specific factors such as receptor expression. On 
the basis of susceptibility, we were able to classify human cell lines/primary 
cells into highly susceptible, partially susceptible and resistant. Most human 
cells showed evidence of APOBEC-mediated mutation of FeLV, but this activity 
was found to be deficient in 293 cells, and presumably MCF7 cells also, where 
rapidly spreading infection was observed. As no primary cells displayed the 
APOBEC-deficient, rapidly-spreading phenotype, it seems likely that this is an 
aberrant property of transformed or established cell lines. It would be 
interesting to extend my observations to a wider panel of cancer cell lines to 
establish how many display this phenotype. Loss of APOBEC activity may be a 
late event affecting immortalised cell lines or an earlier event in the 
development of some tumours. A recent report showed that more than half of all 
human cancers show mobilisation and reinsertions of LINE1 retrotransposons307. 
LINE1 elements constitute ~20% of the human genome and while most are now 
inactive, a small subset remains capable of retrotransposition. They can also 
mediate reinsertion of other repetitive elements such as the Alu family that lack 
independent mobility and can even transduce cellular coding sequences in 
cancer cells. Although most of these new insertions are in heterochromatin and 
become transcriptionally inactive307, the scale of this process suggest that 
cancer driver mutations may arise in some cases. APOBEC3 family members have 
been reported to inhibit LINE1 activity308 suggesting that my observations on the 
low FeLV restricting activity in transformed human cells may be indicative of a 
cancer-specific aberration.     
While the APOBEC gene family are obviously important in preventing cross-
species spread, the ways in which the gammaretroviruses evade this resistance 
mechanism in their natural hosts are not clearly understood. HIV carries an 
accessory gene product, Vif, that mediates the degradation of APOBEC3 proteins 
and it has been suggested that the glycoGag may play a role in resistance of 
murine leukaemia viruses by preventing encapsidation of APOBEC3 proteins91. 
However, a recent exhaustive study concluded that control of encapsidation was 
not involved in MLV resistance to murine APOBEC3 and acknowledged that there 
is currently no clear explanation for the phenomenon309. My studies showed that 
deletion of FeLV glycoGag does not affect the rate of replication in human cells. 
However, it would be interesting to test whether FeLV glycoGag has an 
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analogous role when the virus is grown in the cells of its natural host, the 
domestic cat. 
Another potentially important aspect of my findings is the resistance of primary 
human blood cells (PBMCs) and some leukemic cell lines (e.g. Reh) to infection 
with FeLV and XMLV at an early stage of the replication cycle. In these cells 
proviral DNA is synthesised and persists, but with little evidence of G->A 
mutations, showing that neither APOBEC nor any of the known retroviral 
restriction factors can readily explain my observations. It will be interesting to 
identify the factor(s) responsible as these are likely to have a role as a major 
barrier to cross-species spread by the gammaretroviruses and the lack of 
evidence for sero-conversion in domestically or occupationally exposed 
individuals149. 
Retroviruses are known to be capable of changing the behaviour of cells by 
insertional mutagenesis, or by expression of viral proteins, which may 
subsequently suppress the immune system or may affect the interaction between 
different tissues258. I have shown that XMLV can infect susceptible cells such as 
the MCF7 mammary carcinoma cell line and result in a high proviral copy 
number. I have not examined XMLV insertion sites, but based on the reported 
preference of MLV and XMRV for insertion at transcription start sites and active 
chromatin features182,245 it seems very likely that XMLV will share the same 
preference. XMLV insertion may therefore play an important role in activation of 
genes that can possibly impart a selective advantage to the infected cell. This 
means that there is a high possibility of insertional mutagenesis and clonal 
selection if such infected cells are grown for a long period. Due to the non-
cytopathic nature of XMLV infection in most cells, it is possible that operators 
will not be even aware that their cells are infected, either as a result of 
xenografting or by in vitro contamination. Chronically infected MCF7 cells also 
show a difference in wound healing, though a minor one, as compared to the 
uninfected cells. As the differences were not evident in freshly infected cells, a 
role for insertional mutagenesis in this minor difference has not been excluded. 
  
The effects of a closely similar gammaretrovirus (XMRV) on host cells and cell 
lines189,258,222 have been explored widely due to interest generated by its 
presumed association with human diseases. It has also been claimed that Raji 
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cells, a Burkitt’s lymphoma cell line, form syncytia when infected with XMRV257. 
However I did not observe any such effect of XMLV on Raji cells and my 
observations on the effects of Mycoplasma on THP-1 cells suggest the possibility 
that this report might have been due to a similar contamination artefact.  
XMLV uses the XPR1 receptor to enter cells. As XPR1 is a G protein receptor35 
with a reported role in phosphate transport37, binding of viral Env protein in 
persistently infected cells represents another mechanism by which viral 
infection may alter xenograft properties and experimental outcomes310,311. 
 
The retroviruses have generally been regarded as weak inducers of host innate 
immune responses, but recent careful studies have shown that 
gammaretroviruses can initiate responses that may be significant for host 
resistance45,46. I have shown that the differential expression of genes is much 
more pronounced in Raji cells (a hematopoietic cell line) infected with XMLV as 
compared to that seen in the MCF7 breast cancer cell line infected with XMLV. 
Whether this reflects a general capacity of haematopoietic cells, the sentinel 
cells of the immune system, to respond more actively to gammaretroviral 
infection will require more extensive studies. A further complicating factor is 
the EBV infected status of Raji Burkitt’s lymphoma cells. While these cells 
display only the minimal ‘latency I’ pattern of EBV with expression of EBNA-1 
and non-coding RNAs (EBER), they can be induced to express immediate early 
lytic cycle genes312. It would be interesting to test whether non-EBV infected 
Burkitt’s lymphoma cell lines display a similar response to gammaretroviral 
infection, and whether EBV functions are affected in Raji cells. Changes in EBV 
gene expression would not have been detected in my microarray analysis which 
contained only cellular gene probes, but could in future studies be detected by 
alternative methods of analysis such as RNA-Seq313.  
The differentially expressed genes in Raji cells infected with XMLV included the 
interferon stimulated genes IFI44 and IFI44L, and a series of chemokines that 
play effective roles in the host immune response. Similar results were obtained 
when gene expression of IFI44 and CCl4 was checked in Raji cells infected with 
FeLV B, showing that this is a generic response to gammaretroviral infection. 
Analysis carried out on other leukaemia cell lines e.g. Kyo1 cells showed an up 
regulation of IFI44 up to 15 fold in the cells infected with FeLV B as compared to 
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the uninfected Kyo1 cells. This observation shows that these response pathways 
are intact in other leukaemias, and raises the possibility of harnessing these 
responses for immunotherapy of leukaemia. It is interesting in this regard that I 
observed the regression of Raji tumour nodules formed in BALB/c mice (Chapter 
3), which could conceivably be due to mobilisation and infection of the cells 
with XMLV and subsequent changes in the gene expression resulting in immune 
recognition and removal by the host system. This response should be 
investigated further as it may provide a novel route to cancer therapy.  
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Appendices 
Appendix 1: Primers and their thermal cycling conditions. 
XMLV and NSG defective virus sequencing primers  
 
 Name  5’ to 3’ Sequence Origin 
1 Fn1 G C G C C A G T C A T C C G A T A G  0-18* 
2 Rn1 G T T A C G G T C T G T C C C A T A T T T T T A 630-650* 
3 Fn2 C A A T T G C C C A A T G A G A T C G A G 1541-1561* 
4 Rn2 T G C T C A T C C T C T G C C C T A C 1997-2016* 
5 Fn3** G G A T C T G A G A G A A G T C A A C A A G C 2950-2975* 
6 Rn3** T C T T T T G T C A G A A C G G C A A T G 3856-3877* 
7 Fn4 C A T T G C C G T T C T G A C A A A A G A 3856-3877* 
8 Rn4 C A A A C T G A T C G G G C A T C A C 4751-4769* 
9 Fn5 G T G A T G C C C G A T C A G T T T G 4751-4769* 
10 Rn5 G T C C T T T C C A G C G A G G T T C 5654-5672* 
11 Fn6 G A A C C T C G C T G G A A A G G A C 5654-5672* 
12 Rn6 C G T T G T A C C G A G G C T C C T G 5867-5885* 
13 Fn7 T A C C T C T G C C C C A G C T A A C 6783-6803* 
14 Rn7 C T G G A T C T A T T G A T T T G A G T T G G 7671-7693* 
15 Fn8** C C A A C T C A A A T C A A T A G A T C C A G 7671-7693* 
16 Rn8** G C T T T A T T G G G A A C A C G G G T A 8166-8186* 
All primers were used for sequencing BALB/c XMLV. 
* Primers based on N417 XMLV (accession number HQ246218). 
** Primers used for sequencing both XMLV and NSG defective virus. 
 
 
Primers for detecting XMLV and NSG defective sequences 
 
 Name  5’ to 3’ Sequence Origin 
1 XMLV LTR-gag 
F 
G C G C C A G T C A T C C G A T A G  0-18* 
2 XMLV LTR-gag 
R 
G T T A C G G T C T G T C C C A T A T T T T T A 630-650* 
3 XMLV LTR F** C C A A C T C A A A T C A A T A G A T C C A G 7671-7693* 
4 XMLV LTR R** G C T T T A T T G G G A A C A C G G G T A 8166-8186* 
5 XMLV env F G G C A G G A G C C T C G G T A C A A  
XMLVenv173 
6 XMLV env R T G T C A T T A G G T T G G T A A C T C T C C A A G T  
All primers were used for detecting BALB/c XMLV. 
* Primers based on N417 XMLV (accession number HQ246218) 
** Primers used for detecting both XMLV and NSG defective virus. 
 
Primers for detecting XMRV 
 
 Name  5’ to 3’ Sequence Origin 
1 XMRV gag F A A C C G T T T G T C T C T C C T A A A C C C  XMRV gag173 
2 XMRV gag R G C A G G G T A A A G G G C A G A T C G  
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Primers for detecting endogenous Bxv1 in mouse genome 
 
 Name  5’ to 3’ Sequence Origin 
1 Bxv1-tail2F G G C C T C G C T G T T C C T T G Bxv1 LTR-flanking 
mouse genome on 
mouse chr 1 
2 Bxv1-tail2R G A G A G A G C G T G G C A A A C C T T 
 
 
Primers for detecting BALB/c Emv1 endogenous ecotropic virus 
 
 Name  5’ to 3’ Sequence Origin 
1 Emv1 F1 C A T G G A G A G T A C A A C G C T C T C A A Emv1 env 
(accession no. 
dq366147) 2 Emv1 R1 T G G T G G G G G C T G T T T C C 
3 Emv1 F2 C C A C G G G C C G T C C T A T T 
4 Emv1 R2 C T C C T C A C A A T C T C T G G A A C A 
 
 
Primers for designing XMLV probe 
 
 Name  5’ to 3’ Sequence Origin 
1 XMLV 
Probe F 
G A T G G T A C T C A G A T A A A G C G A A A C T 196-220* 
2 XMLV 
Probe R 
C T G G G T A G T C A A T C A C T C T G A G G 488-510* 
* Primers based on N417 XMLV (accession number HQ246218) 
 
 
Primers for XMLV env cloning 
 
 Name  5’ to 3’ Sequence Origin 
1 F4 G G A G C A G C A T G G A A G G T C 5774-5791* 
2 R1 A A C T T C C T T G T G A C T T T T G A G A A C 7830-7853* 
3 F4-BamHI C C T C C G G G A T C C G C A G C A T G G A A G G 
T C 
 
XMLV env* 
4 R1-SalI C T T C C T T G C A G C T G T T G A G A A C T C A 
G C T C 
 
XMLV env* 
* Primers based on N417 XMLV (accession number HQ246218) 
 
 
Primers for detecting FeLV B 
 
 Name  5’ to 3’ Sequence Origin 
1 FeLV gag F C G A C C A T A C C T G T T G T C C T T  FeLV B gag 
2 FeLV gag R T T C A A C C T G G G A A A T G C T A T  
3 FeLV LTR F C G G C C C A T G C A T C C T T A A C FeLV B LTR 
4 FeLV LTR R A A C A C C G A G A C C A C G A G T C A G  
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Primers for sequencing FeLV B 
 
 Name  5’ to 3’ Sequence Origin 
1 FeLV 
hyper F 
G C A A C C G G T A A G G T G A C T C FeLV B pol 
2 FeLV 
hyper R 
T T C A A A G G G T T T G G T G A T A T C T G  
 
 
 Primers for detecting Mycoplasma 
 
 Name  5’ to 3’ Sequence Origin 
1 Myco 280 
F 
G G G A G C A A A C A G G A T T A G A T A C C C T Zakharova et al256 
2 Myco 280 
R 
T G C A C C A T C T G T C A C T C T G T T A A C C T 
C 
 
 
Human CD14 primers 
 
 Name  5’ to 3’ Sequence Origin 
 CD14 F C G A G G A C C T A A A G A T A A C C G G C 
 
Park et al 254 
 CD14 R G T T G C A G C T G A G A T C G A G C A C 
 
 
 
Human internal control primers 
 
 Name  5’ to 3’ Sequence Origin 
1 Human 
GAPDH F 
C C C C A C A C A C A T G C A C T T A C C  
 
 
Human GAPDH173 
2 Human 
GAPDH R 
C C T A G T C C C A G G G C T T T G A T T  
 
3 Human 
MYC F 
G A G C G G G C G G C C G G C T A G G G T Human MYC 
4 Human 
MYC R 
C T C G G G T G T T G T A A G T T C C A G T G C 
5  Actin F T G A A G T C T G A C G T G G A C A T C  
Park et al 254 
6  Actin R A C T C G T C A T A C T C C T G C T T G 
 
 
 
Mouse internal control primers 
 
 Name  5’ to 3’ Sequence Origin 
1 Mouse 
GAPDH F 
A G T A T G A T G A C A T C A A G A A G G  
  
 
Mouse GAPDH173 
2 Mouse 
GAPDH R 
A T G G T A T T C A A G A G A G T A G G G  
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Thermal cycling conditions 
 
Thermal cycling conditions for XMLV, XMRV, Bxv1, mouse and human internal control 
primers, and Emv1 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 30 seconds 
 
35 
Annealing 60oC 30 seconds 
Extension 72oC 3 minutes 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for FeLV B LTR primers 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 30 seconds 
 
35 
Annealing 50oC 30 seconds 
Extension 72oC 3 minutes 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for XMLV env cloning primers 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 2 minutes 1 
Denaturation 95oC 20 seconds 
 
30 
Annealing 55oC 20 seconds 
Extension 72oC 30 seconds 
Final Extension 72oC 3 minutes 1 
Hold 4oC ∞  
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Thermal cycling conditions for Pfu PCR for sequencing of XMLV 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 2 minutes 1 
Denaturation 95oC 20 seconds 
 
40 
Annealing 60oC 20 seconds 
Extension 72oC 45 seconds 
Final Extension 72oC 3 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for FeLV B env and gag primers 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 30 seconds 
 
35 
Annealing 50oC 30 seconds 
Extension 72oC 30 seconds 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for XMLV probe 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 30 seconds 
 
35 
Annealing 60oC 30 seconds 
Extension 72oC 3 minutes 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for CD14 expression 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 1 seconds 
 
35 
Annealing 60oC 1 seconds 
Extension 72oC 1 minutes 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
186 
 
 
Thermal cycling conditions for  Actin expression 
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 3 minutes 1 
Denaturation 95oC 1 seconds 
 
25 
Annealing 60oC 1 seconds 
Extension 72oC 1 minutes 
Final Extension 72oC 7 minutes 1 
Hold 4oC ∞  
 
Thermal cycling conditions for Pfu PCR for sequencing FeLV B pol  
Cycle Step Temperature Time 
Number of 
cycles 
Initial Denaturation 95oC 2 minutes 1 
Denaturation 95oC 20 seconds 
30 Annealing 62oC 20 seconds 
Extension 72oC 30 seconds 
Final Extension 72oC 3 minutes 1 
Hold 4oC ∞  
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Appendix 2: Alignment of Bxv1 (accession no.AC115959.17) and BALB/c 
XMLV rescued from MCF7 explants. 
Bxv1            GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCGTGTTCCCAATA 
BALB/c XMLV     GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCGTGTTCCCAATA 
                ************************************************** 
 
Bxv1            AAGCCTTTTGCTGTTTGCATCCGAAACGTGGCCTCGCTGTTCCTTGGGAG 
BALB/c XMLV     AAGCCTTTTGCTGTTTGCATCCGAAACGTGGCCTCGCTGTTCCTTGGGAG 
                ************************************************** 
 
Bxv1            GGTCTCCTCAGAGTGATTGACTACCCAGCTCGGGGGTCTTTCATTTGGGG 
BALB/c XMLV     GGTCTCCTCAGAGTGATTGACTACCCAGCTCGGGGGTCTTTCATTTGGGG 
                ************************************************** 
 
Bxv1            GCTCGTCCGGGATTTGGAGACCCCCGCCCAGGGACCACCGACCCACCGTC 
BALB/c XMLV     GCTCGTCCGGGATTTGGAGACCCCCGCCCAGGGACCACCGACCCACCGTC 
                ************************************************** 
 
Bxv1            GGGAGGTAAGCTGGCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGC 
BALB/c XMLV     GGGAGGTAAGCTGGCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGC 
                ************************************************** 
 
Bxv1            GTGTGTGTGTGTGCCGGCATCTACTTTTTGCGCCTGCGTCTGAATCTGTA 
BALB/c XMLV     GTGTGTGTGTGTGCCGGCATCTACTTTTTGCGCCTGCGTCTGAATCTGTA 
                ************************************************** 
 
Bxv1            CTAGTTAGCTAACTAGATCTGTATCTGGCGGTTCCGTGGAAGAACTGACG 
BALB/c XMLV     CTAGTTAGCTAACTAGATCTGTATCTGGCGGTTCCGTGGAAGAACTGACG 
                ************************************************** 
 
Bxv1            AGTTCGTATTCCCGACCGCAGCCCTGGGAGACGTCTCAGAGGCATCAGGG 
BALB/c XMLV     AGTTCGTATTCCCGACCGCAGCCCTGGGAGACGTCTCAGAGGCATCAGGG 
                ************************************************** 
 
Bxv1            GCCCGCTGGGTGGCCCAATCAGTAAGTCCGAGTCCTGACCGATTCGGACT 
BALB/c XMLV     GCCCGCTGGGTGGCCCAATCAGTAAGTCCGAGTCCTGACCGATTCGGACT 
                ************************************************** 
 
Bxv1            ATTTGGAGCCCCTCCTTTGTCGGAGGGGTACGTGGTTCTTTTAGGAGACG 
BALB/c XMLV     ATTTGGAGCCCCTCCTTTGTCGGAGGGGTACGTGGTTCTTTTAGGAGACG 
                ************************************************** 
 
Bxv1            AGAGGTCCAAGCCCTCGCCGCCTCCATCTGAATTTTTGCTTTCGGTTTTT 
BALB/c XMLV     AGAGGTCCAAGCCCTCGCCGCCTCCATCTGAATTTTTGCTTTCGGTTTTT 
                ************************************************** 
 
Bxv1            CGCCGAAACCGCGCCGCGCGTCTTGTCTGTCTCAGTGTTGTTTTGTCATT 
BALB/c XMLV     CGCCGAAACCGCGCCGCGCGTCTTGTCTGTCTCAGTGTTGTTTTGTCATT 
                ************************************************** 
 
Bxv1            TGTCTGTTCGTTATTGTTTTGGACCGTTTCTAAAAATATGGGACAGACCG 
BALB/c XMLV     TGTCTGTTCGTTATTGTTTTGGACCGTTTCTAAAAATATGGGACAGACCG 
                ************************************************** 
 
Bxv1            TAACCACCCCTCTGAGTCTGACCCTAGAACACTGGGGAGACGTCCAGCGC 
BALB/c XMLV     TAACCACCCCTCTGAGTCTGACCCTAGAACACTGGGGAGACGTCCAGCGC 
                ************************************************** 
 
Bxv1            ATCGCGTCCAACCAGTCCGTGGACGTCAAGAAGAGACGCTGGGTCACCTT 
BALB/c XMLV     ATCGCGTCCAACCAGTCCGTGGACGTCAAGAAGAGACGCTGGGTCACCTT 
                ************************************************** 
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Bxv1            CTGCTCTGCCGAGTGGCCAACTTTCGGTGTAGGGTGGCCGCAAGATGGTA 
BALB/c XMLV     CTGCTCTGCCGAGTGGCCAACTTTCGGTGTAGGGTGGCCGCAAGATGGTA 
                ************************************************** 
 
Bxv1            CTTTTAATTTGGACATTATTTTACAGGTTAAATCTAAGGTGTTCTCTCCC 
BALB/c XMLV     CTTTTAATTTGGACATTATTTTACAGGTTAAATCTAAGGTGTTCTCTCCC 
                ************************************************** 
 
Bxv1            GGTCCCCACGGACACCCGGATCAGGTCCCATACATTGTCACCTGGGAGGC 
BALB/c XMLV     GGTCCCCACGGACACCCGGATCAGGTCCCATACATTGTCACCTGGGAGGC 
                ************************************************** 
 
Bxv1            TATTGCCTATGAACCCCCTCCGTGGGTCAAACCTTTTGTCTCTCCCAAAC 
BALB/c XMLV     TATTGCCTATGAACCCCCTCCGTGGGTCAAACCTTTTGTCTCTCCCAAAC 
                ************************************************** 
 
Bxv1            TCTCCCTCTCTCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAA 
BALB/c XMLV     TCTCCCTCTCTCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAA 
                ************************************************** 
 
Bxv1            CCTCCGCCCCGATCTGCCCTTTACCCTGCTCTTACCCCCTCTATAAAACC 
BALB/c XMLV     CCTCCGCCCCGATCTGCCCTTTACCCTGCTCTTACCCCCTCTATAAAACC 
                ************************************************** 
 
Bxv1            CAGACCTTCTAAACCTCAGGTTCTCTCCGATAATGGCGGACCTCTCATTG 
BALB/c XMLV     CAGACCTTCTAAACCTCAGGTTCTCTCCGATAATGGCGGACCTCTCATTG 
                ************************************************** 
 
Bxv1            ACCTTCTCACAGAAGACCCTCCGCCGTACGGAGAACAGGGACCGTCCTCC 
BALB/c XMLV     ACCTTCTCACAGAAGACCCTCCGCCGTACGGAGAACAGGGACCGTCCTCC 
                ************************************************** 
 
Bxv1            TCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC 
BALB/c XMLV     TCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC 
                ************************************************** 
 
Bxv1            TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAAGAGACCCCCCCG 
BALB/c XMLV     TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAAGAGACCCCCCCG 
                ************************************************** 
 
Bxv1            CGGCAGTTTCCACCACCTCTCGGGCTTTCCCACTCCGTTTGGGGGGTAAT 
BALB/c XMLV     CGGCAGTTTCCACCACCTCTCGGGCTTTCCCACTCCGTTTGGGGGGTAAT 
                ************************************************** 
 
Bxv1            GGTCAGTTGCAGTACTGGCCGTTTTCCTCCTCGGATCTATATAACTGGAA 
BALB/c XMLV     GGTCAGTTGCAGTACTGGCCGTTTTCCTCCTCGGATCTATATAACTGGAA 
                ************************************************** 
 
Bxv1            AAATAATAACCCTTCCTTCTCTGAAGATCCAGGTAAATTGACTGCCTTAA 
BALB/c XMLV     AAATAATAACCCTTCCTTCTCTGAAGATCCAGGTAAATTGACTGCCTTAA 
                ************************************************** 
 
Bxv1            TCGAGTCTGTCCTCACCACCCACCAGCCTACTTGGGATGACTGTCAACAG 
BALB/c XMLV     TCGAGTCTGTCCTCACCACCCACCAGCCTACTTGGGATGACTGTCAACAG 
                ************************************************** 
 
Bxv1            TTGCTGGGGACTCTGCTGACAGGAGAAGAAAAGCAGCGGGTGCTCCTGGA 
BALB/c XMLV     TTGCTGGGGACTCTGCTGACAGGAGAAGAAAAGCAGCGGGTGCTCCTGGA 
                ************************************************** 
 
 
Bxv1            AGCCAGAAAGGCAGTCCGGGGCGACGATGGCCGCCCCACCCAATTGCCCA 
BALB/c XMLV     AGCCAGAAAGGCAGTCCGGGGCGACGATGGCCGCCCCACCCAATTGCCCA 
                ************************************************** 
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Bxv1            ATGAGATCGAGGCTGCCTTTCCCCTCGAACGTCCCGACTGGGACTACACC 
BALB/c XMLV     ATGAGATCGAGGCTGCCTTTCCCCTCGAACGTCCCGACTGGGACTACACC 
                ************************************************** 
 
Bxv1            ACCCTTAGAGGTAGGAACCACCTAGTTCTCTATCGCCAGCTGCTCTTGGC 
BALB/c XMLV     ACCCTTAGAGGTAGGAACCACCTAGTTCTCTATCGCCAGCTGCTCTTGGC 
                ************************************************** 
 
Bxv1            GGGTCTCCAAAATGCGGGCAGGAGCCCCACCAATTTGGCTAAGGTAAAAG 
BALB/c XMLV     GGGTCTCCAAAATGCGGGCAGGAGCCCCACCAATTTGGCTAAGGTAAAAG 
                ************************************************** 
 
Bxv1            GAATAACCCAGGGGTCCAACGAGTCGCCCTCGGCCTTTCTAGAGAGACTC 
BALB/c XMLV     GAATAACCCAGGGGTCCAACGAGTCGCCCTCGGCCTTTCTAGAGAGACTC 
                ************************************************** 
 
Bxv1            AAAGAGGCCTATCGCAGATACACTCCTTATGACCCTGAGGACCCTGGGCA 
BALB/c XMLV     AAAGAGGCCTATCGCAGATACACTCCTTATAACCCTGAGGACCCTGGGCA 
                ****************************** ******************* 
 
Bxv1            AGAAACCAATGTATCCATGTCGTTCATCTGGCAGTCTGCTCCAGACATTG 
BALB/c XMLV     AGAAACCAATGTATCCATGTCGTTCATCTGGCAGTCTGCTCCAGACATTG 
                ************************************************** 
 
Bxv1            GTCGAAAGTTAGAGCGGTTAGAAGACTTAAAAAATAAGACCTTAGGGGAC 
BALB/c XMLV     GTCGAAAGTTAGAGCGGTTAGAAGACTTAAAAAATAAGACCTTAGGGGAC 
                ************************************************** 
 
Bxv1            TTAGTGAGAGAAGCAGAAAGGATCTTTAATAAGAGAGAGACCCCAGAAGA 
BALB/c XMLV     TTAGTGAGAGAAGCAGAAAGGATCTTTAATAAGAGAGAGACCCCAGAAGA 
                ************************************************** 
 
Bxv1            GAGAGAAGAACGTATTAAGAGAGAAACAGAGGAAAAAGAGGAGCGCCGTA 
BALB/c XMLV     GAGAGAAGAACGTATTAAGAGAGAAACAGAGGAAAAAGAGGAGCGCCGTA 
                ************************************************** 
 
Bxv1            GGGCAGAGGATGAGCAGAAAGAGAAAGAGAGGGACCGCAGAAGACAGAGA 
BALB/c XMLV     GGGCAGAGGATGAGCAGAAAGAGAAAGAGAGGGACCGCAGAAGACAGAGA 
                ************************************************** 
 
Bxv1            GAAATGAGCAAACTCTTGGCCACCGTAGTTACAGGTCAGAGACAGGATAG 
BALB/c XMLV     GAAATGAGCAAACTCTTGGCCACCGTAGTTACAGGTCAGAGACAGGATAG 
                ************************************************** 
 
Bxv1            ACAGGGGGGAGAGCGAAGGAGGCCCCAACTCGATAAGGACCAATGCGCCT 
BALB/c XMLV     ACAGGGGGGAGAGCGAAGGAGGCCCCAACTCGATAAGGACCAATGCGCCT 
                ************************************************** 
 
Bxv1            ACTGCAAAGAAAAGGGACACTGGGCTAGGGATTGCCCAAAGAAGCCACGG 
BALB/c XMLV     ACTGCAAAGAAAAGGGACACTGGGCTAGGGATTGCCCAAAGAAGCCACGG 
                ************************************************** 
 
Bxv1            GGGCCCCGAGGACCGAGGCCCCAGACCTCCCTCCTGACCCTAGATGACTA 
BALB/c XMLV     GGGCCCCGAGGACCGAGGCCCCAGACCTCCCTCCTGACCCTAGATGACTA 
                ************************************************** 
 
 
Bxv1            GGGAGGTCAGGGTCAGGAGCCCCCCCCTGAACCCAGGATAACCCTTACTG 
BALB/c XMLV     GGGAGGTCAGGGTCAGGAGCCCCCCCCTGAACCCAGGATAACCCTTACTG 
                ************************************************** 
 
Bxv1            TCGGGGGGCAACCAGTCACCTTCCTGGTGGATACTGGGGCCCAACACTCC 
BALB/c XMLV     TCGGGGGGCAACCAGTCACCTTCCTGGTGGATACTGGGGCCCAACACTCC 
                ************************************************** 
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Bxv1            GTGCTGACCCAGAACCCTGGACCCCTAAGTGACAGGTCTGCCTGGGTCCA 
BALB/c XMLV     GTGCTGACCCAGAACCCTGGACCCCTAAGTGACAGGTCTGCCTGGGTCCA 
                ************************************************** 
 
Bxv1            AGGGGCTACTGGAGGAAAGCGGTATCACTGGACCACAGATCGCAAGGTGC 
BALB/c XMLV     AGGGGCTACTGGAGGAAAGCGGTATCACTGGACCACAGATCGCAAGGTGC 
                ************************************************** 
 
Bxv1            ACCTGGCTACCGGTAAGGTCACTCACTCTTTCCTCCATGTGCCGGACTGC 
BALB/c XMLV     ACCTGGCTACCGGTAAGGTCACTCACTCTTTCCTCCATGTGCCGGACTGC 
                ************************************************** 
 
Bxv1            CCTTATCCTTTGCTAGGAAGGGACTTGTTGACTAAGTTAAAGGCCCAGAT 
BALB/c XMLV     CCTTATCCTTTGCTAGGAAGGGACTTGTTGACTAAGTTAAAGGCCCAGAT 
                ************************************************** 
 
Bxv1            CCACTTCGAGGGATCGGGAGCTCAGGTTGTGGGACCAAAAGGACAGCCCC 
BALB/c XMLV     CCACTTCGAGGGATCGGGAGCTCAGGTTGTGGGACCAAAAGGACAGCCCC 
                ************************************************** 
 
Bxv1            TGCAGGTGTTGACCCTTGGCATAGAGGATGAGTATCGGCTACATGAGACC 
BALB/c XMLV     TGCAGGTGTTGACCCTTGGCATAGAGGATGAGTATCGGCTACATGAGACC 
                ************************************************** 
 
Bxv1            TCAACAGAGCCGGATGTTTCTCTAGGGTCCACCTGGCTTTCTGACTTTCC 
BALB/c XMLV     TCAACAGAGCCGGATGTTTCTCTAGGGTCCACCTGGCTTTCTGACTTTCC 
                ************************************************** 
 
Bxv1            CCAGGCCTGGGCAGAAACCGGGGGCATGGGACTGGCAGTTCGCCAAGCGC 
BALB/c XMLV     CCAGGCCTGGGCAGAAACCGGGGGCATGGGACTGGCAGTTCGCCAAGCGC 
                ************************************************** 
 
Bxv1            CTCTGATTATACCTCTAAAGGCAACCTCCACCCCTGTGTCCATCAAACAG 
BALB/c XMLV     CTCTGATTATACCTCTAAAGGCAACCTCCACCCCTGTGTCCATCAAACAG 
                ************************************************** 
 
Bxv1            TACCCCATGTCACACGAAGCCAGACTGGGGATCAAGCCCCACATACAGAG 
BALB/c XMLV     TACCCCATGTCACACGAAGCCAGACTGGGGATCAAGCCCCACATACAGAG 
                ************************************************** 
 
Bxv1            ACTGTTGGACCAGGGAATATTGGTACCTTGCCAGTCCCCCTGGAACACAC 
BALB/c XMLV     ACTGTTGGACCAGGGAATATTGGTACCTTGCCAGTCCCCCTGGAACACAC 
                ************************************************** 
 
Bxv1            CCCTGCTGCCCGTTAAGAAACCAGGGACTAATGATTACAGGCCTGTCCAG 
BALB/c XMLV     CCCTGCTGCCCGTTAAGAAACCAGGGACTAATGATTACAGGCCTGTCCAG 
                ************************************************** 
 
Bxv1            GATCTGAGAGAAGTCAACAAGCGGGTGGAAGATATCCACCCCACCGTGCC 
BALB/c XMLV     GATCTGAGAGAAGTCAACAAGCGGGTGGAAGATATCCACCCCACCGTGCC 
                ************************************************** 
 
 
Bxv1            CAATCCTTACAACCTCTTAAGTGGACTCCCTCCGTCCCACCAGTGGTACA 
BALB/c XMLV     CAATCCTTACAACCTCTTAAGTGGACTCCCTCCGTCCCACCAGTGGTACA 
                ************************************************** 
 
Bxv1            CTGTGCTTGATTTAAAAGATGCCTTTTTCTGCCTGAGACTCCACCCCACC 
BALB/c XMLV     CTGTGCTTGATTTAAAAGATGCCTTTTTCTGCCTGAGACTCCACCCCACC 
                ************************************************** 
 
Bxv1            AGTCAGCCTCTCTTTGCCTTTGAGTGGAGAGATCCAGAAATGGGAATCTC 
BALB/c XMLV     AGTCAGCCTCTCTTTGCCTTTGAGTGGAGAGATCCAGAAATGGGAATCTC 
                ************************************************** 
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Bxv1            TGGACAATTGACCTGGACCAGACTCCCACAGGGTTTCAAAAACAGTCCCA 
BALB/c XMLV     TGGACAATTGACCTGGACCAGACTCCCACAGGGTTTCAAAAACAGTCCCA 
                ************************************************** 
 
Bxv1            CCCTGTTTGATGAGGCATTGCACAGAGACCTAGCAGACTTCCGGATCCAG 
BALB/c XMLV     CCCTGTTTGATGAGGCATTGCACAGAGACCTAGCAGACTTCCGGATCCAG 
                ************************************************** 
 
Bxv1            CACCCAGACTTGATCCTGCTACAGTACGTGGATGACTTACTGCTGGCCGC 
BALB/c XMLV     CACCCAGACTTGATCCTGCTACAGTACGTGGATGACTTACTGCTGGCCGC 
                ************************************************** 
 
Bxv1            TACTTCCGAACTAGACTGCCAACAAGGTACTCGGGCCCTTCTACAAACCC 
BALB/c XMLV     TACTTCCGAACTAGACTGCCAACAAGGTACTCGGGCCCTTCTACAAACCC 
                ************************************************** 
 
Bxv1            TAGGGGACCTCGGATACCGGGCCTCGGCCAAGAAAGCCCAAATCTGCCAG 
BALB/c XMLV     TAGGGGACCTCGGATACCGGGCCTCGGCCAAGAAAGCCCAAATCTGCCAG 
                ************************************************** 
 
Bxv1            AAACAGGTTAAATACCTGGGGTACCTTCTGAGGGAGGGTCAGAGATGGCT 
BALB/c XMLV     AAACAGGTTAAATACCTGGGGTACCTTCTGAGGGAGGGTCAGAGATGGCT 
                ************************************************** 
 
Bxv1            GACTGAGGCTAGAAAAGAGACTGTGATGGGGCAACCCGTTCCAAAGACTC 
BALB/c XMLV     GACTGAGGCTAGAAAAGAGACTGTGATGGGGCAACCCGTTCCAAAGACTC 
                ************************************************** 
 
Bxv1            CTCGACAACTAAGGGAGTTCCTAGGGACGGCAGGCTTCTGCCGCCTCTGG 
BALB/c XMLV     CTCGACAACTAAGGGAGTTCCTAGGGACGGCAGGCTTCTGCCGCCTCTGG 
                ************************************************** 
 
Bxv1            ATCCCTGGGTTTGCGGAAATGGCGGCCCCCTTGTATCCTCTTACCAAAAC 
BALB/c XMLV     ATCCCTGGGTTTGCGGAAATGGCGGCCCCCTTGTATCCTCTTACCAAAAC 
                ************************************************** 
 
Bxv1            GGGGACTCTGTTTAATTGGGGCCCAGACCAGCAAAAGGCCTATCAAGAAA 
BALB/c XMLV     GGGGACTCTGTTTAATTGGGGCCCAGACCAGCAAAAGGCCTATCAAGAAA 
                ************************************************** 
 
Bxv1            TCAAACAGGCCCTTCTAACTGCCCCCGCCCTGGGATTGCCAGATTTGACT 
BALB/c XMLV     TCAAACAGGCCCTTCTAACTGCCCCCGCCCTGGGATTGCCAGATTTGACT 
                ************************************************** 
 
Bxv1            AAGCCCTTTGAACTCTTTGTCGACGAGAAGCAGGGCTACGCCAAAGGCGT 
BALB/c XMLV     AAGCCCTTTGAACTCTTTGTCGACGAGAAGCAGGGCTACGCCAAAGGCGT 
                ************************************************** 
 
 
Bxv1            CCTAACGCAAAAACTGGGACCTTGGCGTCGGCCTGTGGCCTACCTGTCCA 
BALB/c XMLV     CCTAACGCAAAAACTGGGACCTTGGCGTCGGCCTGTGGCCTACCTGTCCA 
                ************************************************** 
 
Bxv1            AAAAGCTAGACCCAGTGGCAGCCGGGTGGCCCCCTTGCCTACGGATGGTA 
BALB/c XMLV     AAAAGCTAGACCCAGTGGCAGCCGGGTGGCCCCCTTGCCTACGGATGGTA 
                ************************************************** 
 
Bxv1            GCAGCCATTGCCGTTCTGACAAAAGATGCAGGCAAGCTAACTATGGGACA 
BALB/c XMLV     GCAGCCATTGCCGTTCTGACAAAAGATGCAGGCAAGCTAACTATGGGACA 
                ************************************************** 
 
Bxv1            GCCGCTAGTCATCCTGGCCCCCCATGCAGTAGAGGCACTGGTCAAGCAAC 
BALB/c XMLV     GCCGCTAGTCATCCTGGCCCCCCATGCAGTAGAGGCACTGGTCAAGCAAC 
                ************************************************** 
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Bxv1            CCCCTGACCGCTGGCTATCCAACGCCCGCATGACCCACTACCAGGCAATG 
BALB/c XMLV     CCCCTGACCGCTGGCTATCCAACGCCCGCATGACCCACTACCAGGCAATG 
                ************************************************** 
 
Bxv1            CTCCTAGACACTGACCGAGTTCAGTTCGGACCAGTGGTGGCCCTCAATCC 
BALB/c XMLV     CTCCTAGACACTGACCGAGTTCAGTTCGGACCAGTGGTGGCCCTCAATCC 
                ************************************************** 
 
Bxv1            TGCCACCTTGCTCCCTCTACCGGAAAAAGGAGCCCCCCATGATTGCCTCG 
BALB/c XMLV     TGCCACCTTGCTCCCTCTACCGGAAAAAGGAGCCCCCCATGATTGCCTCG 
                ************************************************** 
 
Bxv1            AGATCTTGGCTGAAACGCATGGAACCAGACCGGATCTCACCGACCAGCCC 
BALB/c XMLV     AGATCTTGGCTGAAACGCATGGAACCAGACCGGATCTCACCGACCAGCCC 
                ************************************************** 
 
Bxv1            ATCCCAGACGCCGACCACACCTGGTATACCGATGGGAGCAGCTTTCTGCA 
BALB/c XMLV     ATCCCAGACGCCGACCACACCTGGTATACCGATGGGAGCAGCTTTCTGCA 
                ************************************************** 
 
Bxv1            AGAAGGACAGCGAAAGGCTGGGGCAGCAGTGACGACTGAAACCGAGGTAA 
BALB/c XMLV     AGAAGGACAGCGAAAGGCTGGGGCAGCAGTGACGACTGAAACCGAGGTAA 
                ************************************************** 
 
Bxv1            TCTGGGCGAGGGCCCTGCCAGCTGGAACGTCAGCCCAGCGAGCCGAACTG 
BALB/c XMLV     TCTGGGCGAGGGCCCTGCCAGCTGGAACGTCAGCCCAGCGAGCCGAACTG 
                ************************************************** 
 
Bxv1            ATCGCACTCACCCAAGCCCTGAAAATGGCAGAAGGTAAGAAGCTAAATGT 
BALB/c XMLV     ATCGCACTCACCCAAGCCCTGAAAATGGCAGAAGGTAAGAAGCTAAATGT 
                ************************************************** 
 
Bxv1            TTACACTGATAGCCGCTATGCCTTCGCTACGGCCCATGTTCATGGGGAAA 
BALB/c XMLV     TTACACTGATAGCCGCTATGCCTTCGCTACGGCCCATGTTCATGGGGAAA 
                ************************************************** 
 
Bxv1            TATATAGGAGACGGGGGTTGCTGACCTCAGAAGGCAAGGAAATCAAGAAC 
BALB/c XMLV     TATATAGGAGACGGGGGTTGCTGACCTCAGAAGGCAAGGAAATCAAGAAC 
                ************************************************** 
 
Bxv1            AAAAGCGAGATCCTAGCCTTGCTGAAAGCCCTCTTTTTGCCAAAGAGACT 
BALB/c XMLV     AAAAGCGAGATCCTAGCCTTGCTGAAAGCCCTCTTTTTGCCAAAGAGACT 
                ************************************************** 
 
 
Bxv1            CAGTATTATCCATTGCCCAGGACATCAGAAAGGAGACAGTGCCGAAGCCA 
BALB/c XMLV     CAGTATTATCCATTGCCCAGGACATCAGAAAGGAGACAGTGCCGAAGCCA 
                ************************************************** 
 
Bxv1            GAGGCAACCGTATGGCAGACCAGGCGGCCCGAGAGGCAGCCACAAAAACA 
BALB/c XMLV     GAGGCAACCGTATGGCAGACCAGGCGGCCCGAGAGGCAGCCACAAAAACA 
                ************************************************** 
 
Bxv1            GTTCCAGAAGCCTCTACACTCCTTATAGAGGACTCGACCCCGTACACGCC 
BALB/c XMLV     GTTCCAGAAGCCTCTACACTCCTTATAGAGGACTCGACCCCGTACACGCC 
                ************************************************** 
 
Bxv1            TGCCTATCTCCATTACACCGAAACAGATCTAAAAAGATTGCGAGAACTGG 
BALB/c XMLV     TGCCTATCTCCATTACACCGAAACAGATCTAAAAAGATTGCGAGAACTGG 
                ************************************************** 
 
Bxv1            GGGCCACCTATAATCAGATAAAAGGATATTGGGTCCTACAAGGCAAGCCG 
BALB/c XMLV     GGGCCACCTATAATCAGATAAAAGGATATTGGGTCCTACAAGGCAAGCCG 
                ************************************************** 
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Bxv1            GTGATGCCCGATCAGTTTGTGTTTGAATTATTAGACTCCCTTCATAGACT 
BALB/c XMLV     GTGATGCCCGATCAGTTTGTGTTTGAATTATTAGACTCCCTTCATAGACT 
                ************************************************** 
 
Bxv1            CACCCATCTCAGCCCTCAAAAGATGAAGGCGCTCCTTGACAGAGAAGAAA 
BALB/c XMLV     CACCCATCTCAGCCCTCAAAAGATGAAGGCGCTCCTTGACAGAGAAGAAA 
                ************************************************** 
 
Bxv1            GCCCCTACTACATGTTAAACAGGGACAGAACTCTTCAGTATGTGGCAGAA 
BALB/c XMLV     GCCCCTACTACATGTTAAACAGGGACAGAACTCTTCAGTATGTGGCAGAA 
                ************************************************** 
 
Bxv1            TCCTGCACAGTCTGTGCTCAAGTAAATGCTAGTAAAGCCAAAATCGGGGC 
BALB/c XMLV     TCCTGCACAGTCTGTGCTCAAGTAAATGCTAGTAAAGCCAAAATCGGGGC 
                ************************************************** 
 
Bxv1            AGGGGTACGAGTACGCGGACATCGACCAGGTACCCATTGGGAAATTGACT 
BALB/c XMLV     AGGGGTACGAGTACGCGGACATCGACCAGGTACCCATTGGGAAATTGACT 
                ************************************************** 
 
Bxv1            TCACTGAAGTTAAACCAGGGCTGTACGGGTACAAGTACCTCCTGGTGTTC 
BALB/c XMLV     TCACTGAAGTTAAACCAGGGCTGTACGGGTACAAGTACCTCCTGGTGTTC 
                ************************************************** 
 
Bxv1            GTAGACACCTTCTCTGGCTGGGTGGAAGCCTTCCCAACTAAACGTGAAAC 
BALB/c XMLV     GTAGACACCTTCTCTGGCTGGGTGGAAGCCTTCCCAACTAAACGTGAAAC 
                ************************************************** 
 
Bxv1            TGCCAAGGTTGTGACCAAGAAGCTATTAGAAGAAATATTCCCAAGATTCG 
BALB/c XMLV     TGCCAAGGTTGTGACCAAGAAGCTATTAGAAGAAATATTCCCAAGATTCG 
                ************************************************** 
 
Bxv1            GGATGCCACAGGTATTGGGTTCCGATAATGGGCCTGCCTTCGTCTCCCAG 
BALB/c XMLV     GGATGCCACAGGTATTGGGTTCCGATAATGGGCCTGCCTTCGTCTCCCAG 
                ************************************************** 
 
Bxv1            GTAAGTCAGTCGGTGGCCGATTTACTGGGGATCGATTGGAAATTACATTG 
BALB/c XMLV     GTAAGTCAGTCGGTGGCCGATTTACTGGGGATCGATTGGAAATTACATTG 
                ************************************************** 
 
 
Bxv1            TGCTTATAGACCCCAGAGTTCAGGTCAGGTAGAAAGAATGAATAGAACCA 
BALB/c XMLV     TGCTTATAGACCCCAGAGTTCAGGTCAGGTAGAAAGAATGAATAGAACCA 
                ************************************************** 
 
Bxv1            TCAAGGAGACTCTAACTAAATTAACGCTTGCAGCTGGCACTAGAGACTGG 
BALB/c XMLV     TCAAGGAGACTCTAACTAAATTAACGCTTGCAGCTGGCACTAGAGACTGG 
                ************************************************** 
 
Bxv1            GTACTCCTACTCCCCTTAGCCCTCTACCGAGCCCGGAACACTCCGGGCCC 
BALB/c XMLV     GTACTCCTACTCCCCTTAGCCCTCTACCGAGCCCGGAACACTCCGGGCCC 
                ************************************************** 
 
Bxv1            CCATGGACTGACTCCGTATGAAATTCTGTATGGGGCACCCCCGCCCCTTG 
BALB/c XMLV     CCATGGACTGACTCCGTATGAAATTCTGTATGGGGCACCCCCGCCCCTTG 
                ************************************************** 
 
Bxv1            TCAATTTTCATGATCCTGAAATGTCAAAGTTAACTAATAGTCCCTCTCTC 
BALB/c XMLV     TCAATTTTCATGATCCTGAAATGTCAAAGTTAACTAATAGTCCCTCTCTC 
                ************************************************** 
 
Bxv1            CAAGCTCACTTACAGGCCCTCCAAGCAGTACAACGAGAGGTCTGGAAGCC 
BALB/c XMLV     CAAGCTCACTTACAGGCCCTCCAAGCAGTACAACGAGAGGTCTGGAAGCC 
                ************************************************** 
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Bxv1            GCTGGCCGCTGCTTATCAGGACCAGCTAGATCAGCCAGTGATACCACACC 
BALB/c XMLV     GCTGGCCGCTGCTTATCAGGACCAGCTAGATCAGCCAGTGATACCACACC 
                ************************************************** 
 
Bxv1            CCTTCCGTGTCGGTGACGCCGTGTGGGTACGCCGGCACCAGACTAAGAAC 
BALB/c XMLV     CCTTCCGTGTCGGTGACGCCGTGTGGGTACGCCGGCACCAGACTAAGAAC 
                ************************************************** 
 
Bxv1            TTGGAACCTCGCTGGAAAGGACCCTACACCGTCCTGCTGACCACCCCCAC 
BALB/c XMLV     TTGGAACCTCGCTGGAAAGGACCCTACACCGTCCTGCTGACCACCCCCAC 
                ************************************************** 
 
Bxv1            CGCTCTCAAAGTTGACGGCATCTCTGCGTGGATACACGCCGCTCACGTAA 
BALB/c XMLV     CGCTCTCAAAGTTGACGGCATCTCTGCGTGAATACACGCCGCTCACGTAA 
                ****************************** ******************* 
 
Bxv1            AGGCGGCGACAACTCCTCCGGCCGGAGCAGCATGGAAGGTCCAGCGTTCT 
BALB/c XMLV     AGGCGGCGACAACTCCTCCGGCCGGAGCAGCATGGAAGGTCCAGCGTTCT 
                ************************************************** 
 
Bxv1            CAAAACCCCTTAAAGATAAGATTAACCCGTGGGGCCCCCTAATAGTTATA 
BALB/c XMLV     CAAAACCCCTTAAAGATAAGATTAGCCCGTGGGGCCCCCTAATAGTTATA 
                ************************ ************************* 
 
Bxv1            GGGATCTTGGTGAGGGCAGGAGCCTCGGTACAACGTGACAGCCCTCACCA 
BALB/c XMLV     GGGATCTTGGTGAGGGCAGGAGCCTCGGTACAACGTGACAGCCCTCACCA 
                ************************************************** 
 
Bxv1            GGTCTTCAATGTCACTTGGAGAGTTACCAACCTAATGACAGGACAAACAG 
BALB/c XMLV     GGTCTTCAATGTCACTTGGAGAGTTACCAACCTAATGACAGGACAAACAG 
                ************************************************** 
 
Bxv1            CTAACGCTACCTCCCTCCTGGGGACGATGACAGACACCTTCCCTAAACTA 
BALB/c XMLV     CTAACGCTACCTCCCTCCTGGGGACGATGACAGACACCTTCCCTAAACTA 
                ************************************************** 
 
 
Bxv1            TATTTTGACTTGTGTGATTTAGTTGGAGACCATTGGGATGACCCAGAACC 
BALB/c XMLV     TATTTTGACTTGTGTGATTTAGTTGGAGACCATTGGGATGACCCAGAACC 
                ************************************************** 
 
Bxv1            CGATATTGGAGATGGTTGCCGCTCTCCGGGGGGAAGAAAAAGGACAAGAC 
BALB/c XMLV     CGATATTGGAGATGGTTGCCGCTCTCCGGGGGGAAGAAAAAGGACAAGAC 
                ************************************************** 
 
Bxv1            TGTATGACTTCTATGTTTGCCCCGGTCATACTGTACCAATAGGGTGTGGA 
BALB/c XMLV     TGTATGACTTCTATGTTTGCCCCGGTCATACTGTACCAATAGGGTGTGGA 
                ************************************************** 
 
Bxv1            GGGCCGGGAGAGGGCTACTGTGGCAAATGGGGATGTGAGACCACTGGACA 
BALB/c XMLV     GGGCCGGGAGAGGGCTACTGTGGCAAATGGGGATGTGAGACCACTGGACA 
                ************************************************** 
 
Bxv1            GGCATACTGGAAGCCATCATCATCATGGGACCTAATTTCCCTTAAGCGAG 
BALB/c XMLV     GGCATACTGGAAGCCATCATCATCATGGGACCTAATTTCCCTTAAGCGAG 
                ************************************************** 
 
Bxv1            GAAACACTCCTAAGGATCAGGGCCCCTGTTATGATTCCTCGGTCTCCAGT 
BALB/c XMLV     GAAACACTCCTAAGGATCAGGGCCCCTGTTATGATTCCTCGGTCTCCAGT 
                ************************************************** 
 
Bxv1            GGCGTCCAGGGTGCCACACCGGGGGGTCGATGCAACCCCCTAGTCTTAGA 
BALB/c XMLV     GGCGTCCAGGGTGCCACACCGGGGGGTCGATGCAACCCCCTAGTCTTAGA 
                ************************************************** 
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Bxv1            ATTCACTGACGCGGGTAAAAAGGCCAGCTGGGATGCCCCCAAAGTTTGGG 
BALB/c XMLV     ATTCACTGACGCGGGTAAAAAGGCCAGCTGGGATGCCCCCAAAGTTTGGG 
                ************************************************** 
 
Bxv1            GACTAAGACTCTACCGATCCACGGGGGCCGACCCGGTGACCCGGTTCTCT 
BALB/c XMLV     GACTAAGACTCTACCGATCCACGGGGGCCGACCCGGTGACCCGGTTCTCT 
                ************************************************** 
 
Bxv1            TTGACCCGCCAGGTCCTCAATGTAGGACCCCGCGTCCCCATTGGGCCTAA 
BALB/c XMLV     TTGACCCGCCAGGTCCTCAATGTAGGACCCCGCGTCCCCATTGGGCCTAA 
                ************************************************** 
 
Bxv1            TCCCGTGATCACTGAACAGCTACCCCCCTCCCAACCCGTGCAGATCATGC 
BALB/c XMLV     TCCCGTGATCACTGAACAGCTACCCCCCTCCCAACCCGTGCAGATCATGC 
                ************************************************** 
 
Bxv1            TCCCCAGGCCTCCTCATCCTCCTCCTTCAGGCGCGGCCTCTATGGTGCCT 
BALB/c XMLV     TCCCCAGGCCTCCTCATCCTCCTCCTTCAGGCGCGGCCTCTATGGTGCCT 
                ************************************************** 
 
Bxv1            GGGGCTCCCCCGCCTTCTCAACAACCTGGGACGGGGGACAGGCTGCTAAA 
BALB/c XMLV     GGGGCTCCCCCGCCTTCTCAACAACCTGGGACGGGGGACAGGCTGCTAAA 
                ************************************************** 
 
Bxv1            CCTAGTAAAAGGAGCCTATCAAGCACTCAACCTCACCAGTCCCGACAGAA 
BALB/c XMLV     CCTAGTAAAAGGAGCCTATCAAGCACTCAACCTCACCAGTCCCGACAGAA 
                ************************************************** 
 
Bxv1            CCCAAGAGTGCTGGCTGTGTCTGGTATCGGGACCCCCCTACTACGAAGGG 
BALB/c XMLV     CCCAAGAGTGCTGGCTGTGTCTGGTATCGGGACCCCCCTACTACGAAGGG 
                ************************************************** 
 
 
Bxv1            GTTGCCGTCCTAGGTACCTACTCCAACCATACCTCTGCCCCAGCTAACTG 
BALB/c XMLV     GTTGCCGTCCTAGGTACCTACTCCAACCATACCTCTGCCCCAGCTAACTG 
                ************************************************** 
 
Bxv1            CTCCGTGGCCTCCCAACACAAGCTGACCCTGTCCGAAGTGACCGGGCAGG 
BALB/c XMLV     CTCCGTGGCCTCCCAACACAAGCTGACCCTGTCCGAAGTGACCGGGCAGG 
                ************************************************** 
 
Bxv1            GACTCTGCGTAGGAGCAGTTCCCAAAACCCATCAGGCCCTGTGTAATACC 
BALB/c XMLV     GACTCTGCGTAGGAGCAGTTCCCAAAACCCATCAGGCCCTGTGTAATACC 
                ************************************************** 
 
Bxv1            ACCCAGAAGGCGAGCGACGGGTCCTACTATCTGGCTGCTCCCGCCGGGAC 
BALB/c XMLV     ACCCAGAAGGCGAGCGACGGGTCCTACTATCTGGCTGCTCCCGCCGGGAC 
                ************************************************** 
 
Bxv1            CATCTGGGCTTGCAACACCGGGCTCACTCCCTGCCTATCTACCACTGTAC 
BALB/c XMLV     CATCTGGGCTTGCAACACCGGGCTCACTCCCTGCCTATCTACCACTGTAC 
                ************************************************** 
 
Bxv1            TCAACCTCACCACCGATTACTGTGTCCTGGTTGAGCTCTGGCCAAAGGTG 
BALB/c XMLV     TCAACCTCACCACCGATTACTGTGTCCTGGTTGAGCTCTGGCCAAAGGTG 
                ************************************************** 
 
Bxv1            ACCTACCACTCCCCTGGTTATGTTTATGACCAGTTTGAGAGAAAAACCAA 
BALB/c XMLV     ACCTACCACTCCCCTGGTTATGTTTATGACCAGTTTGAGAGAAAAACCAA 
                ************************************************** 
 
Bxv1            ATATAAAAGAGAGCCGGTGTCATTAACTCTGGCCCTGCTGTTGGGAGGAC 
BALB/c XMLV     ATATAAAAGAGAGCCGGTGTCATTAACTCTGGCCCTGCTGTTGGGAGGAC 
                ************************************************** 
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Bxv1            TTACTATGGGCGGCATAGCTGCAGGAGTAGGAACAGGGACTACAGCCCTA 
BALB/c XMLV     TTACTATGGGCGGCATAGCTGCAGGAGTAGGAACAGGGACTACAGCCCTA 
                ************************************************** 
 
Bxv1            GTGGCCACCAAACAATTCGAGCAGCTCCAGGCAGCCATACATACAGACCT 
BALB/c XMLV     GTGGCCACCAAACAATTCGAGCAGCTCCAGGCAGCCATACATACAGACCT 
                ************************************************** 
 
Bxv1            TGGGGCCTTAGAAAAATCAGTCAGTGCCCTAGAAAAGTCTCTGACCTCGT 
BALB/c XMLV     TGGGGCCTTAGAAAAATCAGTCAGTGCCCTAGAAAAGTCTCTGACCTCGT 
                ************************************************** 
 
Bxv1            TGTCTGAGGTGGTCCTACAGAACCGGAGAGGATTAGATCTGCTGTTCCTA 
BALB/c XMLV     TGTCTGAGGTGGTCCTACAGAACCGGAGAGGATTAGATCTGCTGTTCCTA 
                ************************************************** 
 
Bxv1            AAAGAAGGAGGATTATGTGCTGCCCTAAAAGAAGAATGCTGTTTCTATGC 
BALB/c XMLV     AAAGAAGGAGGATTATGTGCTGCCCTAAAAGAAGAATGCTGTTTCTATGC 
                ************************************************** 
 
Bxv1            AGACCACACTGGCGTAGTAAGGGATAGCATGGCTAAGCTAAGAGAAAGGC 
BALB/c XMLV     AGACCACACTGGCGTAGTAAGGGATAGCATGGCTAAGCTAAGAGAAAGGC 
                ************************************************** 
 
Bxv1            TAAACCAGAGGCAAAAATTGTTCGAATCAGGACAAGGGTGGTTTGAGGGA 
BALB/c XMLV     TAAACCAGAGGCAAAAATTGTTCGAATCAGGACAAGGGTGGTTTGAGGGA 
                ************************************************** 
 
 
Bxv1            CTGTTTAACAGGTCCCCATGGTTCACGACCCTGATATCCACCATTATGGG 
BALB/c XMLV     CTGTTTAACAGGTCCCCATGGTTCACGACCCTGATATCCACCATTATGGG 
                ************************************************** 
 
Bxv1            CCCTCTGATAGTACTTTTATTAATCCTACTCCTCGGACCCTGCATTCTCA 
BALB/c XMLV     CCCTCTGATAGTACTTTTATTAATCCTACTCCTCGGACCCTGCATTCTCA 
                ************************************************** 
 
Bxv1            ACCGCTTGGTCCAGTTTGTAAAAGACAGAATTTCGGTGGTGCAGGCCCTG 
BALB/c XMLV     ACCGCTTGGTCCAGTTTGTAAAAGACAGAATTTCGGTGGTGCAGGCCCTG 
                ************************************************** 
 
Bxv1            GTTCTGACCCAACAGTATCACCAACTCAAATCAATAGATCCAGAAGAAGT 
BALB/c XMLV     GTTCTGACCCAACAGTATCACCAACTCAAATCAATAGATCCAGAAGAAGT 
                ************************************************** 
 
Bxv1            AGAATCGCGTGAATAAAAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAA 
BALB/c XMLV     AGAATCGCGTGAATAAAAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAA 
                ************************************************** 
 
Bxv1            TGAAAGACCCCACCATAAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTT 
BALB/c XMLV     TGAAAGACCCCACCATAAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTT 
                ************************************************** 
 
Bxv1            TGCAAGGCATGAAAAAGTACCAGAGCTGAGTTCTCAAAAGTCACAAGGAA 
BALB/c XMLV     TGCAAGGCATGAAAAAGTACCAGAGCTGAGTTCTCAAAAGTCACAAGGAA 
                ************************************************** 
 
Bxv1            GTTTAGTTAAAGAATAAGGCTGAACAAAACTGGGACAGGGGCCAAACAGG 
BALB/c XMLV     GTTTAGTTAAAGAATAAGGCTGAACAAAACTGGGACAGGGGCCAAACAGG 
                ************************************************** 
 
Bxv1            ATATCTGTGGTCGAGCACCTGGGCCCCGGCTCAGGGCCAAGAACAGATGG 
BALB/c XMLV     ATATCTGTGGTCGAGCACCTGGGCCCCGGCTCAGGGCCAAGAACAGATGG 
                ************************************************** 
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Bxv1            TACTCAGATAAAGCGAAACTAGCAACAGTTTCTGGAAAGTCCCACCTCAG 
BALB/c XMLV     TACTCAGATAAAGCGAAACTAGCAACAGTTTCTGGAAAGTCCCACCTCAG 
                ************************************************** 
 
Bxv1            TTTCAAGTTCCCCAAAAGACCGGGAAAAACCCCAAGCCTTATTTAAACTA 
BALB/c XMLV     TTTCAAGTTCCCCAAAAGACCGGGAAAAACCCCAAGCCTTATTTAAACTA 
                ************************************************** 
 
Bxv1            ACCAATCAGCTCGCTTCTCGCTTCTGTAACCGCGCTTTTTGCTCCCCAGC 
BALB/c XMLV     ACCAATCAGCTCGCTTCTCGCTTCTGTAACCGCGCTTTTTGCTCCCCAGC 
                ************************************************** 
 
Bxv1            CCTATAAAAAGGGTAAAAACCCCACACTCGGTGCGCCAGTCATCCGATAG 
BALB/c XMLV     CCTATAAAAAGGGTAAAAACCCCACACTCGGTGCGCCAGTCATCCGATAG 
                ************************************************** 
 
Bxv1            ACTGAGTCGCCCGGGTACCCGTGTTCCCAATAAAGC 
BALB/c XMLV     ACTGAGTCGCCCGGGTACCCGTGTTCCCAATAAAGC 
                ************************************ 
 
 
Appendix 3: Virus Sequence from NSG explants (gag/pol region) compared with 
endogenous PMLV like MLV (murine chromosome 13, accession no. 154849.2) 
Bxv1 (accession no.AC115959.17) and Mo MLV (accession no. JO2255.1). 
 
NSG gag/pol     TCTTTTGTCAGAACGGCAATGGCTGCTACCATCCGTAGGCAAGGGGGCCA 
PMLV            TCTTTTGTCAGAACGGCAATGGCTGCTACCATCCGTAGGCAAGGGGGCCA 
Bxv1            TCTTTTGTCAGAACGGCAATGGCTGCTACCATCCGTAGGCAAGGGGGCCA 
Mo MLV          TCCTTTGTCAGTACGGCAATGGCTGCTACCATCCGTAGGCAAGGGGGCCA 
                ** ******** ************************************** 
 
NSG gag/pol     CCCAGCTGCCACTGGGTCTAGCTTTTTGGACAGGTAGGCCACCGGCCGAC 
PMLV            CCCAGCTGCCACTGGGTCTAGCTTTTTGGACAGGTAGGCCACCGGCCGAC 
Bxv1            CCCGGCTGCCACTGGGTCTAGCTTTTTGGACAGGTAGGCCACAGGCCGAC 
Mo MLV          CCCAGCTGCTACTGGGTCTAGCTTTTTGGACAGGTAGGCCACCGGCCGAC 
                *** ***** ******************************** ******* 
 
NSG gag/pol     GCCAAGGTCCCAGTTTTTGCGTTAGGACGCCTTTGGCGTAGCCCTGCTTC 
PMLV            GCCAAGGTCCCAGTTTTTGCGTTAGGACGCCTTTGGCGTAGCCCTGCTTC 
Bxv1            GCCAAGGTCCCAGTTTTTGCGTTAGGACGCCTTTGGCGTAGCCCTGCTTC 
Mo MLV          GCCAAGGTCCCAGTTTTTGCGTTAGGACACCTTTGGCGTAGCCCTGCTTC 
                **************************** ********************* 
 
NSG gag/pol     TCGTCGACAAAGAGTTCAAAGGGCTTAGTCAAATCTGGCAATCCCAGGGC 
PMLV            TCGTCGACAAAGAGTTCAAAGGGCTTAGTCAAATCTGGCAATCCCAGGGC 
Bxv1            TCGTCGACAAAGAGTTCAAAGGGCTTAGTCAAATCTGGCAATCCCAGGGC 
Mo MLV          TCGTCGACAAAGAGTTCAAAGGGCTTAGTCAAATCTGGCAACCCCAGGGC 
                ***************************************** ******** 
 
NSG gag/pol     TGGGGCAGTTAGAAGAGCCTGTTTGATTTCTTGATAGGCCTTTTGCTGGT 
PMLV            TGGGGCAGTTAGAAGAGCCTGTTTGATTTCTTGATAGGCCTTTTGCTGGT 
Bxv1            GGGGGCAGTTAGAAGGGCCTGTTTGATTTCTTGATAGGCCTTTTGCTGGT 
Mo MLV          TGGGGCAGTTAGAAGAGCTTGCTTGATTTCTTGATAGGCCTTTTGTTGGT 
                 ************** ** ** *********************** **** 
 
NSG gag/pol     CTGGGCCCCAATTAAACAGAGTCCCCGTTTTGGTGAGAGGGTACAAGGGG 
PMLV            CTGGGCCCCAATTAAACAGAGTCCCCGTTTTGGTGAGAGGGTACAAGGGG 
Bxv1            CTGGGCCCCAATTAAACAGAGTCCCCGTTTTGGTAAGAGGATACAAGGGG 
Mo MLV          CTGGGCCCCAATTAAACAGAGTCCCCGTTTTGGTGAGAGGGTACAAGGGG 
                ********************************** ***** ********* 
198 
 
NSG gag/pol     GCTGCCATTTCTGCAAACCCAGGGATCCAGAGGCGACAGAAGCCTGCCGT 
PMLV            GCTGCCATTTCTGCAAACCCAGGGATCCAGAGGCGACAGAAGCCTGCCGT 
Bxv1            GCCGCCATTTCCGCAAACCCAGGGATCCAGAGGCGGCAGAAGCCTGCCGT 
Mo MLV          GCTGCCATTTCTGCAAACCCAGGGATCCAGAGGCGACAGAAGCCTGCCGT 
                ** ******** *********************** ************** 
 
NSG gag/pol     CTCTAGGAACTCCCTTAGTTGTCGAGGGGTCTTCGGAGTAGGCTGCCCCA 
PMLV            CCCTAGGAACTCCCTTAGTTGTCGAGGGGTCTTCGGAGTAGGCTGCCCCA 
Bxv1            CCCTAGGAACTCCCTTAGTTGTCGAGGAGTCTTTGGAACGGGTTGCCCCA 
Mo MLV          CCCTAGGAACTCCCTTAGTTGTCGAGGGGTCTTCGGAGTAGGCTGCCCCA 
                * ************************* ***** ***   ** ******* 
 
NSG gag/pol     TCACAGTCTCTTTTCTGGCCTCAGTCAGCCATCTCTGACCCTCTTTTAGA 
PMLV            TCACAGTCTCTTTTCTGGCCTCAGTCAGCCATCTCTGACCCTCTTTTAGA 
Bxv1            TCACAGTCTCTTTTCTAGCCTCAGTCAGCCATCTCTGACCCTCCCTCAGA 
Mo MLV          TCACAGTCTCTTTTCTGGCCTCAGTCAGCCATCTCTGACCCTCTTTTAGA 
                **************** **************************  * *** 
 
NSG gag/pol     AGATACCCCAGATACTTGACCTGTTTCTGGCAAATTTGGGCTTTCTTGGC 
PMLV            AGATACCCCAGATACTTGACCTGTTTCTGGCAAATTTGGGCCTTCTTGGC 
Bxv1            AGGTACCCCAGGTATTTAACCTGTTTCTGGCAGATTTGGGCTTTCTTGGC 
Mo MLV          AGATACCCCAGATACTTGACCTGTTTCTGGCAAATTTGGGCTTTCTTGGC 
                ** ******** ** ** ************** ******** ******** 
 
NSG gag/pol     CGAGGCCCGATACCCGAGGTCCCCTAGGGTTTGTAACAGGGCCCGAGTAC 
PMLV            CGAGGCCCGATACCCGAGGTCCCCTAGGGTTTGTAACAGGGCCCGAGTAC 
Bxv1            CGAGGCCCGGTATCCGAGGTCCCCTAGGGTTTGTAGAAGGGCCCGAGTAC 
Mo MLV          CGAGGCCCGATACCCGAGGTTCCCTAGGGTTTGTAACAGGGCCCGAGTAC 
                ********* ** ******* **************  ************* 
 
NSG gag/pol     CTTGTTGGCAGTCGAGCTCAGAAGTGGCGGCCAGCAGTAAGTCATCCACG 
PMLV            CTTGTTGGCAGTCGAGCTCAGAAGTGGCGGCCAGCAGTAAGTCATCCACG 
Bxv1            CTTGTTGGCAGTCTAGTTCGGAAGTAGCGGCCAGCAGTAAGTCATCCACG 
Mo MLV          CTTGTTGGCAGTCTAGCTCAGAAGTGGCGGCCAGCAGTAAGTCATCCACG 
                ************* ** ** ***** ************************ 
 
NSG gag/pol     TACTGTAGCAGGATCAAGTCTGGGTGCTGGATCCGGAAGCCTGCTAGGTC 
PMLV            TACTGTAGCAGGATCAAGTCTGGGTGCTGGATCCGGAAGCCTGCTAGGTC 
Bxv1            TACTGTAGCAGGATCAAGTCTGGGTGCTGGATCCGGAAGTCTGCTAGGTC 
Mo MLV          TACTGTAGCAGGATCAAGTCTGGGTGCTGGATCCGGAAGTCTGCTAGGTC 
                *************************************** ********** 
 
NSG gag/pol     TCTGTGCAGTGCCTCATCAAACAGGGTGGGACTGTTTTTGAAACCCTGTG 
PMLV            TCTGTGCAGTGCCTCATCAAACAGGGTGGGACTGTTTTTGAAACCCTGTG 
Bxv1            TCTGTGCAATGCCTCATCAAACAGGGTGGGACTGTTTTTGAAACCCTGTG 
Mo MLV          TCTGTGCAGTGCCTCATCAAACAGGGTGGGACTGTTTTTGAAACCCTGTG 
                ******** ***************************************** 
 
NSG gag/pol     GGAGTCTGGTCCAGGTTAATTGTCCTGAGATTCCCATCTCTGGGTCTCTC 
PMLV            GGAGTCTGGTCCAGGTTAATTGTCCTGAGATTCCCATCTCTGGGTCTCTC 
Bxv1            GGAGTCTGGTCCAGGTCAATTGTCCAGAGATTCCCATTTCTGGATCTCTC 
Mo MLV          GGAGTCTGGTCCAGGTCAATTGTCCTGAGATTCCCATCTCTGGATCTCTC 
                **************** ******** *********** ***** ****** 
 
NSG gag/pol     CACTCAAAGGCGAAGAGAGGCTGACTGGTGGGGTGGAGTCTCAGGCAGAA 
PMLV            CACTCAAAGGCGAAGAGAGGCTGACTGGTGGGGTGGAGTCTCAGGCAGAA 
Bxv1            CACTCAAAGGCAAAGAGAGGCTGACTGGTGGGGTGGAGTCTCAGGCAGAA 
Mo MLV          CACTCAAAGGCGAAGAGAGGCTGACTGGTGGGGTGGAGTCTCAGGCAGAA 
                *********** ************************************** 
 
NSG gag/pol     AAAGGCATCCTTTAAGTCAAGCACAGTGTACCACTGGTGGGACGGTGGGA 
PMLV            AAAGGCATCCTTTAAGTCAAGCACAGTGTACCACTGGTGGGACGGTGGGA 
Bxv1            AAAGGCATCTTTTAAATCAAGCACAGTGTACCACTGGTGGGACGGAGGGA 
Mo MLV          AAAGGCATCCTTTAAATCAAGCACAGTGTACCACTGGTGGGACGGTGGGA 
                ********* ***** ***************************** **** 
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NSG gag/pol     GCCCGCTCAAGAGGTTGTAAGGGTTGGGCACGGTGGGGTGGATGTCTTCC 
PMLV            GCCCGCTCAAGAGGTTGTAAGGGTTGGGCACGGTGGGGTGGATGTCTTCC 
Bxv1            GTCCACTTAAGAGGTTGTAAGGATTGGGCACGGTGGGGTGGATATCTTCC 
Mo MLV          GCCCGCTCAAGAGGTTGTAAGGGTTGGGCACGGTGGGGTGGATGTCTTCC 
                * ** ** ************** ******************** ****** 
 
NSG gag/pol     ACCCGCTTGTTGACTTCTCTCAGATCC 
PMLV            ACCCGCTTGTTGACTTCTCTCAGATCC 
Bxv1            ACCCGCTTGTTGACTTCTCTCAGATCC 
Mo MLV          ACCCGCTTGTTGACTTCTCTCAGATCC 
                *************************** 
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Appendix 4: Virus Sequence from NSG explants (LTR region) compared with 
endogenous PMLV like MLV (murine chromosome 13, accession no. 154849.2) 
Bxv1 (accession no.AC115959.17) and Mo MLV (accession no. JO2255.1). 
 
NSG LTR         CCAAC----TCAAATCAATAGATCCAGAAGAAGTGGAATCACGTGAATAA 
PMLV            CCAAC----TCAAATCAATAGATCCAGAAGAAGTGGAATCACGTGAATAA 
Bxv1            CCAAC----TCAAATCAATAGATCCAGAAGAAGTAGAATCGCGTGAATAA 
Mo MLV          ATCACCAGCTGAAGCCTATAGA------GTACGAGCCATAGATAAAATAA 
                   **    * **  * *****        * *    **      ***** 
 
NSG LTR         AAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACCAT 
PMLV            AAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACCAT 
Bxv1            AAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACCAT 
Mo MLV          AAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTG 
                *********** *** ******** ***********************   
 
NSG LTR         CAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAA 
PMLV            CAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAA 
Bxv1            AAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAA 
Mo MLV          TAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAA 
                 *** ** ***********  ************************ **** 
 
NSG LTR         GTACCAGAGCTGAGTTCTCAAAAGTTACAAGAAAGTTCAGTTAAAAATTA 
PMLV            GTACCAGAGCTGAGTTCTCAAAAGTTACAAGAAAGTTCAGTTAAAGATTA 
Bxv1            GTACCAGAGCTGAGTTCTCAAAAGTCACAAGGAAGTTTAGTTAA------ 
Mo MLV          ATAC-ATAACTGAGAATAGAG-----------AAGTTCAGATCAAGGTCA 
                 *** * * *****     *            ***** ** * *       
 
NSG LTR         ACAGTTAAAGATT--AAGGCTGAATAATACTGGGACAGGGGCCAA----- 
PMLV            ACAGTTAAAGATT--AAGGCTGAATAATACTGGGACAGGGGCCAA----- 
Bxv1            --------AGAAT--AAGGCTGAACAAAACTGGGACAGGGGCCAAACAGG 
Mo MLV          GGAAC---AGATGGAACAGCTGAATA----TGGGCCAA--ACAGG----- 
                        ***    *  ****** *    **** **    *         
 
NSG LTR         ATATCGGTGGTCAAGCACCT-GGGCCCCGGCTCAGGGCCAAGAACAGATG 
PMLV            ATATCGGTGGTCAAGCACCT-GGGCCCCGGCTCAGGGCCAAGAACAGATG 
Bxv1            ATATCTGTGGTCGAGCACCT-GGGCCCCGGCTCAGGGCCAAGAACAGATG 
Mo MLV          ATATCTGTGGT-AAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATG 
                ***** *****  ****  *   *************************** 
 
NSG LTR         GCTCTCAGACGTCAGTGTTAGCAGAACTAGCTTCACTGATTTAGAAAAAT 
PMLV            GCTCTCAGACGTCAGTGTTAGCAGAACTAGCTTCACTGATTTAGAAAAAT 
Bxv1            GTACTCAGATA-------AAGCGAAACTAGCA------------------ 
Mo MLV          GAAC--AGCT--GAATATGGGCCAAACA-GGA--------------TATC 
                *  *  **            **  ***  *                     
 
NSG LTR         AGAGGTGCACAGTGCTCTGGCCACTCCTTGAACCTGTGTGTCTGCCAATG 
PMLV            AGAGGTGCACAGTGCTCTGGCCACTCCTTGAACCTGTGTGTCTGCCAATG 
Bxv1            --------ACAG-------------------------------------- 
Mo MLV          TGTGGTAAGCAGTTC-C-TGCCCCGGCTC-----------AGGGCCAA-- 
                         ***                                       
 
NSG LTR         TTCTGACCAGGTGTGTGCCCATTGTTGAACCTTCATTAGACCCTTTCCTC 
PMLV            TTCTGACCAGGTGTGTGCCCATTGTTGAACCTTCATTAGACCCTTTCCTC 
Bxv1            -------------------------------------------------- 
Mo MLV          ----GAACAGATG-GTCCCCA-----------------GATGCGGTCC-- 
                                                                   
 
NSG LTR         GTACCCCTCCCATACCCATTTCTTGAAAATAGACATTGTTTAAAACTAAA 
PMLV            GTACCCCTCCCATACCCATTTCTTGAAAATAGACATTGTTTAGAACTAAA 
Bxv1            ------------------TTTCTGGAAAG-TCCCACC-----------TC 
Mo MLV          --AGCCCT----CAGCAGTTTCTAGAGAAC---CAT----CAG------- 
                                  ***** ** *     **                
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NSG LTR         AAGTCCCACCTCAGTTTCCCCAAATGACCGAGAAATACCCCAAGCCTTAT 
PMLV            AAGTCCCACCTCAGTTTCCCCAAATGACCGAGAAATACCCCAAGCCTTAT 
Bxv1            A-GTTT-----CAAGTTCCCCAAAAGACCGGGAAAAACCCCAAGCCTTAT 
Mo MLV          ATGTTT----CCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTAT 
                * **       **   * *** ** ****   **  ****   ******* 
 
NSG LTR         TCGAACTAACCAACCAGCTCGCTTCTCGCTTCTGTAACCGCGCTTTTTGC 
PMLV            TCAAACTAACCAACCAGCTCGCTTCTCGCTTCTGTAACCGCGCTTTTTGC 
Bxv1            TTAAACTAACCAATCAGCTCGCTTCTCGCTTCTGTAACC----------- 
Mo MLV          TTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTCGCGCGCTTC-TGC 
                *  ********** *** *****************   *            
 
NSG LTR         TCCC-CAG 
PMLV            TCCC-CAG 
Bxv1            ------GC 
Mo MLV          TCCCCGAG 
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Appendix 5: List of differentially expressed genes 
Raji cells up regulated FC ≥1.5 
SYMBOL ENTREZ GENE NAME LOCATION TYPE(S) P-VALUE 
FOLD 
CHANGE 
IFI44 interferon-induced protein 44 Cytoplasm other 1.12E-04 5.13 
CCL4 chemokine (C-C motif) ligand 4 
Extracellular 
Space cytokine 1.59E-03 2.99 
VTRNA1-1 vault RNA 1-1 Other other 1.27E-02 2.86 
IFI44L interferon-induced protein 44-like Other other 2.66E-04 2.58 
CCL4L1/CCL4L2 chemokine (C-C motif) ligand 4-like 1 
Plasma 
Membrane other 5.30E-04 2.47 
CCL3L1/CCL3L3 chemokine (C-C motif) ligand 3-like 1 
Plasma 
Membrane other 8.33E-04 2.40 
CCNB1 cyclin B1 Cytoplasm kinase 5.25E-04 2.37 
MIR4254 microRNA 4254 Cytoplasm microRNA 1.57E-02 2.22 
GMFG glia maturation factor, gamma Cytoplasm growth factor 2.25E-03 2.11 
UBE2T ubiquitin-conjugating enzyme E2T (putative) Nucleus enzyme 1.90E-05 2.09 
MIR548 microRNA 548c Cytoplasm microRNA 1.64E-02 2.07 
C17orf78 chromosome 17 open reading frame 78 Other other 9.21E-03 2.01 
LOC100287704/LOC1002
87834 uncharacterized LOC100287704 Other other 1.26E-02 1.95 
MELK maternal embryonic leucine zipper kinase Cytoplasm kinase 3.55E-04 1.92 
CENPI centromere protein I Nucleus other 7.55E-03 1.89 
DEFB122 defensin, beta 122 (pseudogene) Other other 2.63E-02 1.89 
FAM83D family with sequence similarity 83, member D Other other 1.68E-02 1.89 
ZNF826P zinc finger protein 826, pseudogene Other other 7.35E-03 1.87 
SNORA70E small nucleolar RNA, H/ACA box 70E Other other 2.28E-02 1.87 
POLH polymerase (DNA directed), eta Nucleus enzyme 1.66E-03 1.85 
CDC6 cell division cycle 6 Nucleus other 2.45E-03 1.84 
SLC9C2 solute carrier family 9, member C2 (putative) Other other 7.08E-03 1.83 
CCNB2 cyclin B2 Cytoplasm other 1.92E-04 1.83 
PLK1 polo-like kinase 1 Nucleus kinase 1.63E-02 1.82 
SPAG5 sperm associated antigen 5 Nucleus peptidase 2.58E-03 1.82 
CDC25C cell division cycle 25C Nucleus phosphatase 3.11E-02 1.81 
GINS2 GINS complex subunit 2 (Psf2 homolog) Nucleus other 8.26E-03 1.81 
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 Cytoplasm enzyme 4.71E-03 1.78 
ERH enhancer of rudimentary homolog (Drosophila) Nucleus other 8.77E-04 1.77 
TNF tumor necrosis factor 
Extracellular 
Space cytokine 6.19E-03 1.74 
KIF20A kinesin family member 20A Cytoplasm transporter 3.10E-03 1.74 
PSMB6 
proteasome (prosome, macropain) subunit, 
beta type, 6 Other peptidase 7.69E-03 1.74 
OR4D11 
olfactory receptor, family 4, subfamily D, 
member 11 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2.10E-02 1.73 
DEFB119 defensin, beta 119 
Extracellular 
Space other 1.07E-02 1.72 
AURKB aurora kinase B Nucleus kinase 2.01E-02 1.72 
CKS2 CDC28 protein kinase regulatory subunit 2 Other kinase 2.10E-03 1.72 
FANCD2 Fanconi anemia, complementation group D2 Nucleus other 4.75E-04 1.72 
MIR2909 microRNA 2909 Cytoplasm microRNA 1.72E-02 1.72 
MIR154/MIR382 microRNA 494 Cytoplasm microRNA 4.17E-02 1.71 
GINS1 GINS complex subunit 1 (Psf1 homolog) Nucleus other 1.56E-03 1.70 
IGLL3P 
immunoglobulin lambda-like polypeptide 3, 
pseudogene Other other 2.00E-02 1.69 
CDK1 cyclin-dependent kinase 1 Nucleus kinase 1.87E-04 1.69 
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DEFB121 defensin, beta 121 
Extracellular 
Space other 6.91E-03 1.69 
OR1A2 
olfactory receptor, family 1, subfamily A, 
member 2 
Plasma 
Membrane 
G-protein 
coupled 
receptor 1.45E-02 1.69 
NCAPH non-SMC condensin I complex, subunit H Nucleus other 3.98E-03 1.69 
AURKA aurora kinase A Nucleus kinase 6.73E-03 1.68 
DEPDC1B DEP domain containing 1B Cytoplasm other 1.07E-03 1.68 
SPC25 SPC25, NDC80 kinetochore complex component Cytoplasm other 1.76E-03 1.68 
PSMB3 
proteasome (prosome, macropain) subunit, 
beta type, 3 Cytoplasm peptidase 4.04E-03 1.68 
DEFB123 defensin, beta 123 
Extracellular 
Space other 8.13E-03 1.65 
MIR548/MIR603 microRNA 548c Cytoplasm microRNA 1.94E-03 1.65 
EME1 
essential meiotic structure-specific 
endonuclease 1 Nucleus other 2.30E-02 1.65 
DIAPH3 diaphanous-related formin 3 Cytoplasm enzyme 1.59E-02 1.65 
FBXL7 F-box and leucine-rich repeat protein 7 Cytoplasm enzyme 3.03E-02 1.64 
CDC20 cell division cycle 20 Nucleus other 1.00E-02 1.64 
USP51 ubiquitin specific peptidase 51 Other peptidase 3.42E-02 1.64 
KNSTRN/C15orf23 
kinetochore-localized astrin/SPAG5 binding 
protein Cytoplasm other 3.11E-02 1.63 
UBE2C ubiquitin-conjugating enzyme E2C Cytoplasm enzyme 1.96E-03 1.63 
KIAA0101 KIAA0101 Nucleus other 1.42E-03 1.63 
TPX2 TPX2, microtubule-associated Nucleus other 1.84E-04 1.62 
PSMD8 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 8 Cytoplasm other 1.85E-02 1.62 
TROAP trophinin associated protein Cytoplasm peptidase 2.53E-03 1.62 
CEP55 centrosomal protein 55kDa Cytoplasm other 8.45E-03 1.62 
CDCA8 cell division cycle associated 8 Nucleus other 8.47E-03 1.62 
MANF 
mesencephalic astrocyte-derived neurotrophic 
factor 
Extracellular 
Space other 4.55E-04 1.62 
PRC1 protein regulator of cytokinesis 1 Nucleus other 1.24E-03 1.61 
KRT76 keratin 76 Cytoplasm other 3.62E-02 1.60 
SNORD53 small nucleolar RNA, C/D box 53 Other other 3.97E-03 1.60 
NUSAP1 nucleolar and spindle associated protein 1 Nucleus other 9.39E-04 1.60 
ANXA2P2 annexin A2 pseudogene 2 Other other 2.88E-02 1.60 
BNIP2 
BCL2/adenovirus E1B 19kDa interacting protein 
2 Cytoplasm other 1.80E-02 1.59 
RGR retinal G protein coupled receptor 
Plasma 
Membrane 
G-protein 
coupled 
receptor 3.12E-02 1.59 
BCAS4 breast carcinoma amplified sequence 4 Cytoplasm other 3.03E-02 1.59 
RAPGEF4-AS1 RAPGEF4 antisense RNA 1 Other other 2.56E-04 1.59 
SGOL2 shugoshin-like 2 (S. pombe) Nucleus other 5.59E-03 1.59 
SNORA49 small nucleolar RNA, H/ACA box 49 Other other 4.45E-02 1.58 
THSD1 thrombospondin, type I, domain containing 1 
Extracellular 
Space other 3.33E-02 1.58 
NUF2 NUF2, NDC80 kinetochore complex component Nucleus other 2.75E-03 1.58 
MIR150 microRNA 150 Other microRNA 3.18E-03 1.58 
NQO2 NAD(P)H dehydrogenase, quinone 2 Cytoplasm enzyme 1.65E-02 1.57 
NDUFB10 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa Cytoplasm enzyme 6.81E-03 1.57 
CENPW centromere protein W Nucleus other 1.92E-02 1.57 
ORC6 origin recognition complex, subunit 6 Nucleus other 5.68E-04 1.57 
SNORD78 small nucleolar RNA, C/D box 78 Other other 1.89E-03 1.57 
CEP128 centrosomal protein 128kDa Cytoplasm other 4.60E-03 1.57 
DLGAP5 
discs, large (Drosophila) homolog-associated 
protein 5 Nucleus phosphatase 2.66E-04 1.56 
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LRRCC1 
leucine rich repeat and coiled-coil centrosomal 
protein 1 Nucleus transporter 4.55E-02 1.56 
MAPT-IT1 MAPT intronic transcript 1 (non-protein coding) Other other 3.07E-02 1.56 
C3orf36 chromosome 3 open reading frame 36 Other other 2.23E-04 1.55 
GLA galactosidase, alpha Cytoplasm enzyme 4.15E-02 1.55 
OR5B21 
olfactory receptor, family 5, subfamily B, 
member 21 
Plasma 
Membrane 
G-protein 
coupled 
receptor 4.67E-02 1.55 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase Cytoplasm enzyme 2.18E-03 1.55 
LOC81691 exonuclease NEF-sp Nucleus enzyme 1.01E-02 1.55 
LOC400682 zinc finger protein 100-like Other other 3.59E-02 1.55 
F8A1 (includes others) coagulation factor VIII-associated 1 Nucleus other 1.04E-02 1.54 
AUNIP aurora kinase A and ninein interacting protein Cytoplasm other 6.28E-03 1.53 
CLIC1 chloride intracellular channel 1 Nucleus ion channel 2.45E-03 1.53 
SOX2-OT 
SOX2 overlapping transcript (non-protein 
coding) Other other 1.87E-02 1.53 
TPRX1 tetra-peptide repeat homeobox 1 Other other 2.78E-02 1.52 
PRDX1 peroxiredoxin 1 Cytoplasm enzyme 9.85E-03 1.52 
RAB4B RAB4B, member RAS oncogene family 
Plasma 
Membrane enzyme 1.15E-02 1.52 
ESRRA estrogen-related receptor alpha Nucleus 
ligand-
dependent 
nuclear 
receptor 8.96E-03 1.52 
ODF2 outer dense fiber of sperm tails 2 Cytoplasm other 1.25E-02 1.52 
MCM8 
minichromosome maintenance complex 
component 8 Nucleus enzyme 3.40E-03 1.51 
MIR345 microRNA 345 Cytoplasm microRNA 4.01E-02 1.51 
KIFC1 kinesin family member C1 Nucleus enzyme 1.86E-02 1.51 
GBP3 guanylate binding protein 3 Other enzyme 1.79E-02 1.51 
LACTBL1 lactamase, beta-like 1 Other other 1.14E-02 1.51 
GDF7 growth differentiation factor 7 
Extracellular 
Space growth factor 2.38E-02 1.51 
WNT9B 
wingless-type MMTV integration site family, 
member 9B 
Extracellular 
Space other 4.67E-02 1.51 
KIF20B kinesin family member 20B Nucleus enzyme 1.52E-03 1.51 
ACOT1 acyl-CoA thioesterase 1 Cytoplasm enzyme 2.80E-02 1.51 
TUBBP5 tubulin, beta pseudogene 5 Other other 5.28E-03 1.50 
ORC1 origin recognition complex, subunit 1 Nucleus other 3.04E-02 1.50 
FSIP2 fibrous sheath interacting protein 2 Cytoplasm other 2.74E-02 1.50 
HIST2H2BA histone cluster 2, H2ba (pseudogene) Other other 2.37E-02 1.50 
COX8A cytochrome c oxidase subunit VIIIA (ubiquitous) Cytoplasm enzyme 1.38E-03 1.50 
      
Raji cells down regulated FC ≥1.5 
SYMBOL ENTREZ GENE NAME LOCATION TYPE(S) P-VALUE 
FOLD 
CHANGE 
TSPAN2 tetraspanin 2 
Extracellular 
Space other 9.92E-03 -3.57 
MIR944 microRNA 944 Cytoplasm microRNA 1.51E-02 -2.77 
PCOLCE2 procollagen C-endopeptidase enhancer 2 
Extracellular 
Space other 1.31E-03 -2.72 
SLC30A4 
solute carrier family 30 (zinc transporter), 
member 4 Cytoplasm transporter 7.27E-04 -2.32 
TMED10P1 
transmembrane emp24-like trafficking protein 
10 (yeast) pseudogene 1 Other other 2.62E-02 -2.27 
IL7R interleukin 7 receptor 
Plasma 
Membrane 
transmembra
ne receptor 4.38E-02 -2.26 
OR2T29/OR2T5 
olfactory receptor, family 2, subfamily T, 
member 5 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2.25E-03 -2.24 
MIR1204 microRNA 1204 Cytoplasm microRNA 1.67E-03 -2.18 
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OR2T3/OR2T34 
olfactory receptor, family 2, subfamily T, 
member 34 
Plasma 
Membrane other 4.26E-03 -2.12 
OR2T29/OR2T5 
olfactory receptor, family 2, subfamily T, 
member 5 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2.05E-03 -2.12 
MIR4477A microRNA 4477b Cytoplasm microRNA 9.00E-03 -2.11 
SSPN sarcospan 
Plasma 
Membrane other 1.84E-02 -2.03 
SH2D1A SH2 domain containing 1A Cytoplasm other 2.25E-02 -2.01 
HIST1H2BG histone cluster 1, H2bg Nucleus other 3.08E-02 -2.01 
RAET1K retinoic acid early transcript 1K pseudogene Other other 7.99E-04 -2.00 
FLJ46066 uncharacterized LOC401103 Other other 3.81E-02 -1.98 
CEP19 centrosomal protein 19kDa Cytoplasm other 9.74E-04 -1.97 
GADD45B growth arrest and DNA-damage-inducible, beta Cytoplasm other 3.71E-03 -1.97 
TNFSF4 
tumor necrosis factor (ligand) superfamily, 
member 4 
Extracellular 
Space cytokine 1.06E-03 -1.95 
ZNF563 zinc finger protein 563 Nucleus other 3.36E-02 -1.95 
TRIM55 tripartite motif containing 55 Cytoplasm other 6.95E-03 -1.95 
TCP11L2 t-complex 11, testis-specific-like 2 Other other 4.79E-03 -1.93 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 
Extracellular 
Space other 4.77E-03 -1.92 
TNKS 
tankyrase, TRF1-interacting ankyrin-related 
ADP-ribose polymerase Nucleus enzyme 2.32E-02 -1.91 
TYW5 tRNA-yW synthesizing protein 5 Other enzyme 9.32E-04 -1.91 
CD200 CD200 molecule 
Plasma 
Membrane other 3.30E-02 -1.91 
OR8H2 
olfactory receptor, family 8, subfamily H, 
member 2 
Plasma 
Membrane 
G-protein 
coupled 
receptor 3.31E-02 -1.88 
LINC-ROR 
long intergenic non-protein coding RNA, 
regulator of reprogramming Other other 1.33E-02 -1.85 
CYP39A1 
cytochrome P450, family 39, subfamily A, 
polypeptide 1 Cytoplasm enzyme 5.97E-03 -1.83 
VCAM1 vascular cell adhesion molecule 1 
Plasma 
Membrane 
transmembra
ne receptor 1.22E-03 -1.83 
IKZF3 IKAROS family zinc finger 3 (Aiolos) Nucleus 
transcription 
regulator 4.12E-03 -1.81 
RNF144B ring finger protein 144B Other enzyme 2.13E-04 -1.79 
ATP5S 
ATP synthase, H+ transporting, mitochondrial Fo 
complex, subunit s (factor B) Cytoplasm transporter 1.61E-02 -1.79 
TMEM242 transmembrane protein 242 Other other 1.94E-02 -1.78 
POPDC2 popeye domain containing 2 Other other 4.04E-02 -1.77 
ZMYM5 zinc finger, MYM-type 5 Nucleus other 5.25E-04 -1.77 
ZNF441 zinc finger protein 441 Nucleus other 2.08E-02 -1.77 
ZNF253 zinc finger protein 253 Nucleus 
transcription 
regulator 9.39E-03 -1.77 
HUNK hormonally up-regulated Neu-associated kinase Cytoplasm kinase 7.50E-03 -1.77 
ADPRH ADP-ribosylarginine hydrolase Other enzyme 5.62E-04 -1.77 
ABCD2 
ATP-binding cassette, sub-family D (ALD), 
member 2 Cytoplasm transporter 3.95E-02 -1.76 
PRTFDC1 phosphoribosyl transferase domain containing 1 Cytoplasm enzyme 1.42E-02 -1.75 
TP53BP2 tumor protein p53 binding protein, 2 Nucleus other 1.13E-02 -1.75 
OLAH oleoyl-ACP hydrolase Other enzyme 1.76E-03 -1.75 
OR10R2 
olfactory receptor, family 10, subfamily R, 
member 2 
Plasma 
Membrane other 1.68E-03 -1.75 
MYB 
v-myb avian myeloblastosis viral oncogene 
homolog Nucleus 
transcription 
regulator 2.27E-02 -1.74 
LOC100133050 glucuronidase, beta pseudogene Other other 3.41E-02 -1.73 
RASSF6 
Ras association (RalGDS/AF-6) domain family 
member 6 Other other 8.03E-04 -1.73 
RSPH1 radial spoke head 1 homolog (Chlamydomonas) Nucleus other 2.14E-02 -1.72 
RAB23 RAB23, member RAS oncogene family Cytoplasm enzyme 1.04E-02 -1.71 
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SLC41A2 
solute carrier family 41 (magnesium 
transporter), member 2 
Plasma 
Membrane transporter 2.80E-04 -1.71 
CHIC2 cysteine-rich hydrophobic domain 2 
Plasma 
Membrane other 9.76E-05 -1.70 
ZNF322 zinc finger protein 322 Cytoplasm other 2.86E-02 -1.69 
TAS2R46 taste receptor, type 2, member 46 
Plasma 
Membrane 
G-protein 
coupled 
receptor 4.85E-02 -1.69 
WNT5A 
wingless-type MMTV integration site family, 
member 5A 
Extracellular 
Space cytokine 5.31E-03 -1.69 
DCAF8 DDB1 and CUL4 associated factor 8 Other other 1.47E-03 -1.68 
SGCB 
sarcoglycan, beta (43kDa dystrophin-associated 
glycoprotein) 
Plasma 
Membrane other 4.01E-03 -1.68 
FBXO3 F-box protein 3 Other enzyme 1.45E-02 -1.68 
SPATA17 spermatogenesis associated 17 Other other 6.39E-03 -1.68 
SNX11 sorting nexin 11 Cytoplasm transporter 1.79E-02 -1.67 
ZNF815P zinc finger protein 815, pseudogene Other other 2.43E-02 -1.67 
CCT6P1 
chaperonin containing TCP1, subunit 6 (zeta) 
pseudogene 1 Other other 1.12E-03 -1.67 
TRAT1 
T cell receptor associated transmembrane 
adaptor 1 
Plasma 
Membrane kinase 1.95E-02 -1.66 
CALCRL calcitonin receptor-like 
Plasma 
Membrane 
G-protein 
coupled 
receptor 1.70E-02 -1.66 
ZNF260 zinc finger protein 260 Nucleus other 1.37E-02 -1.66 
ZNF429 zinc finger protein 429 Nucleus other 2.35E-02 -1.65 
RYBP RING1 and YY1 binding protein Nucleus 
transcription 
regulator 1.99E-02 -1.65 
ADPRM 
ADP-ribose/CDP-alcohol diphosphatase, 
manganese-dependent Other other 9.88E-03 -1.65 
ZNF253 zinc finger protein 253 Nucleus 
transcription 
regulator 3.16E-02 -1.65 
MTUS2-AS2 MTUS2 antisense RNA 2 Other other 5.24E-03 -1.65 
LOC374443 
C-type lectin domain family 2, member D 
pseudogene Other other 1.09E-03 -1.65 
NPL 
N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) Other enzyme 4.68E-04 -1.65 
TXNIP thioredoxin interacting protein Cytoplasm other 7.35E-03 -1.65 
NR1D2 
nuclear receptor subfamily 1, group D, member 
2 Nucleus 
ligand-
dependent 
nuclear 
receptor 6.00E-03 -1.65 
RANBP3L RAN binding protein 3-like Other other 1.17E-02 -1.64 
BAZ2B 
bromodomain adjacent to zinc finger domain, 
2B 
Extracellular 
Space other 4.51E-04 -1.64 
FAM206A family with sequence similarity 206, member A 
Extracellular 
Space other 2.05E-02 -1.64 
HTR3B 
5-hydroxytryptamine (serotonin) receptor 3B, 
ionotropic 
Plasma 
Membrane ion channel 3.46E-02 -1.64 
NT5DC1 5'-nucleotidase domain containing 1 Other other 1.19E-02 -1.64 
TPRG1-AS2 TPRG1 antisense RNA 2 Other other 1.65E-02 -1.64 
FOXP1 forkhead box P1 Nucleus other 7.13E-04 -1.63 
ALPK2 alpha-kinase 2 Nucleus kinase 4.87E-02 -1.63 
TBC1D9 
TBC1 domain family, member 9 (with GRAM 
domain) 
Plasma 
Membrane other 3.55E-02 -1.63 
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 
Plasma 
Membrane transporter 2.86E-03 -1.63 
ACBD7 acyl-CoA binding domain containing 7 Other other 1.11E-02 -1.63 
LPP-AS2 LPP antisense RNA 2 Other other 2.68E-02 -1.63 
PRDM1 PR domain containing 1, with ZNF domain Nucleus 
transcription 
regulator 1.87E-02 -1.63 
LOC100132057 
phosphodiesterase 4D interacting protein 
pseudogene Other other 3.90E-02 -1.62 
COX19 
cytochrome c oxidase assembly homolog 19 (S. 
cerevisiae) Cytoplasm other 9.98E-03 -1.61 
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RBM18 RNA binding motif protein 18 Other other 2.52E-04 -1.61 
DEFB114 defensin, beta 114 
Extracellular 
Space other 3.47E-02 -1.61 
AURKA aurora kinase A Nucleus kinase 9.86E-03 -1.61 
CPEB4 
cytoplasmic polyadenylation element binding 
protein 4 
Plasma 
Membrane other 1.15E-02 -1.61 
PIM1 pim-1 oncogene Cytoplasm kinase 1.62E-02 -1.61 
PCDHB8 protocadherin beta 8 Other other 3.25E-02 -1.61 
TXNL4B thioredoxin-like 4B Nucleus enzyme 7.27E-04 -1.61 
EPB41L5 erythrocyte membrane protein band 4.1 like 5 
Plasma 
Membrane other 5.28E-03 -1.60 
TBC1D3P2 TBC1 domain family, member 3 pseudogene 2 Other other 6.26E-03 -1.60 
TTC32 tetratricopeptide repeat domain 32 Other other 6.89E-03 -1.60 
FAM105B/OTULIN 
OTU deubiquitinase with linear linkage 
specificity Cytoplasm peptidase 1.39E-04 -1.60 
TXNIP thioredoxin interacting protein Cytoplasm other 2.04E-02 -1.60 
SLAMF6 SLAM family member 6 
Plasma 
Membrane 
transmembra
ne receptor 4.03E-03 -1.60 
CRYZ crystallin, zeta (quinone reductase) Cytoplasm enzyme 5.54E-03 -1.60 
FBXO8 F-box protein 8 Cytoplasm other 3.73E-03 -1.60 
PIEZO2 
piezo-type mechanosensitive ion channel 
component 2 Other ion channel 2.03E-02 -1.60 
ZNF347 zinc finger protein 347 Nucleus other 3.02E-02 -1.59 
UNQ6494 uncharacterized LOC100129066 Other other 3.61E-02 -1.59 
CD59 CD59 molecule, complement regulatory protein 
Plasma 
Membrane other 1.84E-03 -1.59 
FRRS1 ferric-chelate reductase 1 
Plasma 
Membrane 
transmembra
ne receptor 8.27E-03 -1.59 
CLN5 ceroid-lipofuscinosis, neuronal 5 Cytoplasm other 2.73E-03 -1.59 
GDAP1 
ganglioside induced differentiation associated 
protein 1 Cytoplasm other 2.53E-03 -1.59 
DPH3P1 diphthamide biosynthesis 3 pseudogene 1 Other other 1.29E-02 -1.59 
FCRL3 Fc receptor-like 3 Other other 6.17E-06 -1.59 
CDH12 cadherin 12, type 2 (N-cadherin 2) 
Plasma 
Membrane other 5.90E-04 -1.59 
CREBRF CREB3 regulatory factor Other other 7.37E-04 -1.59 
REPS2 RALBP1 associated Eps domain containing 2 Cytoplasm other 2.61E-02 -1.58 
LOC284930 uncharacterized LOC284930 Other other 1.28E-02 -1.58 
OR7E12P 
olfactory receptor, family 7, subfamily E, 
member 12 pseudogene Other other 1.06E-02 -1.58 
HIST2H4B // HIST4H4 // 
HIST2H4A // HIST1H4L // 
HIST1H4E // HIST1H4B // 
HIST1H4H // HIST1H4C 
// HIST1H4J // HIST1H4K 
// HIST1H4F // 
HIST1H4D // HIST1H4A 
// HIST1H4I  
histone cluster 1, H4a H4b H4c H4d H4e H4f 
H4h H4i H4j H4k H4l histone cluster 2, H4a H4b 
histone cluster 4, H4 
 
 
 
 
Nucleus 
 
 
 
 
 
 
Other 
 
 
 
 
 
 
2.06E-03 
 
 
 
 
 
 
-1.58 
 
 
 
 
 
 
HIST2H4B // HIST4H4 // 
HIST2H4A // HIST1H4L // 
HIST1H4E // HIST1H4B // 
HIST1H4H // HIST1H4C 
// HIST1H4J // HIST1H4K 
// HIST1H4F // 
HIST1H4D // HIST1H4A 
// HIST1H4I  
histone cluster 1, H4a H4b H4c H4d H4e H4f 
H4h H4i H4j H4k H4l histone cluster 2, H4a H4b 
histone cluster 4, H5 
 
 
 
 
 
Nucleus 
 
 
 
 
 
 
 
Other 
 
 
 
 
 
 
 
2.06E-03 
 
 
 
 
 
 
 
-1.58 
 
 
 
 
 
 
 
KLHL42 kelch-like family member 42 Nucleus other 2.26E-02 -1.58 
KCTD3 
potassium channel tetramerization domain 
containing 3 Other ion channel 1.39E-02 -1.58 
PHLDA1 
pleckstrin homology-like domain, family A, 
member 1 Cytoplasm other 4.58E-03 -1.58 
DMXL2 Dmx-like 2 Cytoplasm other 4.02E-03 -1.58 
GNG2 
guanine nucleotide binding protein (G protein), 
gamma 2 
Plasma 
Membrane enzyme 4.11E-02 -1.58 
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C16orf87 chromosome 16 open reading frame 87 Other other 9.23E-03 -1.58 
FCRL3 Fc receptor-like 3 Other other 1.18E-02 -1.58 
IL7 interleukin 7 
Extracellular 
Space cytokine 1.95E-02 -1.58 
IKZF3 IKAROS family zinc finger 3 (Aiolos) Nucleus 
transcription 
regulator 5.37E-03 -1.58 
CDK17 cyclin-dependent kinase 17 Cytoplasm kinase 3.63E-02 -1.58 
NUDT4P1 
nudix (nucleoside diphosphate linked moiety X)-
type motif 4 pseudogene 1 Other other 4.56E-02 -1.57 
ZNF480 zinc finger protein 480 Nucleus other 2.25E-02 -1.57 
ARID4A AT rich interactive domain 4A (RBP1-like) Nucleus 
transcription 
regulator 1.14E-03 -1.57 
SOX5 SRY (sex determining region Y)-box 5 Nucleus 
transcription 
regulator 2.12E-02 -1.57 
SQRDL sulfide quinone reductase-like (yeast) Cytoplasm enzyme 4.27E-03 -1.57 
MXD1 MAX dimerization protein 1 Nucleus 
transcription 
regulator 3.69E-02 -1.57 
ZDHHC21 zinc finger, DHHC-type containing 21 
Plasma 
Membrane enzyme 3.50E-02 -1.57 
ZNF724P zinc finger protein 724, pseudogene Other other 7.94E-03 -1.57 
GNL3 
guanine nucleotide binding protein-like 3 
(nucleolar) Nucleus other 9.86E-04 -1.57 
SNORD19B small nucleolar RNA, C/D box 19B Other other 9.86E-04 -1.57 
FAS-AS1 FAS antisense RNA 1 Other other 2.14E-02 -1.57 
MSR1 macrophage scavenger receptor 1 
Plasma 
Membrane 
transmembra
ne receptor 1.89E-02 -1.56 
GIN1 gypsy retrotransposon integrase 1 Other other 4.00E-04 -1.56 
FLJ38576 uncharacterized LOC651430 Other other 4.08E-02 -1.56 
LOC729291 uncharacterized LOC729291 Other other 3.32E-02 -1.56 
ZFAT zinc finger and AT hook domain containing Nucleus other 3.55E-02 -1.56 
RPL23AP53 ribosomal protein L23a pseudogene 53 Other other 4.95E-02 -1.56 
FBXL3 F-box and leucine-rich repeat protein 3 Nucleus enzyme 1.20E-02 -1.55 
ATAD2B ATPase family, AAA domain containing 2B Nucleus other 1.49E-03 -1.55 
SMG1 
SMG1 phosphatidylinositol 3-kinase-related 
kinase Cytoplasm kinase 1.00E-03 -1.55 
FANK1 
fibronectin type III and ankyrin repeat domains 
1 Nucleus 
transcription 
regulator 1.47E-02 -1.55 
PPIL4 peptidylprolyl isomerase (cyclophilin)-like 4 Nucleus enzyme 7.61E-04 -1.55 
ISCU iron-sulfur cluster assembly enzyme Cytoplasm other 3.72E-03 -1.55 
MIR1302 microRNA 1302-5 Cytoplasm microRNA 4.01E-02 -1.55 
C6orf62 chromosome 6 open reading frame 62 Other other 8.24E-04 -1.54 
VPS54 
vacuolar protein sorting 54 homolog (S. 
cerevisiae) 
Extracellular 
Space other 2.02E-03 -1.54 
CWC22 
CWC22 spliceosome-associated protein 
homolog (S. cerevisiae) Nucleus other 6.42E-03 -1.54 
HES1 hes family bHLH transcription factor 1 Nucleus 
transcription 
regulator 1.50E-02 -1.54 
HYDIN HYDIN, axonemal central pair apparatus protein Other other 4.63E-02 -1.54 
LINC00339 long intergenic non-protein coding RNA 339 Other other 2.94E-02 -1.54 
POF1B premature ovarian failure, 1B 
Plasma 
Membrane other 4.08E-03 -1.54 
PCMTD2 
protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 2 Cytoplasm enzyme 5.94E-03 -1.54 
KCTD7 
potassium channel tetramerization domain 
containing 7 Other ion channel 1.59E-02 -1.54 
FLJ43681 ribosomal protein L23a pseudogene Other other 2.17E-02 -1.54 
HS3ST3B1 
heparan sulfate (glucosamine) 3-O-
sulfotransferase 3B1 Cytoplasm enzyme 8.99E-03 -1.54 
FAM127B family with sequence similarity 127, member B Other other 4.90E-03 -1.53 
KIR2DS4 (includes 
others) 
killer cell immunoglobulin-like receptor, two 
domains, short cytoplasmic tail, 4 
Plasma 
Membrane 
transmembra
ne receptor 4.20E-02 -1.53 
BCL7A B cell CLL/lymphoma 7A Other other 1.39E-02 -1.53 
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TRMT10B 
tRNA methyltransferase 10 homolog B (S. 
cerevisiae) Other other 1.92E-02 -1.53 
LOC442132 golgin A6 family-like 1 pseudogene Other other 4.20E-02 -1.53 
ZNF639 zinc finger protein 639 Nucleus 
transcription 
regulator 3.59E-03 -1.53 
C1orf186 chromosome 1 open reading frame 186 Other other 7.08E-04 -1.53 
NEK7 NIMA-related kinase 7 Nucleus kinase 7.22E-03 -1.53 
SYCP3 synaptonemal complex protein 3 Nucleus other 7.11E-03 -1.53 
RGCC regulator of cell cycle Cytoplasm other 2.97E-03 -1.53 
GADD45A growth arrest and DNA-damage-inducible, alpha Nucleus other 4.80E-03 -1.52 
FKBP14 FK506 binding protein 14, 22 kDa Cytoplasm enzyme 1.16E-02 -1.52 
ZNF740 zinc finger protein 740 Other other 1.77E-02 -1.52 
LOC441461 uncharacterized LOC441461 Other other 2.00E-02 -1.52 
SLC12A6 
solute carrier family 12 (potassium/chloride 
transporter), member 6 
Plasma 
Membrane transporter 2.85E-02 -1.52 
TYW3 
tRNA-yW synthesizing protein 3 homolog (S. 
cerevisiae) Other other 6.09E-04 -1.52 
ABCA1 
ATP-binding cassette, sub-family A (ABC1), 
member 1 
Plasma 
Membrane transporter 2.36E-03 -1.52 
SAMSN1 
SAM domain, SH3 domain and nuclear 
localization signals 1 Nucleus other 1.87E-02 -1.52 
CYP2E1 
cytochrome P450, family 2, subfamily E, 
polypeptide 1 Cytoplasm enzyme 1.01E-03 -1.52 
TBC1D3P1-DHX40P1 
TBC1D3P1-DHX40P1 readthrough transcribed 
pseudogene Other other 2.71E-02 -1.52 
SNORA46 small nucleolar RNA, H/ACA box 46 Other other 1.10E-02 -1.52 
TBCEL tubulin folding cofactor E-like Other other 1.11E-03 -1.52 
FAM179B family with sequence similarity 179, member B 
Extracellular 
Space other 1.16E-02 -1.52 
KCNJ1 
potassium inwardly-rectifying channel, 
subfamily J, member 1 
Plasma 
Membrane ion channel 8.08E-03 -1.52 
FAM108C1/ABHD17C abhydrolase domain containing 17C Other enzyme 5.26E-03 -1.51 
LRRC70 leucine rich repeat containing 70 Other other 2.95E-02 -1.51 
TAGAP T cell activation RhoGTPase activating protein Cytoplasm other 4.16E-03 -1.51 
CSGALNACT2 
chondroitin sulfate N-
acetylgalactosaminyltransferase 2 Cytoplasm enzyme 3.89E-04 -1.51 
SMAD4 SMAD family member 4 Nucleus 
transcription 
regulator 8.83E-03 -1.51 
BACE2 beta-site APP-cleaving enzyme 2 Cytoplasm peptidase 3.26E-02 -1.51 
KRTAP6-3 keratin associated protein 6-3 Other other 1.31E-02 -1.51 
R3HCC1L R3H domain and coiled-coil containing 1-like Other other 2.98E-02 -1.51 
OR4D5 
olfactory receptor, family 4, subfamily D, 
member 5 
Plasma 
Membrane 
G-protein 
coupled 
receptor 1.57E-02 -1.51 
PILRA paired immunoglobin-like type 2 receptor alpha 
Plasma 
Membrane other 5.81E-03 -1.50 
TRA2B transformer 2 beta homolog (Drosophila) Nucleus other 8.61E-03 -1.50 
MICU3 mitochondrial calcium uptake family, member 3 Other other 4.64E-02 -1.50 
      
MCF7 cells up regulated FC ≥1.5 
SYMBOL ENTREZ GENE NAME LOCATION TYPE(S) P-VALUE 
FOLD 
CHANGE 
EGR1 early growth response 1 Nucleus 
transcription 
regulator 2.11E-02 2.22 
EGR1 early growth response 1 Nucleus 
transcription 
regulator 2.18E-02 2.16 
ZNF826P zinc finger protein 826, pseudogene Other other 2.22E-03 1.76 
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 
Plasma 
Membrane kinase 5.00E-02 1.71 
AGAP6 (includes others) 
ArfGAP with GTPase domain, ankyrin repeat 
and PH domain 6 Other other 4.98E-02 1.67 
ADIRF adipogenesis regulatory factor Nucleus other 4.98E-02 1.67 
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RNU6-83P RNA, U6 small nuclear 83, pseudogene Other other 2.24E-02 1.66 
IRX1 iroquois homeobox 1 Nucleus 
transcription 
regulator 4.05E-02 1.64 
ZNF600 zinc finger protein 600 Other other 2.89E-02 1.64 
MIR140 microRNA 140 Cytoplasm microRNA 4.21E-02 1.63 
FOS 
FBJ murine osteosarcoma viral oncogene 
homolog Nucleus 
transcription 
regulator 1.11E-02 1.63 
MRO maestro Nucleus other 1.17E-02 1.57 
LOC100130964 ADAM metallopeptidase domain 3A-like Other other 3.11E-02 1.55 
TARP TCR gamma alternate reading frame protein Cytoplasm other 1.51E-02 1.55 
OR2V1 
olfactory receptor, family 2, subfamily V, 
member 1 
Plasma 
Membrane 
G-protein 
coupled 
receptor 4.40E-02 1.54 
SNORD108 small nucleolar RNA, C/D box 108 Other other 2.36E-02 1.54 
GBGT1 
globoside alpha-1,3-N-
acetylgalactosaminyltransferase 1 Other enzyme 3.96E-02 1.54 
LOC1720 dihydrofolate reductase pseudogene Other other 3.29E-02 1.53 
SMARCD3 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 3 Nucleus 
transcription 
regulator 4.69E-03 1.53 
MYOCD myocardin Nucleus 
transcription 
regulator 3.17E-02 1.53 
CEACAM5 
carcinoembryonic antigen-related cell adhesion 
molecule 5 
Plasma 
Membrane other 6.54E-03 1.51 
PAPPA 
pregnancy-associated plasma protein A, 
pappalysin 1 
Extracellular 
Space peptidase 3.28E-02 1.50 
PCDHB13 protocadherin beta 13 
Extracellular 
Space other 1.37E-03 1.50 
      
MCF7 cells down regulated FC ≥1.5 
SYMBOL ENTREZ GENE NAME LOCATION TYPE(S) P-VALUE 
FOLD 
CHANGE 
SNORA30 small nucleolar RNA, H/ACA box 30 Other other 1.48E-03 -2.08 
SNORD72 small nucleolar RNA, C/D box 72 Other other 7.37E-03 -2.02 
TAS2R31 taste receptor, type 2, member 31 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2.26E-02 -2.01 
TAS2R45 taste receptor, type 2, member 45 
Plasma 
Membrane 
G-protein 
coupled 
receptor 2.26E-02 -2.01 
CCNYL2 cyclin Y-like 2 Other other 3.18E-02 -1.94 
MTMR6 myotubularin related protein 6 Cytoplasm phosphatase 2.42E-02 -1.87 
MIR15/MIR16-2 microRNA 15a Cytoplasm microRNA 3.39E-03 -1.85 
MIR619 microRNA 619 Cytoplasm microRNA 4.86E-03 -1.84 
SIAE sialic acid acetylesterase Cytoplasm enzyme 3.64E-02 -1.83 
MIR3184 microRNA 3184 Cytoplasm microRNA 3.98E-03 -1.82 
MIR423 microRNA 423 Cytoplasm microRNA 3.98E-03 -1.82 
TVP23B 
trans-golgi network vesicle protein 23 homolog 
B (S. cerevisiae) Other other 1.33E-02 -1.79 
PF4 platelet factor 4 
Extracellular 
Space cytokine 4.88E-02 -1.75 
MIR3685 microRNA 3685 Cytoplasm microRNA 2.13E-02 -1.71 
FSD2 
fibronectin type III and SPRY domain containing 
2 Other other 4.43E-02 -1.68 
SCARNA15 small Cajal body-specific RNA 15 Other other 4.43E-02 -1.68 
ANKRD20A4 (includes 
others) ankyrin repeat domain 20 family, member A3 
Plasma 
Membrane other 3.02E-02 -1.68 
LOC401357 uncharacterized LOC401357 Other other 3.99E-02 -1.65 
C14orf178 chromosome 14 open reading frame 178 Other other 1.01E-02 -1.64 
HSD52 uncharacterized LOC729467 Other other 3.22E-02 -1.58 
MIR1293 microRNA 1293 Cytoplasm microRNA 6.60E-03 -1.56 
211 
 
LOC338963 epididymal protein pseudogene Other other 2.16E-02 -1.53 
STX17 syntaxin 17 
Plasma 
Membrane transporter 4.09E-02 -1.52 
MIR4794 microRNA 4794 Cytoplasm microRNA 1.90E-02 -1.52 
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